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Chagas disease affects millions of people in Latin America and is now spreading to the 
whole world. Causing by the infection of Trypanosoma cruzi (T. cruzi), Chagas disease 
can be fatal, patients suffering from severe intestinal and cardiac disorders. The 
development of diagnosis and therapeutic drugs against Chagas disease is slow so far 
due to limited investment. T. cruzi trans sialidase (TcTS) is a surface-anchored 
glycoside transferase which plays a critical role in host cell invasion and immune 
evasion. Its uniqueness and role in parasite survival and pathogenicity indicates the 
importance of TcTS as a potential target for therapeutic drug development. However, 
no sufficiently strong inhibitors of TcTS have been described. Based on the structure of 
sialyl-lactose, a natural substrate of TcTS, we have designed a new type of inhibitor, α-
aminophosphonate, which inhibits TcTS effectively and selectively when compared to 
inhibition of bacterial sialidases/neuraminidases.  
 
Interestingly, although the compound was designed to interact with the catalytic site, it 
showed noncompetitive inhibition. Crystal structures suggest an allosteric binding site 
and the interaction between TcTS and α-aminophosphonate causes only minor 
conformational changes. Binding of α-aminophosphonate may inhibit TcTS activity by 
inducing these conformational changes and increasing the structural stability of 
catalytic site This results in stable binding of lactose, which is also shown through 
thermodynamics. Additionally, anthraquinone derivatives, whether an individual 
compound or as a part of an α-aminophosphonate, inhibit TcTS non-competitively, but 
these are shown to bind to the lactose-binding site, part of the catalytic pocket, also 
giving new insight into the inhibition and catalytic mechanisms of TcTS. 
 
In conclusion, α-aminophosphonate may be a potential drug candidate for Chagas 
disease. The crystal structure of TcTS in complex with α-aminophosphonate compound 
is the first report of the TcTS allosteric binding site, which may be crucial for better 
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understanding of the mechanisms and substrate recognition of this vital enzyme and for 
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1.1. Trypanosoma cruzi and Chagas disease 
 
1.1.1. Trypanosomes and Trypanosomiasis 
 
Trypanosoma, the name coming from the Greek trypano (borer) and soma (body), is a 
genus of unicellular protozoa belonging to the class of kinetoplastids (Atwood et al., 
2005). All Trypanosoma are parasitic and can be found in insects, some species can 
infect mammals and cause disease, including the fatal human disease. African sleeping 
sickness, which is caused by Trypanosoma brucei (T. brucei), which normally 
transferred by the tsetse fly, and Chagas disease that is induced by Trypanosoma cruzi 
(T. cruzi) which is transmitted by triatominae (Figure 1.1) (Podlipaev, 2001). T. rangeli 
can also infect humans via triatominae but it shows no evidence of human pathogenesis 
(Stoco et al., 2014). Other types of trypanosomes primarily infect mammals other than 
humans, for example, T. congolense, T. simiae and T. vivax cause nagana, also known 
as animal trypanosomiasis, in different kinds of mammals (Wells, 1972). 
 
Figure 1.1. Two major trypanosomes causing threatening human health: T. brucei (left) and T. 
cruzi (right), together with their carriers: tsetse fly and triatominae, respectively (adapted from 
Pritt, 2011). 
 
African sleeping sickness and Chagas disease are the two types of trypanosomiasis 




with about 10,000 reported cases in 2009, but large numbers of undiagnosed cases occur 
and about 2000 new infections have been reported each year (WHO, 2017). Chagas 
disease is more lethal and caused more than 10,000 deaths annually (Stanaway and 
Roth, 2015) 
 
1.1.2. Chagas disease — a global health challenge 
 
Chagas disease, also known as American trypanosomiasis, was first discovered and 
named by the Brazilian bacteriologist Carlos Chagas in 1909 (Chagas, 1909). During 
the 20th century, huge efforts towards understanding the disease have been carried out 
including identification of T. cruzi and its life cycles, investigation of T. cruzi 
transmission and treatments of Chagas disease (Steverding, 2014a). However, over a 
century following its identification Chagas disease still threatens public health all 
around the world and many details of the pathogenesis, for example, the relationship 
between T. cruzi infection and organ failures in the chronic phase of Chagas disease, 
are still unclear. Furthermore, although several anti-protozoan drugs have been 
developed for the treatment of Chagas disease, they still only have limited therapeutic 
effect on the chronic stage of Chagas disease, and poor early diagnosis is also an issue. 
 
Chagas disease is mainly endemic in Latin America, but today, it has spread all around 
the world, cases of T. cruzi infected patients have been reported in North America, 
Europe, Australia and Japan (Figure 1.2) (Coura and Vinas, 2010). The total number of 
reported cases of Chagas disease all around the world is about 7-8 million (Pereira and 
Navarro, 2013). In endemic regions, T. cruzi is primarily transmitted by triatominae, 
while over 100 species of triatominae have been shown to transmit T. cruzi, 4 species 
are known to be the most important in epidemiology, including Triatoma infestans 
which is the most intensively studied (Cecere et al., 1999). Mammals, especially 
domestic mammals such as dog, cat, pig and goat, can also be infected by T. cruzi 
(Noireau et al., 2009). Whilst being victims of T. cruzi infection, these mammals also 




reported where patients were infected by T. cruzi through eating contaminated fruit 
(Nóbrega, 2009). The spreading of Chagas disease beyond Latin America is mainly 
attributed to migration of population from the endemic region to the whole world. In 
the non-endemic region, Chagas disease can be transmitted through blood transfusions, 
organ transplantation, mother-to-child transmission, and accidental laboratory exposure 
(Guhl et al., 2000).  
 
In endemic countries, mostly developing countries, Chagas disease impacts public 
health and causes substantial financial burdens. The global cost of Chagas disease is 
US$7.2 billion annually, which exceeds the expenditure on many other severe diseases 











The life cycle of T. cruzi has been comprehensively reviewed by Tyler and Engman 
(Tyler and Engman, 2001). During its life cycle, T. cruzi moves between insect hosts 
(triatominae) and mammal hosts include human (Figure 1.3). In insect hosts, the 
parasites multiply and differentiate to metacyclic trypomastigotes (MT), which is an 
infective stage (CDC, 2014). The MT then can enter human peripheral blood via a sting 
by triatominae, are transported to different tissues and organs and invades the host cells. 
After amplification in host cells, the trypomastigotes differentiate into amastigotes, 
which can develop to trypomastigotes and enter the bloodstream through lysis of the 
host cell.  
Figure 1.3. Life cycle of T. cruzi (Clayton, 2010) 
 
The clinical aspects of Chagas disease can be divided into two stages: the acute and 
chronic phases. Regarded as a “silent killer” (Maguire, 2006), many patients that catch 
Chagas disease present mild symptoms during most of the time of pathogenesis 
processes. In the acute stage of Chagas disease, over 50% of patients could be 




as fever, subcutaneous edema, and enlargement in liver, most of these symptoms will 
resolve in several months spontaneously (Rassi et al., 2010). Some inflammatory 
manifestations are also used to identify acute Chagas disease, for example, unilateral 
periorbital edema, also called Romaña sign (Figure 1.4 A), which is caused by 
conjunctival infection through rubbing eyelids (Rassi et al., 2010). Even with treatment 
against infect parasites, over 90% of patients will progress to the chronic phase during 
the development of the disease (Bern et al., 2007), which is more concealed and lethal 
than acute phase Chagas disease. 30% of chronic patients suffer from digestive problem 
such as megaesophagus and secondary achalasia (Rassi et al., 2010; Salamanca-Dejour 
et al., 2012). Around two thirds of chronic Chagas disease patients will develop cardiac 
disorders including heart damage (Figure 1.4 B), and Chagas disease may induce 
sudden death through by heart rate abnormalities (Machado et al., 2012). Another 
manifestation is neurological symptoms, e.g. neuritis and dementia, caused by neuronal 
invasion by T. cruzi (Cordova et al., 2010).  
 
Figure 1.4. (A) Romana’s sign and (B) Heart of Chagas patient compared with normal 
heart. (accessed from http://pharmeasy.in) 
 
Since the discovery of Chagas disease, many efforts have been made to find effective 
chemical prevention and therapeutic agents. Lindane and Deltamethrin were found to 
kill triatominae bugs thus they can prevent the transfer of Chagas disease (Steverding, 
2014). The first compound that was identified that killed T. cruzi was crystal violet, 




Benznidazole and Nifurtimox were discovered as two effective anti-parasite drug 
against T. cruzi and these are the only drugs available for Chagas disease medication 
today (Steverding, 2014). However, both are still controversial due to their severe 
adverse side effects (Castro et al., 2006). Benznidazole can lead to hypersensitivity, 
polyneuropathy and bone marrow problems (Pinazo et al., 2010). Nifurtimox can also 
induce anorexia, psychic alterations, excitability, and sleepiness (Castro et al., 2006). 
So far, there is also no commercially available vaccine against Chagas disease (Lee et 
al., 2010). More importantly, both Benznidazole and Nifurtimox have better effect in 
early diagnosed cases and only show limited effect on chronic Chagas disease (Hamers 
et al., 2016; Morillo et al., 2015; Munoz et al., 2013). Therefore, there is an urgent need 












1.2. Sialic acid and T. cruzi trans sialidase 
 
1.2.1. Sialic acids 
 
In the broad sense, the term sialic acid (SA), also known as neuraminic acid, covers a 
family of N- or O-substituted 9 carbon acidic sugar derivatives which can be a part of 
glycans that can be found in both eukaryotic and prokaryotic cells. More precisely, SA 
is often regarded as the name of the most common member of this family, 2-keto-3-
deoxy-5- acetamido-D-glycero-D-galacto-nonulosonic acid, simply called N-
acetylneuraminic acid (Neu5Ac or NANA) (Figure 1.6.) (Varki, 2009), Throughout this 
thesis SA will represent Neu5Ac unless defined otherwise. In some cases, two other 
members of this family, 2-keto-3-deoxynononic acid (KDN) and N-glycolylneuraminic 
acid (Neu5Gc) are also called SA (Figure 1.6.). The substituents on C4, C5, C7, C8 and 
C9 positions lead to more than 50 members of the wider SA family (Varki, 2009).  
 
Figure 1.6. Structure of sialic acid  
 
Neu5Ac is the most ubiquitous member of the SA family in nature. After first isolation 
from bovine submaxillary gland in 1936, the structure, synthesis and function of 
Neu5Ac has been studied intensively in the last century. Neu5Gc differs from Neu5Ac 
only by a single hydroxyl group at the end of the N-acetamido group. Neu5Gc is the 
second ubiquitous SA in nature following Neu5Ac, however, it is not present in humans 
Neu5Ac: R= CH3-CO-NH- 
KDN: R=OH 




(Varki, 2010). Therefore, the human immune system normally recognizes Neu5Gc as a 
foreign molecule. It is also reported that binding between Neu5Gc and its antibody 
might induce chronic inflammation and be correlated to human cancer (Coussens and 
Werb, 2002; Samraj et al., 2014; Tan and Coussens, 2007). KDN is a relatively newly 
discovered molecule in the SA family having been studied for around 20 years. KDN 
mainly occurs in bacterial cells with the similar occurrence level of Neu5Ac, however 
in human body it is only enriched in fetal erythrocytes and tumor cells rather than 
healthy cells (Inoue and Kitajima, 2006).  
 
As negatively charged carbohydrates, SAs are hydrophilic. Sialic acid can decorate 
almost all kinds of glycans as the terminal sugar, by formation of glycosidic bond via 
C2 (3’-sialylglycan) or C4 (6’-sialylglycan), various substituents can also link at the 
C4, C5, C7, C8 and C9 position (Figure 1.7) (Angata and Varki, 2002; Arnaud et al., 
2013; Varki and Varki, 2007). Apart from the presentation and structure, the universality 
and diversity of SA on both human and microbial cell is shown from its many functions. 
An essential function for SA is to maintain membrane stability and modulate 
interactions between cell and environment, SA also paly important role in protecting 
cell surface antigens and regulate the immune response (Wiederschain, 2009). The 
essential functions of SA are often exploited by cancer cells and infecting microbes. By 
significant overexpression of SA-rich glycoproteins on the cell membrane, cancer cell 
can generate a strongly negative-charged surface which can lead to cell opposition and 







SA also has critical roles in infection and pathogenicity of infecting microbes including 
bacteria, parasites and viruses. Many bacteria and parasites can incorporate SA on their 
surface for evasion from immune surveillance (Hicks et al., 2000; Severi et al., 2007). 
In virus infection, SA contributes to cell attachment and regulation of membrane 
penetration (Stencel-Baerenwald et al., 2014). 
 
1.2.2. T. cruzi trans sialidase 
 
1.2.2.1. Structure and function  
 
T. cruzi trans-sialidase (TcTS) is a critical enzyme located on the surface of the parasite. 
The SA terminated mucin was discovered to play an important role in host cell invasion 
of T. cruzi in 1991 (Schenkman et al., 1991), from where the SA hydrolyzed and 
transferred to the surface of the parasite. Later, the SA transfer and hydrolysis activity 
were proved to be mediated by the same enzyme, which has been identified as TcTS 





(Schenkman et al., 1992). TcTS belongs to the glycoside hydrolase GH33 family, which 
contain most of prokaryotic and some eukaryotic sialidases/neuraminidases (Amaya, et 
al., 2004; Henrissat and Davies, 1997). TcTS can be divided into two different parts 
(Figure1.8 A), the N-terminal functional part and the C-terminal shed acute-phase 
antigen (SAPA) domain.  
 
The SAPA domain is a non-structural repeat of a 12-residue unit (DSSAHGTPSTPV), 
which is not involved in the catalytic activity, but can increase immune response 
towards TcTS (Buscaglia et al., 1999; Buscaglia et al., 1998). The C-terminus of the 
SAPA domain links TcTS to the cell surface of T. cruzi by a Glycosyl-
phosphatidylinositol (GPI) anchor (Agusti et al., 1997). The N-terminal part of TcTS 
contains a 6-stranded β-propeller catalytic domain, which is structurally similar to other 
members of GH33 family, and a β-sandwich lectin-like domain (Figure 1.8B) 
(Buschiazzo et al., 2002). The catalytic domain directly contributes to the trans-
glycosylation activity from host glycoconjugate to parasite surface mucin, through the 
catalytic site located in the centre of the β-propeller (Figure 1.8 B). A lectin-like domain 
has been found in several sialidases, for example, the sialidases from Vibrio cholerae, 
Streptococcus pneumoniae, and trans-sialidase from Trypanosoma congolense 
(Crennell et al., 1994; Waespy, Mario et al., 2015). In most cases, the sialidase lectin-
domain shows sugar binding activity and has been proved to be involved in substrate 
recognition and catalytic activity (Moustafa et al., 2004; Waespy, M. et al., 2015; Yang 
et al., 2015). However, there has been no evidence to show that the TcTS lectin-like 






T. cruzi cannot synthesize SA, therefore, the transfer activity of TcTS is the only source 
of sialic acid for T. cruzi. Additionally, an in vivo study suggests that injection of TcTS 
in infected mice enhances parasitemia symptoms and mortality rate (Freire-De-Lima et 
al., 2012). Therefore, TcTS is critical for the pathogenicity and survival of T. cruzi. 
Using TcTS activity, T. cruzi can decorate the terminus of its mucin glycans with SA, 
in order to bury the surface antigen, thus evade attack by anti-galactosyl antibodies and 
the complement system (Morrot, 2013).  
 
Moreover, SA is believed to play important roles in TcTS cell invasion. A recent 
N-terminal region









Figure 1.8. A. Domains of TcTS; B. Crystal structure of TcTS, the catalytic domain is 
presented in orange and the catalytic site is in green, the lectin-like domain is presented in 




hypothesis for the molecular mechanisms of TcTS in the cell invasion process is that 
sialylation of the parasite surface glycans by TcTS produces ligands for SA binding Ig-
like lectins (siglecs) on host cells (Jacobs et al., 2010). By interacting with sialylated 
glycans, siglecs can increase cell-cell interaction, and adherence of the parasite to the 
host cell (Varki and Gagneux, 2012). Activation of siglecs also modulates the innate 
immune response which would be beneficial to the persistence of T. cruzi in the host 
(Freire-de-Lima et al., 2016). However, Yoshida’s group reported that removal of the 
SA from T. cruzi surface resulted in even stronger cell-cell interactions, arguing that SA 
is not necessary for cell invasion (Yoshida et al., 1997). However, inhibition or decrease 
of TcTS levels on the T. cruzi surface was reported to eliminate trypomastigote 
virulence (Agusti et al., 2004; Freire-De-Lima et al., 2012; Jacobs et al., 2010; San 
Francisco et al., 2017), which suggests that some undetermined mechanism, not the 
catalytic process, is responsible for the contribution of TcTS to cell invasion by 
trypomastigotes. In the interaction between parasite and the host cell, TcTS hydrolyzes 
host cell surface glyconjugates, result in exposure of the β-Galp residue, which could 
interact with TcTS and TcTS-like glycoproteins. Meanwhile, TcTS and TcTS-like 
glycoproteins can also bind to the sialyl-glycans on parasite surface, increasing the 
adherence between T. cruzi and host cell (Varki and Gagneux, 2012). The absence of 
the SA residue and exposure of β-Galp also increases penetration of host cell surface, 
which creates favorable conditions for parasite invasion (Monteiro et al., 1998). By 
interacting with the immune cells, TcTS can favour the immune evasion of T. cruzi 
whilst, it can also contribute to infection of the parasite by cellular interactions.  
 
TcTS and its trans-sialylation activity can also induce other host cellular processes apart 
from cell invasion. As a critical factor in T. cruzi immune evasion, TcTS contributes to 
the immune response by interaction with a number of different immune cells. The SAPA 
region of TcTS has been shown to cause T-cell independent B-cell activation and 
production of non-specific antibodies, which protects T. cruzi from specific attack (Gao 
et al., 2002). Additionally, both active and inactive TcTS can also activate CD4+ T cells, 




(Todeschini et al., 2002). For cytotoxic CD8+ T cell against T. cruzi, TcTS can mask the 
surface β-Galp residues through its SA transfer activity and thus decrease CD8+ T cell 
activity (Freire-De-Lima et al., 2010). It is reported that TcTS activates the NF-κB 
signaling pathway of endothelial cells, which will prevent the cell from undergoing 
apoptosis and increase susceptibility to parasite infection (Dias et al., 2008). A imilar 
function of TcTS was also found in neuron and Schwann cells (Chuenkova et al., 2001; 
Chuenkova and Perrin, 2004). Moreover, TcTS can remove SA residues from platelet 
surfaces then induce platelet clearance (Tribulatti et al., 2005) 
 
As well as being anchored on the T. cruzi surface, TcTS can also be secreted by the 
parasite. It is worth noting that secretion of TcTS is not the release of single protein 
molecules, but through shed vesicles formed of plasma membrane (Agusti et al., 2000). 
The shed TcTS can achieve multiple biological functions without direct parasite 
attachment. Injection of these TcTS-rich shed vesicles into mice induces severe heart 
damage and inflammatory responses (Torrecilhas et al., 2009), suggesting that shed 
TcTS participates in multiple pathogenicities of T. cruzi infection including the Chagas 
heart disease. The majority of cellular function studies of TcTS were studied using 
purified recombinant TcTS due to the lack of a strong inhibitor or knock-out T. cruzi 
strains (Freire-de-Lima et al., 2016). Thus, these functions can be classified into the 






Figure 1.9. Functions of TcTS (adapted from Buscaglia et al., 2006; Nardy et al., 2016)  
 
In conclusion, TcTS is involved in multiple processes during T. cruzi infection, it can 
play a role as SA modifier, immune modulator and even cell adhesion agent. TcTS 
performs its functions either anchored on the parasite surface or shed into the plasma. 
However, the lack of an effective and selective inhibitor or a gene modified T. cruzi 
model lead to difficulties in the study of TcTS function. Therefore, in many cases, it is 
still unclear whether the functions of TcTS are domain-dependent or catalytic activity 
dependent, and the molecular mechanisms of many functions are still unknown. The 
development of a new generation of TcTS inhibitors might favor intensive studies of 
the molecular details of this critical enzyme and further our understanding of Chagas 




1.2.2.2.  Substrate and catalytic mechanisms  
 
 
Figure 1.10. A. Structure of Neu5Ac-α2,3-Gal and B. Neu5Ac-α2,6-Gal C. Rate of sialyl 
transfer with different donor substrate. D. Rate of sialyl transfer with different acceptor 
substrate (adapted from Vandekerckhove et al., 1992) 
 
 
TcTS is highly selective in its substrates for both hydrolysis and sialylation. As a donor 
substrate, TcTS specifically hydrolyzed Neu5Ac-α2,3-Gal (Figure 1.10A) rather than 
Neu5Ac-α2,6-Gal (Figure 1.10B) (Vandekerckhove et al, 1992). However, any 
Neu5Ac-α2,3-Gal terminal glycan can be the SA donor for TcTS (Figure 1.10 C), for 
example, ganglioside GM3. A terminal galactose residue is critical for an acceptor 
substrate, and only Gal-β- glycans are able to be sialylated by TcTS (Figure 1.10 D), 
but a single galactose is only a weak acceptor substrate for TcTS (Vandekerckhove et 
al., 1992)     
 




reaction following a “ping-pong” mechanism (Figure 1.11) (Damager et al., 2008). 
Initially, the donor SAL would enter the catalytic site of TcTS, leading to a 
conformational change of Tyr119 (Figure 1.12 A, B) which is then able to form the 
stacking interaction of the galactose binding site. The sialyl moiety would also fit into 
the sialyl binding site including the binding of the carboxyl group with the enzyme’s 
arginine triad and hydrogen bond formation between the 4-OH and Arg53, the 
acetamido side chain and Asp96, and the glycerol side chain and Trp120 (Amaya, et al., 
2004).  
 
Figure 1.11. Catalytic mechanism of TcTS (Damager et al., 2008) 
 
Tyr342 then attacks the C2 of the sialic acid in a SN2-type reaction with the assistance 
of Glu230 (Buschiazzo et al., 2000). These interactions immobilize the sialyl moiety in 
the sialic acid binding pocket. When SAL binds to the catalytic site, Asp59 is 
deprotonated on the hydroxyl group then provides a proton to the galactoside of cleaved 
glyosidic bond of donor substrate, followed by the release of the donor galactose 






Figure 1.12. Arrangement of lactose binding site (Tyr119 and Trp312) during hydrolysis 
process: A. un-ligand TcTS catalytic site (PDB: 1MS3); B. Intermediate structure of TcTS 
complex with SAL (PDB: 1S0I); C. TcTS catalytic site complex with cleaved SA (DANA) and 
lactose (PDB: 1MS0). D. TcTS catalytic site complex with DANA (PDB: 1MS8) (Buschiazzo 
et al., 2000, Amaya et al., 2004).  
 
The acceptor galactose enters the catalytic site only when the sialyl binding site is filled 
(Buschiazzolejandro et al., 2002), the intermediate Asp59 then captures the proton from 
the acceptor galactose and triggers completion of the synthesis of SA-acceptor 
galactose complex (Amaya et al., 2004).  
       
The sialic acid binding site of TcTS is conserved with other GH family sialidases. 
Therefore, the unique sialylation is believed to be achieved by a gate formed by Tyr119 
and Trp312 (Amaya et al., 2004). Tyr119 is present in two different conformation in 




flipped toward the sialic acid binding site (open conformation). In unliganded structures, 
Tyr119 can be in either of two conformation, indicating the flexibility of this residue in 
the absence of bound ligand (Figure 1.12 A). When the donor substrate SAL is bound 
to the active site, Tyr119 stays in the closed conformation and forms a sandwich 
stacking structure with the lactose moiety of SAL and Trp312 (Amaya et al., 2004). 
After the hydrolysis process, Tyr119 flips to the open conformation, stabilizing the 
sialic acid binding by hydrogen bond formation and allowing the donor lactose to be 
released. In sialylation process, binding of the acceptor glycan triggers the 
conformational change of Tyr119 from open to closed conformation (Buschiazzo et al., 
2002). In published crystal structure studies, no conformational change of Trp312 has 
been identified. However, mutagenesis and molecular dynamic simulation (MDS) 
studies suggest that conformation changes of Trp312 also occur during the catalytic 
process and may be important for lactose binding and release of lactose (Mitchell et al., 
2010).  
 




In the investigation of Chagas disease, TcTS has several characteristics of a potential 
drug target. Firstly, trans sialidase (TS) is unique to trypanosomes. Sialidase is a 
common enzyme in both prokaryotic and eukaryotic cells, however, trypanosome TcTS 
is the only type of enzyme which was found that has both hydrolase and transferase 
activity (Colli, 1993). This unique function of TcTS comes from its structure at the 
catalytic site which contains a lactose binding portion that can interact with donor or 
acceptor oligosaccharides. All the strong inhibitors of sialidases, only inhibit TcTS very 
weakly (Watts et al., 2003). Additionally, TcTS is known as a key virulence factor in T. 
cruzi infection and critical for the survival of the parasite. T. cruzi has reduced ability 




acid on its surface. The other functions of TcTS, such as assistance in cell invasion and 
the effect on the immune system, would also be removed by inactivation of TcTS. The 
importance and uniqueness make TcTS a potential drug target against Chagas disease. 
Also, the catalytic mechanisms and structure of TcTS has been intensively investigated 
during the last decade, these results are fundamental to structure-based rational drug 
design.  
 
During the past three decades, many efforts were focused on identifying and developing 
new inhibitors of TcTS for applications in chemical therapy and biological investigation. 
As well as being a drug target, TcTS was also identified as a potential vaccination target, 
since it occurs in substantial quantity and is highly conserved on the T. cruzi surface.  
 
1.3.2. Sialic acid analogue inhibitors 
 
SA, SA analogue or SA-like molecules were often tested as potential transition state 
inhibitors of TcTS. Large number of these molecules were good sialidase inhibitors, but 
the inhibition effect was significantly weaker for TcTS in most cases. For example, 2, 
3-Dehydro-2-deoxy-N-acetylneuraminic acid (DANA) (1) is a good inhibitor against 
the influenza neuraminidase (Ki=4 μM) (Smith et al., 2001), and T. rangeli sialidase 
(Ki=1.5 μM) (Paris et al., 2005). However, it is only an extremely weak inhibitor against 
TcTS (Ki=12.3 mM) (Paris et al., 2005).  
 
Unsurprisingly, other DANA derivatives, such as 4-guanidino-2,4-dideoxy-2,3-
dehydro-N-acetylneuraminic acid (zanamivir) (2) and (3R, 4R, 5S)-4-acetamido-5-
amino-3-(1-ethylpropoxy)-1-cyclohex-ene-1-carboxylic acid (oseltamivir) (3), which 
are both clinically approved drugs against influenza virus and inhibit sialidase at the 
nanomolar level, can only inhibit TcTS in very high concentration (Ki= 12.3 mM). 3-
((1S)-1-(acetylamino)-2-ethylbutyl)-4- ((aminoimino-methyl) amino) - 2- hydroxy- 
(1S,2S,3R,4R)-cyclopentanecarboxylic acid (peramivir) (4) inhibits influenza 




concentrations up to 10 mM (McLaughlin et al., 2015; Paris et al., 2005). Another 
DANA analogue, 4-Amino-2-deoxy-2,3-didehydro-N-acetylneuraminic acid (5), 
which is also a successful influenza neuraminidase inhibitor, has no effect on TcTS 
(Kashif et al., 2017).  
 
The 2,3-difluorosialic acid (DFSA) (6) has also been shown to be a weak TcTS inhibitor 
(Ki = 20mM) which shows time-dependent inhibition and covalent bond formation with 
Tyr342 (Watts et al., 2003). As an irreversible inhibitor, intensive modification and 
screening of DFSA was carried out during the last decade. C7 modification of DFSA 
was performed to improve TcTS inhibition, the 7-N-anilino derivatives gave a IC50 of 
3.2 mM (Resende, 2010). Modification at C9 was performed Withers group (8), this 
type of compound can also inhibit TcTS activity in a time-dependent manner and the 
introduction of lactose can result in reactivation (Buchini et al., 2008). Modification at 
the glycerol side chain could be another strategy for TcTS inhibitor development, but 
further design and screening are still necessary. Therefore, traditional sialidase/ 
neuraminidase inhibitors have only a limited inhibition effect on TcTS, which possibly 





Figure 1.13. Structure of sialic acid analogue inhibitors (1: Smith et al., 2001, 2-3: McLaughlin 
et al., 2015, 4: Paris et al., 2005, 5: Kashif et al., 2017, 6: Watts et al., 2003, 7: Resende, 
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1.3.3. Glycoside analogue inhibitors 
 
As a consequence of the unique transfer sialic acid activity, TcTS has developed an 
extra lactose binding site compared to sialidases. Thus, lactose and other glycans have 
also been considered as potential inhibitors against TcTS. TcTS has strong substrate 
specificity, some acceptor glycan molecules which can bind to the lactose binding site 
but only to be a poor sialic acid acceptor could be an inhibitor of TcTS. Lactitol (9) is 
the only commercial available TcTS inhibitor (Figure 1.13). As an acceptor analogue, 
which can bind to the catalytic site of TcTS with a Km of 0.24mM, lactitol can inhibit 
TcTS in vitro (IC50=0.57mM) and can reduce cell invasion of T. cruzi (Agusti et al., 
2004). Further research generating modifications on lactitol by adding Galp, Galf, or 
phenyl, failed to improve TcTS inhibition, the best compound Penta 5ol (10) gave an 
IC50 of 0.61mM. (Agusti et al., 2007).  
 
Substituted galactosides (11) were proved to reduce TcTS activity down to 37% but 
they are still a type of weak inhibitor and the best compound from the screen (11) has 
high cytotoxicity (Carvalho et al., 2010). β-thiogalactopyranosides (12, 13, 14) are 
another type of glycoside which can inhibit TcTS activity with IC50s in the 0.5-1mM 
range (Harrison et al., 2011).     
 
Another strategy of galactoside substitution is phosphorylation. Three types of 
phosphorylated galactose have been screened as TcTS inhibitors by Busse et. al. 
Compound 17, the best inhibitor among their tested compounds, gives an IC50 of 
1.5mM. However, other compounds (15, 16, 18) are within a range of IC50 from 3-8mM, 
suggesting that they cannot be potential tight binding TcTS inhibitors, but they could 
be compounds of interest for further development and potential inhibitors after 







Figure 1.14. Structure of glycoside analogue inhibitors (9: Agusti et al., 2004, 10: Agusti et 
al., 2007, 11: Carvalho et al., 2010, 12-14: Harrison et al., 2011, 15-18: Busse et al., 2007) 
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Figure 1.15. Structure of glycoside analogue inhibitors (19-22: Cano et al., 2014, 23-25: Agusti 








In 2014, Cano et. al synthesized mono and divalent β-N- and β-S- galactopyranosides 
(Galp), which are analogues of β-galactopyranosides (βGalp), a terminal glycan and 
TcTS acceptor substrate on T. cruzi mucin. These βGalp analogues still can act as an 
acceptor substrate, but also reduce TcTS activity. The mono β-N-Galp (19) and β-S-
Galp (20) play a major role as sialic acid acceptor and only can inhibit 32% and 41% 
of TcTS activity at 1mM respectively. The divalent analogues show better inhibition 
effect, which is 70% inhibition at 1mM for divalent-β-N-Galp (21) and 53% for 
divalent-β-N-Galp (22) (Cano et al., 2014). 
 
Recently, Cano and co-workers synthesized multivalent β-thiogalactopyranosides and 
thiolactosides. With same concentration of inhibitor, the mono glycocluster compound 
23 shows 68% inhibition of TcTS whilst the divalent compound (24) have 58% 
inhibition, and the multivalent glycocluster (25) can inhibit 82% of TcTS activity 
(Agusti et al., 2016). Most of the glycoside analogue inhibitors show competitive 
binding with acceptor substrate, and reduce the transfer activity, but none of these 
inhibitors has a greater effect than lactitol, and none of them can fully inhibit TcTS at 
the sub-millimolar level. 
 
1.3.4. Sialyl-glycan analogue inhibitors 
 
The unique dual-site catalytic pocket of TcTS resulted in the design of sialyl-glycan 
analogue inhibitors, a group of inhibitors which were designed to interact with both the 
sialic acid binding site and the lactose binding site. Ganglioside GM3 (20) is a natural 
substrate of TcTS, and it was found to inhibit TcTS activity (IC50=10-100μM) 
(Vandekerckhove et al., 1992). Later, several types of small molecule compounds were 
designed based on dual-site binding and evaluated as TcTS inhibitors. Carvalho et al. 
reported that 2-difluoromethyl-4- nitrophenyl-3,5-dideoxy-D-glycero-α-D-galacto-2-
nonulopyranosid acid (NeuNAFNP, 21) and its analogue dansyl-NeuNAcFP (22), can 
inhibit TcTS in vitro time-dependently and reduce cell invasion of T. cruzi. However, 




presence of a high concentration of substrates (Carvalho et al., 2010). Neu5Aca2–3-
Galb-O-octyl (23), another sialiyl disaccharide, has been proved to be a weak inhibitor 
that can reduce TcTS activity at the millimolar level (Harrison et al., 2001). 
 
In most of the designs of sialyl-lactose based inhibitors, the structure of sialic acid is 
generally maintained to interact with the sialic acid binding site. By contrast, a recent 
design for a TcTS inhibitor used a molecular simplification of sialyllactose (SAL), 
keeping the full structure of the galactoside, replacing the glucoside with aryl groups 
and simplifing the sialic acid into a carboxyl group (24) or tetrazolyl group (25). 
However, 3-O-substituted-aryl-β-D-galactopyranosides inhibitors (24, 25) achieved 
only 20% inhibition at 1mM. Moreover, lack of inhibition-mode evaluation and the 
different binding manner of compound 24 and 25 given by docking evaluation, make it 
difficult to explain the inhibitory mechanism of this type of compound (Silva et al., 
2014).  
 






Figure 1.16. Structure of sialyl-glycan analogue inhibitors (20: Vandekerckhove et al., 1992, 
21-22: Carvalho et al., 2010, 23: Harrison et al., 2001, 24-25) 
 
Consequently, no strong inhibitor has been discovered from sialyl-glycan analogues. 
Most of the designs of this group of inhibitors keep the un-modified SA structure for 
SA pocket binding, and links the SA moiety and glycan moiety with a glycosidic bond, 
which can be cleaved by TcTS or other sialidases. Therefore, how to achieve a stable 
binding between inhibitor and TcTS without hydrolysis should be considered in further 
development. 
 
1.3.5. TcTS inhibitors not related to carbohydrate 
 
As well as the inhibitors described above, some inhibitors have been described that are 
not related to carbohydrate structure. This group of inhibitors can be either molecules 
retrieved from database screening or known sialidase inhibitors, or molecules designed 
based on the structural architecture of TcTS catalytic site. Unlike sugar-based inhibitors, 
the mechanisms of these inhibitors are various, and many of them do not work as 
competitive inhibitors. However, so far, the best reported inhibitors have been these 
sugar independent molecules, and this group of inhibitors normally show high 
specificity against TcTS rather than cross-reacting with other sialidases. 
 
N-(4-Nitrophenyl)-oxamic acid (26, Figure 1.16) is a good sialidase inhibitor which can 
inhibit Vibrio cholerae neuraminidase in a non-competitive manner, but it can only 
inhibit TcTS weakly (Engstler et al., 1994). Pyridoxal phosphate (27) has been proved 





acetyl-α-D-neuraminic acid (MuNANA) was applied as the substrate, and none of its 
analogues, such as pyridoxine and pyridoxamine phosphate were a stronger inhibitor 
(Ferrerogarcia et al., 1993). Another type of phosphonate inhibitor, 
cyclohexenephosphonate derivatives, can inhibit TcTS in a similar range, the best 
compound of this group are N-acetyl-cyclohexenephosphonates monoalkyl esters (28, 
Ki=4.7 mM), but the inhibitory mechanism has not been evaluated (Streicher and Busse, 
2006).  
 
Benzonic acid has been proved to be an influenza neuraminidase inhibitor which 
interacted with the catalytic site (Chand et al., 1997). Further structural based design of 
benzonic acid derivatives against TcTS has been performed by Neres et. al. (2007) 
Compounds were designed based on catalytic site architecture and inhibited TcTS 
activity successfully at sub-micromolar level (29 and 30, IC50 about 0.5mM). 
Furosemide (31), also known as Lasix, a drug already in clinical use for treatment of 
hypertension and edema, was unexpectedly found to inhibit TcTS with IC50 of 0.67mM, 
inhibiting TcTS by either non-competitive or mixed mechanisms, suggesting that 
benzonic derivatives cannot bind to the TcTS active site (Neres et al., 2007). Later, 
Neres et. al. performed in vitro screening using a library containing 305,000 compounds 
based on the structural geometry of the TcTS catalytic site. The best candidate was 3-
benzothiazol-2-yl-4-(2-isopropoxy) phenyl-but-3-enoic acid (32), which gave an IC50 
of 0.15mM and 92% inhibition at 1mM. However, enzyme kinetics data showed that it 
is either a non-competitive or mixed inhibitor, indicating that a second inhibitor binding 





Figure 1.17. Structure of non-sugar-related inhibitors (26: Engstler et al., 1994, 27: 
Ferrerogarcia et al., 1993, 28: Streicher and Busse, 2006, 29-31: Neres et al., 2007, 32: Neres 
et al., 2009, 33-34: Kim et al., 2009, 35: Lara-Ramirez et al., 2017, 36-37: Arioka et al., 2010 ) 
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Sulfonamide chalcone (SC) and derivatives were first designed as α-glucosidase 
inhibitors, and Kim et.al (2009) found that they can also inhibit TcTS. The 3, 4-
dihydroxyl derivative (33) gave an IC50 of 0.9 μM. Another type of SC derivative, 
Quinolinone, also presents reasonable inhibition, tetra-hydroxy quinolinone (34) is one 
of the best known competitive inhibitors, with an IC50 of 0.6 μM (Kim et al., 2009). 
Recently, in vitro screening based on the TcTS catalytic site structure using over 3000 
FDA approved drug candidates has been carried out to find a TcTS inhibitor, 
sulfasalazine (35) which is structurally similar to sulfonamide chalcone, was found to 
show anti-trypanosoma activity (Lara-Ramirez et al., 2017). 
 
High throughput screening of TcTS inhibitors from a natural product library was 
performed by the Arioka and co-workers, and two scaffolds, flavonoid and 
anthraquinone were identified to have significant inhibition of TcTS. 4′,5,7-
trihydroxyflavone (Apigenin, 36) gave the minimum IC50 (78 μM) among flavonoid 
compounds, and 6-chloro-9,10-dihydro-4,5,7-trihydroxy-9,10-dioxo-2-anthracene-
carboxylic acid (37, IC50=0.58 μM) is the best potential inhibitor with a anthraquinone 




Following the discovery of this unique enzyme, many efforts have been made to 
develop an inhibitor against TcTS. However, so far there are still no strong, specific, 
and clinically safe inhibitors. Although some good candidates, such as lactitol, 
quinolinone and anthraquinone have been reported, all of them still have many 
clinically proven difficulties for profited use in therapy, further improvement and 
optimization in effect, specificity, cytotoxicity, and pharmacokinetics is required. Apart 
from the mechanism-based inhibitors, which are mostly weak inhibitors, many decent 
inhibitors are not related to TcTS substrate structure. Understanding the binding 





Since TcTS is not readily crystallized compared with many other sialidases, only two 
inhibitors, DANA (1) and compound 7, have had their crystal structure in complex with 
TcTS published (Buchini et al., 2008; Buschiazzo et al., 2002). Both two inhibitors are 
sialic acid derivatives, which can be better recognized by TcTS and interact with the 
catalytic site. Some structural efforts have also been carried out for the substrate-
unrelated inhibitors, but no crystal structure was able to be obtained by either co-
crystallization or crystal soaking (Neres et al., 2009). Knowing the binding site details 
and inhibition mechanisms are particularly important for the group of inhibitors that are 
unrelated to the TcTS substrate. Firstly, they are generally better inhibitors than sugar 
analogues and there is more potential for further development. Moreover, many of these 
inhibitors were designed based on catalytic site architecture but show either non-
competitive or mixed inhibition (29, 30, and 32). Some compounds discovered by 
screening also tend to inhibit TcTS by interacting with other binding sites rather than 
catalytic site (27, 36, and 37). 
 
1.4. Protein crystallography: history, principle and applications 
 
In the investigation of biological and biochemical process, structural biology plays a 
pivotal role. The interaction details between the macromolecule acceptor (e.g. protein 
and nucleic acid) and the ligand, which could be small molecules or bio-
macromolecules, can be interpreted visually by analysis of the structure of the 
molecules or complex. To interpret the structure of biomolecules, several methods have 
been developed, the two most commonly used high-resolution methods are X-ray 
crystallography (XRC) and nuclear magnetic resonance (NMR).  
 
As a mature method, which has been developed and applied for 100 years, XRC has 
contributed 90% of the structures in the protein data bank (PDB). It can be used to 
analyse high resolution three-dimensional structures from small molecules up to 




acids (Rupp, 2015). NMR is another major technique used to determine bio-
macromolecule structure. Unlike XRC, NMR will provide 3D structure information in 
the solution state, and it can also yield dynamic information of protein or protein-ligand 
complexes. However, normally NMR can only be used for proteins smaller than 30 
KDa (Cavanagh et al., 1995). In the past decade, several techniques have been 
developed to improve the data quality in structure determination or break through the 
limitations of current techniques. For example, cryo-electron microscopy (Cryo-EM) is 
becoming a powerful technique for the determination of large molecular structures 
especially large proteins or protein complexes, which are not able to be crystallized and 
too big for NMR, and the highest resolution of Cryo-EM structures can reach 3Å (Bai 
et al., 2015). Another technique applied in solution state is small-angle X-ray scattering 
(SAXS), which can detect structural parameters such as shape distribution for larger 
protein (>30KDa) (Blanchet and Svergun, 2013). For proteins for which large high 
quality crystal cannot be obtained, X-ray free electron laser diffraction (XFEL) or 
electron diffraction can also help to solve the structure. 
 
The first protein crystal of earthworm hemoglobin was obtained in 1840s and several 
protein crystals were reported during the 19th century. In early years of the 20th century, 
protein crystallization was mainly applied as a technique for protein purification 
(McPherson and Gavira, 2014). The first protein crystal structure, sperm whale 
myoglobin, was determined by John Kendrew in the 1950s (Kendrew et al., 1958), 
about 60 years after X-ray were discovered by Wilhelm Röntgen. Later, with the 
increasing importance of protein crystallography in studies of protein three-
dimensional structure and function, number of new approaches have been developed in 
protein purification methods, crystal growth, improvement in data collection techniques 
and processing of diffraction data. Presently, X-ray crystallography is the most 
important technique in determination of protein and protein complex structures, whilst 





Similar to many other molecules, proteins tend to form crystals in supersaturated 
aqueous solution (Rupp, 2010). However, the crystallization of macromolecules, 
including protein, nucleic acid or macromolecule complex, still has no comprehensive 
theory. The production of macromolecule crystals is based on several principles, 
previous experience and even an exhaustive search of conditions. The solution of 
macromolecule structure through XRC can be divided into several steps: (1). 
requirement of single crystal, (2) X-ray diffraction, (3) processing of X-ray data and (4) 
model building and refinement (Figure 1.18).  
 
 
Figure 1.18. Brief procedure of protein XRC from crystal to structrure (Acharya and Lloyd, 
2005) 
 
XRC techniques rely on the exclusive scattering of X-rays, which is known as 
diffraction, by the electrons in the analyte molecule. X-ray diffraction from single 
crystals can be described by Bragg’s law: 
2      =    
where λ is the wavelength of the X-ray, d is the distance between planes of identical 
repeating atoms in crystal, and θ is the angle of the incident light (Bragg and Bragg, 
1913). The initial X-ray data collected is a set of diffraction images which reflect the 
periodicity of the crystal architecture, including the location and intensity of each set of 
planes in a crystal. The diffraction pattern contains diffraction spots, each of which 
correspond to a point of reciprocal lattice representing an X-ray wave with an amplitude 
(intensity of the light) and relative phase (a position of point of time). However, the 




overall scattering from a particular set of Bragg planes cannot be calculated, that is 
called “the phase problem”. There several ways to solve the phase problem, for example, 
multiple isomorphous replacement (MIR), in which heavy atoms are inserted into the 
crystal then the scattering factors are calculated using the location of heavy atoms in 
the lattice which dominate the scattering (de La Fortelle and Bricogne, 1997). The phase 
problem can also be solved through molecular replacement (MR) if there is analogous 
structure with known phase (Scapin, 2013). 
 
The structure factor F: 
 
contains both the amplitudes “f(j)” and phases “exp[2π·i(hx(j)+ky(j)+lz(j))” of all the atom 
in the crystal, then the summation of these leads to an initial electron density map, 
through Fourier synthesis (Rupp, Bernhard, 2009): 
.  
Based on the electron density map, a model of the crystallized molecules can be built 
and refined. The structure factor used in calculation of the initial map, Fobs (or Fo), is 
only an approximation of the true F due to the phases being only an estimation. Fcalc (or 
Fc) generated from the initial model is used to calculate the Fobs-Fcalc map, also known 
as the difference map. During rebuilding, a 2Fobs-Fcalc map, which is calculated using 
both the observed structure factor and that calculated from the model, is normally used 
to inform the structural features and quality of the result in practice (Wlodawer et al., 
2008).   
 
At the stage of initial phasing and subsequent model building, the model is still far from 
perfect. Therefore, additional rounds of refinement are required, to improve the phase 
and quality of the model. Refinement is normally achieved through statistical 




the important parameters of the refinement process is the “working R factor” (Rfactor or 
Rwork):  
R ( ) ( ) / ( )factor obs cal obs
hld hld
F hkl F hkl F hkl    
which describes the difference between the calculated structure amplitudes and the 
experimental amplitudes. However, approaches to reduce the Rfactor, may introduce bias, 
because the refined model is changed to fit features of the electric density map, which 
might be incorrect or incomplete. Thus, the “free R factor” (Rfree), which is calculated 
by the same methodology as the Rfactor but using a section of data not used in the Rfactor 
calculation, was introduced to validate the accuracy of the refined model (Brunger, 
1992). Two methods are frequently used in refinement, maximum likelihood, which 
tries to minimize the Rfactor (Murshudov et al., 1997), and simulated annealing, which 
allows the introduction of additional randomness by heating then rerefining the 
coordinates while they are being “cooled down” (Brunger and Rice, 1997).  
 
However, XRC also has some limitations. Firstly, large molecules are not easy to 
crystallize, the large size, high complexity and flexibility of biological macromolecules 
results in difficulty in crystallization. Secondly, the conditions under which a protein 
crystallises are normally unpredictable. Therefore, it can be a time-consuming process 
to find appropriate crystallization conditions. Additionally, it can be a problem to obtain 
the phases when direct methods cannot be used, for example, at lower resolution, when 
heavy atom soaking breaks the crystals, and no analogous structure can be used for MR. 
These several reasons restrict the application of XRC. Nevertheless, XRC is still one of 
the most reliable approaches in bio-macromolecule structure determination.   
 
1.5. Summary of previous X-ray crystallography structure studies of TcTS 
 
During the last decade, many efforts have been carried out to investigate the 
mechanisms and inhibition of TcTS using crystallographic methods. 10 crystal 




structure of TcTS was determined by Buschiazzo et. al. in 2002, after introducing 7 
surface mutations based on T. rangeli sialidase which has already been crystallized 
(Buschiazzo. et al., 2002), including the unliganded structure in different crystal forms 
(PDB: 1MR5, 1MS3, 1MS4), the structure in complex with substrates (PDB code: 
1MS0, 1MS5) and in complex with inhibitors (1MS1). These crystal structures showed 
the structure of TcTS, indicated the catalytic mechanisms which differ from other 
sialidases, and also presented the secondary binding site for lactose constituted by 
Tyr119 and Trp312. 
 
Table 1.1 List of the crystal structures of TcTS in the PDB 
PDB code Structure details Reference 
1MS0 




Buschiazzo et. al. 2002  
  
  
1MS1 Monoclinic form of TcTS, in complex with DANA 
1MS3 Monoclinic form of TcTS 
1MS4 Triclinic form of TcTS 
1MR5 Orthorhombic form of TcTS 
1S0I TcTS in complex with sialyl-lactose 
Amaya et al., 2004 1S0J TcTS in complex with MuNANA  
2AH2 TcTS in complex with 2,3-difluorosialic acid  
3B69 
TcTS complex with benzoylated NANA derivative 
(inhibitor) 
Buchini et al., 2008  
3POZ 
TcTS in complex with the Fab fragment of a 
neutralizing monoclonal IgG antibody 
Buschiazzo et. al. 2012 
 
However, the first series of TcTS structures failed to obtain a structure with the full-
length substrate, neither the natural substrate SAL nor the non-natural substrate 




crystal, the substrate can still be hydrolysed and sialyated in the presence of an 
appropriate acceptor, therefore, when soaking or co-crystallizing active TcTS with 
substrate it is difficult to obtain a catalytic intermediate structure with high occupancy 
level of substrate. In addition, conformational changes of TcTS during the catalytic 
process might damage the crystal, leading to poor diffraction. To solve this problem, 
Amaya et.al introduced an extra mutation D59A in the catalytic pocket, removing the 
negative side chain of residue Asp59 which breaks the substrate glycosidic bond, thus 
the natural ligand can bind stably without hydrolysis (Amaya et al., 2004). The 
Michaelis complex structure of mutated TcTS and substrate is the first structure in 
which both SA moiety and lactose moiety were present in the catalytic site. Even though 
the construct using in this study is inactive, the Michaelis complex structures (Figure 
1.19) provide strong evidence of the catalytic mechanisms, especially the mechanism 
of transfer SA activity.  
 
Crystal structure studies are also widely used in drug discovery. So far, only limited 
numbers of drug-bound TcTS structures have been reported since there is still no 
effective inhibitor for TcTS. As a weak inhibitor (IC50=12mM), DANA is the most 
intensively studied inhibitor against TcTS. Based on both crystal soaking and co-
crystallized structures, DANA binds to the SA binding site of the TcTS active site and 
has similar interaction with TcTS compared to those seen with SA. Moreover, when a 
TcTS crystal was soaked with NA-S-Gal (PDB: 1MS05) only DANA could be defined 
in the catalytic site instead of SA, and no galactose could be seen in the structure 
(Buschiazzo. et al., 2002). These results suggest that DANA can be a by-product of the 
catalytic activity and explains why it is only a weak inhibitor of TcTS. Although it binds 
well to the active site, it is unable to form the glycosidic bond due to its lack of the C2-
oxygen. Another two NANA derivatives, 2,3-difluoroSA and 5-(acetylamino)-9-
(benzoylamino)-3,5,9-trideoxy-3-fluoro-D-erythro-α-L-manno-non-2-ulopyranosonic 
acid (BFN), were also study by XRC (Buchini et al., 2008). All these ligand-soaked 
structures were of TcTS in complex with SA derivatives inhibitors, however, neither a 




although molecular dynamic simulations have been predicted the interaction between 
inhibitor and TcTS catalytic site. Interestingly, a large number of SA derivatives have 
been reported to be good binders in the active site due to their high occupancy in crystal 
structure, but they are only weak inhibitors of TcTS.  
 
However, some of the best reported inhibitors are non-competitive inhibitors, which 
means they do not bind in the catalytic site of TcTS but in another unknown binding 
site (Arioka et al., 2010). Apart from the catalytic pocket, no other binding site has been 
defined for TcTS, not even in the lectin-like domain, which has been shown to bind 
carbohydrates in many sialidases and T. congolense trans-sialidases (Waespy et al., 
2015). Therefore, interpreting the structure of TcTS complex with non-competitive 
inhibitors will be helpful to understand more details of the protein-ligand interaction 
and the multiple functions of TcTS. 
 
1.6. Overview of this thesis 
 
The aim of this PhD project was to design, synthesis and evaluate α-aminophosphonate 
compounds as a new type of TcTS inhibitor which was designed by structure mimicry 
of the natural substrate of TcTS.  
 
Chapter 2 describes the design and the synthesis of α-aminophosphonates derivatives. 
The expected binding manner of these α-aminophosphonates is competitive binding 
with both the SA binding site and lactose binding site, and the substituents were 
designed based on a stable interaction with the catalytic site. The structural geometry 
and binding energy have also been predicted by molecular docking. In the second step, 
α-aminophosphonate compounds were synthesized through a one-pot microwave 






Chapter 3 discusses the structure-activity relationship (SAR) of α-aminophosphonates. 
The best compound shows good inhibition and high selectivity compared with the 
previously-reported TcTS inhibitors. Nevertheless, after determination of the inhibition 
mode, all compounds were shown to inhibit in a non-competitive manner, suggesting 
that α-aminophosphonate does not interact with the TcTS active site.  
 
Chapter 4 describes the crystal structures of TcTS complexes with inhibitors. Crystal 
structures of TcTS-α-aminophosphonate complexes were determined to identify the 
novel binding site between the catalytic and the lectin-like domain, which is the first 
reported allosteric site of TcTS. The novel binding site was validated by site-direct 
mutagenesis and introduction of anthraquinone, a known non-competitive inhibition by 
itself, into the α-aminophosphonate compound.  
 
Chapter 5 provides further investigation of the mechanism of the allosteric inhibition 
by α-aminophosphonate, dual soaking with inhibitor compounds and lactose has been 
measured and lactose was detected in lactose binding site, which is not visible when 
crystals are soaked in lactose alone. From the crystallization results hypothesis was 
drawn that allosteric binding of α-aminophosphonate compounds induce the formation 
of lactose binding site, which is normally induced by SA binding, then blocks the 
entrance or release of substrates, resulting in inactivation.  
 
All results are generally discussed with a conclusion in Chapter 6. The experimental 
details are given in Chapter 7. 
 
The identification of the inter-domain allosteric site provides a new structural site for 
further rational drug design and suggests ideas for investigation of the catalytic 
mechanisms. This study favors further TcTS inhibitor development as a potential 

































TcTS has been considered as a potential target for therapy of Chagas disease. However, 
the unique structure of the catalytic site compared to other sialidases results in 
traditional sialidase inhibitor only presenting weak inhibition against TcTS. Therefore, 
it is urgent to develop novel inhibitors based on the uniqueness of TcTS, not only to 
develop drug candidates against Chagas disease, but also to benefit further investigation 
of TcTS mechanism and functions. However, the broad screening of compounds using 
databases has been done without any strong inhibitor being identified. The design of 
new compounds could be a potential approach to discover potential TcTS inhibitors. 
 
In modern drug discovery and development, structure-based drug design plays an 
increasingly important role as better structure determination techniques have increased 
the quality of target-ligand complex structures. Structure-based drug design has been 
successfully applied in development of influenza neuraminidase inhibitors. In terms of 
TcTS, as an enzyme which has unique structure and catalytic mechanism within the 
sialidase/neuraminidase family, there is the potential to develop specific inhibitors 
through investigating the protein-ligand structure. 
 
This chapter describes the structure-based design of α-aminophosphonate derivatives 
as effective and selective inhibitors against TcTS activity. Initially, the α-
aminophosphonate scaffold was designed based on structure mimicry of sialyllactose 
(SAL), the natural substrate of TcTS. Molecular docking also shows that the α-
aminophosphonate compounds bind to TcTS catalytic site with a high predicted binding 
affinity, as designed. α-aminophosphonate compounds are synthesized by a two-step 







2.2. Design of α-aminophosphonate derivatives as TcTS inhibitors 
 
Structure-based drug design is regarded as a useful, rational, and promising method in 
drug development. In the past few decades, the improvement of protein structure 
determination techniques such as X-ray crystallography and NMR makes it possible to 
design specific new drugs via analyzing the structural characteristics of specific targets. 
Although there are still limitations of structure-based drug design, for example 
candidate compounds might not interact with the predicted binding site even though 
calculations predict good docked geometry and binding energy, there are still some 
success stories. For example, the discovery of zanamivir, an inhibitor toward influenza 
neuraminidase (which also targets sialic acid), was based on the crystal structure of 
influenza neuraminidase, and the structural characteristics of the active site were also 
considered in the inhibitor’s further development. Thus, for discovery of novel 
inhibitors targeting TcTS, structure-based drug design could be a useful strategy to find 
drug candidates which are specific to TcTS.    
 
The natural substrate of sialidase family is sialyl-glycans (Palese et al., 1973). However, 
TcTS only shows hydrolysis and transfer activity for 3’- sialyl rather than 6’-sialyl, and 
shows highly effective activity on 3’-Gal substrates (Vandekerckhove et al., 1992). 
Therefore, a common substrate, α-NeuNAc-(2→3)-β-D-Gal-(1→4)-D-Glc 
(sialyllactose, SAL, Figure 2.1 A) was selected as a model for rational design of 
potential TcTS inhibitors by structure simplification and mimicry. 
 
Based on the interaction with TcTS, the structure of SAL can be divided into four 
functional regions for rational drug design: lactose, sialic acid, sialic acid carboxyl and 
glycosidic oxygen (Figure 2.1 A). Firstly, the lactose (or other oligosaccharides) moiety 
which stacks within the lactose binding site, and the sialic acid moiety which interacts 
with the sialic acid binding pocket which is structurally conserved among the 
sialidase/trans-sialidase family. Part of the sialic acid moiety, the carboxyl group 




links the sialic acid and lactose moiety through a glycosidic bond, is cleaved by TcTS 
through Asp59, which acts as an acid catalyst (Amaya, et al., 2004).  
 
In the design of inhibitors, to mimic the structure of the lactose, the cyclic 
monosaccharide structure was simplified and replaced by aromatic groups (R2 group, 
Figure 2.1 B), since rigid aromatic groups have more stable structures than the 
monosaccharide cyclic structure and might have stronger π-stacking with TcTS Tyr119 
and Trp312 (Figure 2.1 C) (Hunter and Sanders, 1990). Potential R2 groups could be 
benzene, naphthalene, biaryls, or anthracene (Figure 2.1E).  
 
For the sialic acid moiety, the cyclic configuration of sialic acid was replaced by other 
cyclic structures, for example alkyl, phenyl, C5-6heteroaryl, C5-6carbocyclyl, or C5-
6heterocyclyl, with suitable substituents (RX) (Figure 2.1 D). The carboxyl group is 
another important region for consideration for rational drug design for both sialidase 
and trans-sialidase due to the highly-conserved arginine triad. In most cases of rational 
drug design based on sialic acid structure, the carboxyl group tends to remain, but also 
there are examples where it is replaced by other moieties, and a phosphate group is one 
of the most common substitutes (Wang et al., 2016; White et al., 1995). In the research 
reported here, a phosphonate group is also being used to replace the carboxyl group.  
 
Replacement of the carboxyl group in SA by a phosphate has been used in the 
development of sialidase/neuraminidase inhibitors. For example, the phosphonate 
analogue of SA is an influenza neuraminidase inhibitor (38, Ki= 0.2mM, Figure 2.2) 
(Chan et al., 1997). Replacing the carboxyl group in peramivir to phosphonate also 
improves the inhibition effect against influenza NA (39, IC50 = 5.2 nM, Figure 2.2) 







Figure 2.1. Structure of Sialyllactose: Yellow: carboxyl group of SA; blue: rest of SA, green: 
lactose and red: glycosidic oxygen (A), design of α-aminophosphonate inhibitor by molecular 
mimicry (B), and the interaction between SAL and TcTS, as seen in PDB: 1S0I, diagram 
generated by LigPlot Plus (C) (adapted from Amaya, et al., 2004). Structures of potential R1 








Figure 2.2. Structure of phosphonate analogue of SA (38) and peramivir (39) 
 
Therefore, in this design of TcTS inhibitors, the cyclic structures of SA, lactose and 
glucose are replaced by aromatic groups, which are expected to bind to the lactose 
binding site through π- π interaction. The oxygen at the glycosidic bond is changed to 
be a nitrogen, which is expected to interact with Asp59 stably via acid-base interaction, 
rather than being hydrolyzed. 
 
2.3. Prediction of α-aminophosphonate-TcTS interaction by Molecular 
docking 
 
The α-aminophosphonate compounds were designed to inhibit TcTS activity by 
interacting in the catalytic pocket. To predict the position and affinity of TcTS-inhibitor 
interactions, molecular docking methods were used to simulate the interactions at the 
TcTS sialyllactose binding pocket. Protein models were prepared based on the structure 
of the active state of TcTS (PDB: 1S0I). Firstly, the screening of different R2 groups 
was performed with the sialic acid mimic fixed as benzene. From the prediction by 
Autodock Vina (Table 2.1), the R2 groups with the strongest binding were the 1- 
Naphthalene and 1-Anthracene. Therefore, these two substituents were selected for 
sialic acid moiety virtual screening. The ring of the sialic acid was replaced by a phenyl 
moiety with substituents including nitro, acetamido, and carboxyl groups.  
 






to have appropriate binding with the arginine triad with interaction distances between 
2 and 3 Å. The amino nitrogen and N-linked aryl group are also at the predicted position. 
The introduction of naphthalene or anthracene did not seem to change the overall 
binding conformation. In terms of the substitutions at the sialyl-mimic phenyl, 4-
acetamido and 4-nitro groups interacted with Asp96 and Trp120 respectively (Figure 
2.3 B). 
 






















44 2-Biaryl -4.8 









48 1-anthracene -10.3 




















53 4-acetamido phenyl Asp96 -9.6 
54 4-nitro phenyl Trp120 -9.8 
55 4-nitro phenyl Trp120 2-Biaryl -8.7 
56 4-nitro phenyl Trp120 3-Biaryl -7.9 







59 4-acetamido phenyl Asp96 -12.3 
60 4-methyl ester phenyl Asp96 -11.8 
61 4-benzonic acid Trp120 -12.1 
 
Figure 2.3. Docking conformation of different predicted compounds with TcTS. (A). Binding 
conformation of compound with R1=H, R2=naphthalene (orange) or anthracene (blue), 






2.3.1. Synthesis of α-aminophosphonate compounds 
 
α-aminophosphonate compounds have been shown to have several chemical properties: 
firstly, they are known as effective chelating agents (Kiss et al., 1994), they can also 
inhibit nucleation and crystal growth of small molecules, for example barium sulfate 
and calcium carbonate (Guo and Severtson, 2004; Jones et al., 2003), furthermore, they 
present high stability in harsh chemical environment.  
 
Applications of aminophosphonates can be found from agriculture to medicine; enzyme 
inhibitors, anticancer agents, antibiotics, neuro-modulators, plant growth regulators and 
herbicides, antibacterial, and many other uses (Flynn et al., 1985).   
Aminophosphonate compounds play an important role in medical chemistry since it 
contains a P-C bond and amino bond (Figure 2.4). During last fifty years, plenty of α-
aminophosphonate compounds have been synthesis and intensively studied as the 
analogues of amino acids (Naydenova et al., 2010).  
 
 
Figure 2.4.  Structure of α-aminophosphonate 
 
 
The chemical synthesis of aminophosphonate has been intensively studied and numbers 
of methods are now available. Organophosphorus compounds, which are widely used 
in organic synthesis, are reported to be used in aminoalkanephosphonic acids synthesis. 
However, the most widely used and the earliest reported method for the synthesis of 
amino-phosphonates is the Kabachnik-Fields reaction (KFR), which prepares an α-
aminophosphonic acid using a carbonyl compound, an amine and a dialkyl phosphonate 












KFR can be divided into two steps (Figure 2.4). The first step is the reaction of an 
aldehyde with an amine to form an imine, and the second step is the reaction of P-H 
bond from phosphonate with the C=N bond in the imine (Pudovik reaction) to form the 
aminophosphonate (Naydenova et al., 2010).   
 
Figure 2.5. Mechanism of one-pot KFR (Naydenova et al., 2010) 
 
The reaction methods and conditions were intensively studied. In our study, two 
conditions were tested: microwave heating (solvent free, 90W, 5min) and reflux (THF, 
50°C, 24 hours). The result (Figure 3, MPharm. Thesis, Chang, 2012) presents that 
solvent free microwave heating obtained significantly higher yields than long reflux, 
thus the subsequent reactions followed the one-pot solvent free microwave method. 
 
Figure 2.6. Yield of one-pot KFR through microwave heating and Reflux (adapted from 
Chang, 2012) 
 
An aldehyde and amine (1:1 in molarity equivalent) are desolved in dimethyl phosphite 
(5-10 molarity equivalent). The reaction mixture is heated for 5min at 90W in a kitchen 
microwave. After reaction, the reaction mixture is extracted with CH2Cl2 and washed 

















concentrated. The mixture was chromatographed on silica gel (EtOAc/PetEther) to give 
the protected compound.  
 
In the second step of reaction, the methyl groups in dimethyl phosphite were removed 
using trimethylsilyl bromide (TMSBr) (Figure 2.6). One equivalent (molarity) of 
protected compound was dissolved in anhydrous CH2Cl2 (2ml) and anhydrous DMF 
(1ml), following resting on an ice bath for 10min, the TMSBr was added dropwise (2.5-
5 equivalent). The reaction mixture was stirred on the ice bath for 30min, then was 
allowed to warm up to room temperature for 2.5hr to 24hr. The reaction was monitored 
by detecting the chemical shift of 31P-NMR, which will completely shift from 25ppm 
to around 16ppm. ddH2O is added to the reaction mixture and the content is neutralized 
to pH8 by the addition of 1M NaOH dropwise. The product was concentrated and 




Figure 2.7. Mechanism of deprotection by TMSBr (Gutierrez, et.al., 1999) 
 
α-Aminophosphonate compound 41-61 have been synthesized for SAR screening 
(compound 43, 46, 47, 49 and 56 have been synthesized by MSc student Poyee Kowk). 
The reaction condition and yield of first step microwave assist KFRs are shown in table 
3.2. Conditions and yield of deprotection reaction is listed in table 2.3 (detailed 
























Table 2.2. List of protected aminophosphonate compounds 
 





S41 Phenyl Phenyl 5 75 
S42 Phenyl 1-Naphthalene 5 85 
S44 Phenyl 2-Biaryl 7 84 
S45 Phenyl 3-Biaryl 5 76 
S48 Phenyl 1-Anthracene 9 87 








1-Naphthalene 7 84 
S53 4-Acetamido phenyl 1-Naphthalene 8 72 








1-Anthracene 7 76 
S59 4-acetamido phenyl 1-Anthracene 8 43 
S60 4-methyl ester phenyl 1-Anthracene 7 72 
 
 























Product Yield (%) 
41 S41 5 
 
94 
42 S42 3 
 
82 
44 S44 4.5 
 
74 
45 S45 7.5 
 
86 
48 S48 8 
 
74 
50 S50 4.5 
 
79 
51 S51 5 
 
64 



























Product Yield (%) 
53 S53 2.5 
 
94 
54 S54 4.5 
 
59 
57 S57 5 
 
56 
58 S58 3 
 
63.1 
59 S59 4 
 
41 
60 S60 6.5 
 
76 
61* 60 - 
 
80 









Generally, the KFR step gives averagely good yield about 70 %, and the yield of 
naphthalene/bi-aryl compounds (mainly higher than 70%) are better than the anthracene 
compounds (40 % - 50 %). That might result from the fact that the anthracene 
compounds are more difficult to purify, i.e. compound 57 and 58 require extra column 
chromatography purification to obtain the desirable purity (>95 %), and further purified 
by recrystallization was performed in the synthesis of compounds 59 and 60 to remove 
the impurities. These extra purification steps could significantly reduce the yield of the 
products.  
 
The second step gave the desired compounds which were designed as TcTS inhibitors, 
with a yield from 40 % - 80 %. The deprotected compounds have good solubility, which 
is appropriate for a TcTS inhibitor that will function extra cellularly, since TcTS is 
tethered to the outside of the Tc membrane. And avoiding penetration across the host 
cell membrane can also reduce the potential for cytotoxicity, because within the cell 













































As described before (Chapter 2), initial structure α-aminophosphonate derivatives were 
designed through molecular mimicry of SAL, and further modifications are generated 
based on the interaction between SAL and TcTS catalytic site and virtual screening of 
a series of compounds performed by molecular docking. In computational screening, 
the α-aminophosphonate structure fits the geometry of TcTS catalytic site, and the 
binding energy predicted that the α-aminophosphonates could be potential class of 
TcTS inhibitor with the lowest docking score (predicted binding energy) of about   -
12 kcal/mol, which is equal to micromolar levels of half maximal (50%) inhibitory 
concentration (IC50) (Cosconati et al., 2010).  
 
This chapter will begin with the description of the IC50 screening of synthesized α-
aminophosphonate compounds (41-61) to evaluate inhibition effects of this novel type 
of inhibitor and whether the results of in vitro screening can be related to the virtual 
screening. The specificity of this type of potential TcTS inhibitor through comparing 
inhibition effects against bacterial sialidases will also be described. Furthermore, the 
inhibition mode will be discussed and inhibition constant (Ki) will be calculated. Later, 
time-dependent inhibition and thermodynamic studies were carried out to explain the 
mechanism of TcTS inhibition by α-aminophosphonates. 
 
3.2. Expression, purification and characterization of TcTS 
 
Screening of expression conditions of TcTS had been carried out previously (Chen, 
MSc thesis, 2013) with a range of IPTG from 0.2mM to 1mM, and of temperature from 
16°C to 37°C. Induction at 25°C using 0.5mM IPTG was found to be the optimal 
condition . In His-trap nickel affinity chromatography, a single peak was present in the 
early stage of elution (around 20%-50% of elution buffer). In the example shown, peak 




PAGE (Figure 3.1 B), the darkest band for each fraction at around 71 kDa is the 
predicted product. However some impurity bands are still present at around 50, 45, 30 
and 25 kDa. The fractions that eluted from the His-trap column gave 75-85% purity 
which is adequate for enzyme activity determination or other low-sensitive enzyme-
ligand assays, but did not reach the purity needed for crystallization or high-sensitivity 
assays.  
 
Figure 3.1. Chromatogram of TcTS His-trap purification (A) and SDS gel of peak fractions (B); 
Chromatogram of TcTS Anion-exchange purification (C) and SDS-PAGE gel of peak fractions 
(D). 
 




purification (fraction A4-A7) to eliminate the impurities. An example chromatogram 
showing peaks eluted from the anion exchange column is shown in Figure 3.1 C, from 
which fractions A7 to A9 were collected. As shown on the SDS-PAGE gel (Figure 3.1 
D), all three fractions show a single band which is of the size of TcTS (71kDa), showing 
that the secondary purification has reached a level of purity that is adequate for 
crystallization. 3-5mg of protein was obtained from a 1mL culture. Pure TcTS was 
stored in PBS with 0.2% BSA, pH7.4, and placed at -80 °C until use.  
 
Measurement of enzyme kinetics is important for drug candidate screening. Although 
the enzyme kinetics parameters of these enzymes are known, it was worthwhile to 
determine these before inhibitor screening since differences may occur in different 
environments. The Michaelis constant Km, maximum activity rate Vmax, and turnover 
number kcat were determined.  
Figure 3.2. Non-linear curve fitting of rate against substrate concentration assay of TcTS  
 
Table 3.1. Kinetic parameters for the hydrolysis of MuNANA by the TcTS  
 
Km(mM) kcat (s-1) kcat /Km (mM-1 s-1) 
TcTS 0.15±0.03 3.8±0.43 25.3 
 
The result of kinetics characterization is shown in Figure 3.2 and table 3.1. The Km 
value of TcTS hydrolysis using MuNANA as substrate is about 0.15mM, which is 
similar to that in the literature (0.19 mM, Amino et al., 1998), and the turnover number 
(kcat) is 3.8 S-1. 
 


















3.3. The identification of α-aminophosphonate as TcTS inhibitor 
 
The assay to determine TcTS activity and the inhibition effect of the novel inhibitors 
used 2’-(4-Methylumbelliferyl)-α-D-N-acetylneuraminic acid (MuNANA), which has 
been widely used for detecting the enzyme activity of sialidase and TcTS. In this case, 
MuNANA was employed as the substrate of TcTS, the enzyme activity and inhibition 
being evaluated through fluorescence at the wavelength of 360 nm and 460 nm from 
released 4-methylumbelliferone via catalytic reaction.  
 
The first step of catalytic activity is to cleave sialic acid from host sialyl 
oligosaccharides. Therefore, determining the hydrolysis activity in the presence of 
inhibitors is the quickest way to evaluate a potential inhibitor, and it has been the most 
common strategy in candidate screening of TcTS (Arioka et al., 2010). Structure-
activity (SAR) screening of α-aminophosphonates against TcTS hydrolysis activity 
began by looking at different substitutions in R2 groups, described as the lactose 
mimicry group. Based on the R2 group screening, the best candidates were selected for 
further screening of R1 groups, the sialic acid binding substitutions. The IC50 assays 
were performed using purified TcTS with the concentration 0.05 mg/ml. TcTS in assay 
buffer (TcTSassay, Appendix 8.4) was initially pre-incubated at 35°C for 10 mins with 
10 μl inhibitor (dissolved in distilled water) in a gradient of final concentration from 
15mM to 0.001mM. By detecting the changes florescence levels of reaction mixture 
with different concentration of inhibitor in the same period of time, the percentage of 
inhibition and IC50 can be calculated. 
 
 












SAR analysis of R2 groups 
SAR screening of R2 group sought to optimize the aromatic group that stacks in the 
lactose binding site. This screen substituted R2 for different aromatic groups from a 
single phenyl to multiple ring structures such as naphthalene and anthracene whilst 
maintaining the sialic acid mimicry moiety as a phenyl group. The IC50 results of 
compounds with different R2 group including phenyl, napthyl, biaryl and anthracene, 
are shown in Figure 3.4 and Table 3.2.  
 
Firstly, the inhibition effect is positively correlated to the number of aromatic centres. 
Compound 41 (R2=phenyl) cannot fully inhibit TcTS activity even in high 
concentration (40% activity remaining in 10mM compound 41), but the inhibition 
effect is significantly increased for the compounds which have multiple ring aromatic 
groups in R2, such as naphthalene and anthracene. Additionally, the conformation of 
the R2 groups also has a significant effect on the inhibition effectiveness. For instance, 
compound 42 which has 1-napthalene in R2 gives an IC50 of 0.47mM, whilst the 
compound that has 2- naphthalene in the same place (compound 43) has an IC50 of only 
0.75mM. Similar results are also observed for biaryl compounds, the 2-biaryl 
compound (compound 44) has a significant lower IC50 then the 3-biaryl compound 
(compound 45). Furthermore, an additional methyl group between the amino group and 
the aromatic group does not help to improve the inhibition effect against TcTS, for 
example, both compounds 46 and 47 only show limited inhibitory effect. 
 
R2 group screening indicates that α-aminophosphonate derivatives are possible 
candidates to inhibit the activity of TcTS. The results of molecular docking suggested 
that the type and conformation of R2 group are related to the predicted binding energy, 
which is roughly borne out by the SAR screening. Remarkably, several 
aminophosphonate compounds present IC50 values in low millimolar to high 
micromolar levels, indicating that α-aminophosphonate derivatives could be a potential  




=0.041mM), with naphthalene and anthracene in R2 group, were highlighted in this first 
round of screening and were used for further screening of R1 groups. 




Table 3.2. List of α-aminophosphonate compounds and their IC50 against TcTS for R2 screening 
SAR analysis of R1 groups 







~0.888 ~1.190 ~7.73 
42 
 
-0.321 -0.073 0.470 
43 
 
-0.295 0.076 0.51 
44 
 
-0.204 0.025 0.63 
45 
 
0.746 0.240 5.58 
46 
 
0.621 0.199 4.24 
47 
 
0.375 0.209 2.374 
48 
 




Based on the result of R2 screening, several highlighted candidates were selected for 
the screening of the R1 groups, including 1-naphthalene and 1-anthracene, which are 
two of the R2 groups that have the highest inhibitory effect. Bi-aryl groups are also used 
as R2 in to evaluate the R1 group in the presence of different R2 groups. The R1 group 
screening was carried out to improve the inhibition effect, and possibly, specificity by 
changing various substitutents on the sialic acid moiety phenyl. In this study, the 
alternation of R1 groups in the sialic acid moiety is achieved by changes to different 
modified benzaldehydes in the chemical synthesis. The R1 groups that have been 
screened in this study include nitro, methyl, acetamido, carboxyl, halogens and 
trifluoromethyl. All the screened R1 groups have been evaluated through molecular 
docking for their ability to interact with critical residues in the TcTS catalytic site whilst 
still fitting the structural geometry.    
 
The IC50s resulting from the R1 group screening are shown in figure 3.5 and table 3.3. 
The addition to the R1 group in the sialic acid moiety phenyl group can either increase, 
maintain or decrease the inhibitory effect against TcTS. As a side chain on sialic acid, 
introduction of an acetamido group in the sialic acid moiety can significantly help 
aminophosphonate compounds to inhibit TcTS activity. The IC50 of the 4’-acetamido-
phenyl-naphthalene compound (compound 53) is 0.23 mM, which is about half that of 
the phenyl-naphthalene compound (0.47 mM, compound 42), the IC50 of which is 0.47 
mM. The same effect of an acetamido group has been shown in anthracene compounds, 
compound 59, the 4’-acetamido-phenyl-anthracene compound is the best inhibitor in 
this study, which has an IC50 of 15 μM, significantly lower than the related phenyl-
anthracene compound, compound 48 (IC50 = 45 μM). The addition of a carboxyl group 
at the 4’ position of the sialic acid moiety phenyl group obtains a decent drop of IC50 
(compound 61, IC50 = 21 μM). A 4’-Nitro group was shown to improve inhibition of 
naphthalene and bi-aryl compounds (compound 14, 15 and 16), but synthesis of 











Figure 3.5. Non-linear curve fitting of compounds in R1 screening  
 
Table 3.3. List of α-aminophosphonate compounds and their IC50 against TcTS for R1 screening 







-0.5743 0.053 0.27 
50 
 
-0.151 0.030 0.71 
51 
 
-0.536 0.021 0.29 
52 
 
0.371 0.132 2.35 
53 
 
-0.638 0.047 0.23 
54 
 
-0.677 0.084 0.21 































-0.376 0.102 0.42 
56 
 
-0.193 0.056 0.64 
57 
 
-0.585 0.098 0.26 
58 
 
-0.619 0.087 0.24 
59 
 
-1.816 0.027 0.015 
60 
 
-1.229 0.043 0.059 
61 
 






Halogen bonding plays an increasingly important role in modern drug design because 
of its unique chemical properties (Lu et al., 2012). However, the modification of 
halogens on R1 groups did not show a positive effect for aminophosphonate compounds 
when inhibiting TcTS activity. Although the IC50 was improved for the 4’-
triflouromethyl-phenyl- naphthalene compound (compound 51), the inhibition effect 
become worse when trifluoromethyl group was added to different positions in 
anthracene compounds (compound 57, 58). Chloride modification also resulted in 
weaker inhibition when added at the para position of the sialic acid moiety phenyl group 
(compound 50). 
 
3.4. Evaluation of specificity of α-aminophosphonate 
 
3.4.1. Expression, purification, and characterization of bacterial sialidases 
 
Purified Clostridium perfringens neuraminidase (CpNA) was purchased from sigma. 
The expression conditions for Staphylococcus pneumoniae neuraminidase A (SpNA) 
have been screened by the group of Prof. G. Taylor (University of St Andrews, UK) 
from whom the plasmid was obtained as a gift. 1 L expression in E. coli was performed 
by adding IPTG until concentration to 0.5mM then incubated at 25 °C for 14-16 hours. 
Following cell lysis, His-trap purification resulted in a single peak e.g. from fraction 
A13 to B2 (Figure 3.6 A), the fractions were then evaluated by SDS-PAGE (Figure 3.6 
B). Compared to TcTS, SpNA shows a higher level of both target product (represented 
by the band at 74 KDa) and overall protein expression. Therefore, large numbers of 
impurity proteins were still eluted with target product, resulting in only about 60-65% 
purity. Secondary purification using anion-exchange chromatography effectively 






Figure 3.6. Chromatograph of His-trap purification of SpNA (A) and purity shown by SDS-
page gel (B). Ion-exchange purification of SpNA (C) and SDS-PAGE gel (D). 
 
CpNA has a Km value of 0.15 mM binding with MuNANA, which is similar to TcTS 
(Chapter 3.2). SpNA shows a higher Km to MuNANA (Km=0.041mM). In terms of the 
turnover number, the kcat value of CpNA cannot be determined because the 
concentration is unknown (sold by Unit, not concentration). The kcat of SpNA is 
significantly higher than TcTS using MuNANA as substrate. However, as a non-natural 
substrate, using Km of MuNANA to assess the Km of natural substrates is still difficult, 
but these experiments give a general idea of the kinetic features of three different 







Figure 3.7. Non-linear curve fitting of rate against substrate concentration assay of SpNA (A) 
and CpNA (B)  
 
Table 3.4. Kinetics parameters of SpNA and CpNA using MuNANA as substrate. 
 
Km(mM) kcat (s-1) kcat /Km (mM-1 s-1) 
SpNA 0.041±0.002 109.3±2.5 2.66×103 
CpNA 0.15±0.02 N/A N/A 
 
 
3.4.2. α-aminophosphonate inhibit against bacterial sialidases 
 
For a novel synthesized inhibitor, specificity is another important factor, particularly 
for non-natural molecules. In this section, the inhibition effect of α-aminophosphonate 
compounds was determined against two different bacterial sialidases SpNA and CpNA, 
both have similar structure to TcTS in the catalytic domain with a 6 bladed β-propeller, 
and an extra lectin-like domain. But the lectin-like domain for SpNA and CpNA are 
placed differently from TcTS relative to the catalytic domain and have carbohydrate 






Figure 3.8. Structure alignment of the catalytic domains of TcTS (Blue, PDB: 1MS1), SpNA 
(pink, PDB: 2VVZ and 4C1X) and CpNA (Yellow, PDB: 2VK5) showing the different 
positioning of the lectin-like domains, generated by PyMol. 
 
The IC50s of good α-aminophosphonate candidates (compound 48, 54, 59, and 61) 
were determined against SpNA and CpNA (Figure 3.9, 3.10 and Table 3.4, 3.5). IC50s 
of SpNA and CpNA were determined with the same concentration of TcTS and same 
temperature, but different buffer was used to achieve the optimized activity of bacterial 
sialidases. The α-aminophosphonates show inhibition against bacterial sialidases with 
IC50s in the high micromolar levels, which are all around 8-10 times higher than their 
IC50s against TcTS (Figure 3.11). For example, compound 20 shows an IC50 of 0.015 
mM against TcTS, and for the bacterial sialidases, it has 0.27 and 0.25 mM against 
CpNA and SpNA respectively. The results of bacterial sialidases inhibition indicates 
that the α-aminophosphonates are more specific inhibitors of TcTS rather than bacterial 
sialidases, meaning that the α-aminophosphonates could not inhibit other sialidases 
activity in the concentration at which they can inhibit TcTS. However, even if they act 
as a weak inhibitor for bacterial sialidases, they can still reduce the activity of these 
enzymes. Interestingly, for all three enzymes, the naphthalene compounds have much 




aromatic cores is important for the inhibition. 
 
 
Figure 3.9. Non-linear curve fitting of IC50 of inhibitors against SpNA 
 
 
Table 3.5. Summary of IC50 of inhibitors against SpNA 
Compound LogIC50SpNA Std. error LogIC50SpNA IC50SpNA（mM） 
48 -0.625 0.041 0.237 
54 0.378 0.086 2.388 
59 -0.651 0.031 0.223 







Figure 3.10. Non-linear curve fitting of IC50 of inhibitors against CpNA 
 
Table 3.6. Summary of IC50 of inhibitors against CpNA 
Compound LogIC50CpNA Std. error LogIC50CpNA IC50CpNA（mM） 
48 -0.29 0.11 0.51 
54 0.15 0.052 1.41 
59 -0.56 0.028 0.27 








Figure 3.11. Compilation of IC50 results of α-aminophosphonate compounds against TcTS, 
SpNA and CpNA. Ordinary one-way ANOVA has been calculated by PRISM (p<0.05) 
 
3.5. Mode of inhibition of α-aminophosphonate 
 
The inhibition assays show that α-aminophosphonate can be a potential specific TcTS 
inhibitor as it presents a higher inhibition effect against TcTS than other (bacterial) 
sialidases. Therefore, the mechanism of inhibition becomes important to understand the 
inhibition process and improve the inhibition effect. The mode of inhibition of these 
selected compounds was tested by enzyme kinetics using MuNANA as substrate. Km 
and Vmax were determined with and without inhibitors, and the mode of inhibition 
identified from the change of Km and Vmax with increasing amount of inhibitors. The 
inhibition constant Ki can also be calculated using the appropriate inhibition model. 
 
The Km and Vmax of selected compounds were tested with differing concentration of 
inhibitors. Surprisingly, all detected compounds show a reduction of Vmax with 
increasing inhibitor concentration, whilst the Km values were remaining at the same 
level (Figure 3.12). The characteristics indicate that α-aminophosphonate is a non-












the catalytic pocket. The kinetic results were also fitted to other models such as 
competitive inhibition, mixed inhibition or uncompetitive inhibition, but all of them 
gave large standard error values, suggesting that non-competitive inhibition is the best 
fitting model for the inhibition process of α-aminophosphonates against TcTS.  
 
Since all the compounds investigated show non-competitive inhibition of TcTS, this 
suggest that the binding of this scaffold is not as predicted. Possibly, the simplification 
of the cyclical saccharide structure to an aromatic ring cannot be recognized by TcTS, 
or, unlike other sialidases which can recognize the phosphate group in the inhibitor 
molecules, the TcTS catalytic site can only recognize the carboxyl group at that position. 
Previous reports also identified pyridoxal 5’-phosphate as a weak and non-competitive 
inhibitor of TcTS. Interestingly, the α-aminophosphonates inhibit CpNA by a 
competitive mechanism, with the Vmax unchanged but increasing Km whilst increasing 
the concentration of inhibitor (Figure 3.13), and they also present mixed inhibition 
against SpNA. These kinetics results with bacterial sialidases show the ability of α-
aminophosphonates to bind the sialidase catalytic site, which is also conserved in TcTS, 
but it is unable to be recognized as a substrate mimic in TcTS, suggesting a unique 









Figure 3.12. Non-linear fit (left) and Lineweaver–Burk plot (right) of TcTS activity with 
different concentration of α-aminophosphonate compound 42 (A,B), 48(C, D), 53 (E, F), 54(G, 
H), 59 (I, J), 61 (K, L). 
 
Figure 3.13. Non-linear fit and Lineweaver–Burk plot of CpNA (A, B) and SpNA (C, D) 





3.6. Time-dependent inhibition of α-aminophosphonate against   
TcTS 
 
For most reversible inhibition including competitive, non-competitive and mixed 
inhibition, the inhibition effect does not normally change with increasing time of 
incubation in vitro or dose in vivo. While many irreversible inhibitions, for example, 
covalent inhibition and aggregation-based inhibition, may present time-dependent 
inhibition characteristics (Riley et al., 2007). Therefore, the time dependency of the 
inhibition effect can be an important factor in drug discovery and development to 
evaluate the authenticity of inhibition, to avoid the fake positive of non-specific 
aggregation-based inhibition (Feng and Shoichet, 2006). 
 
The time dependent inhibition (TDI) assay was based on the IC50 assay but the time of 
pre-incubation of TcTS with inhibitors was changed. As in the results shown in Figure 
3.11, the IC50s of two naphthalene compounds (compound 41 and 52) and one 1-
anthracene compound (compound 48) were determined with pre-incubation times of 0, 
10, 30, 60 and 300 mins. Generally, the demand of inhibitor concentration to inhibit the 
activity of TcTS were kept in same level with the pre-incubation time up to 5 hours.  
 
In general, α-aminophosphonate compounds do not show time-dependent inhibition 
against TcTS, which means the inhibition is not affected by the incubation time. 
Although the IC50s without pre-incubation of the three inhibitors were higher than 
samples with longer pre-incubation, this might probably be because of the lack of 
sufficient time for inhibitors to interact with TcTS prior to being challenged with 
substrate. Therefore, from the results of these TDI studies, rather than an irreversible or 
covalent inhibitor, α-aminophosphonate compounds seem to be reversible inhibitors of 










Table 3.7. IC50s of compound 41, 48, 52 with pre-incubation from 0 min to 5 hours. 
Compounds 
0 min 10 min 30 min 60 min 300 min 
IC50 (mM) 
Compound 41 0.51 0.47 0.43 0.55 0.41 
Compound 48 0.08 0.05 0.06 0.07 0.05 

























3.7. Thermodynamic study of α-aminophosphonate-TcTS binding 
 
Thermodynamic characterization, mainly by isothermal titration calorimetry (ITC) is 
useful in drug candidate evaluation, and both binding constants and energy changes 
during the interaction may be obtained. However, some limitations result in not all 
protein-ligand or protein-protein interactions being detectable by ITC.  
 
In an ITC experiment, a large amount of protein sample at high concentration (10-50 
times the Kd) is required to achieve a full titration curve (Damian, 2013). The demands 
of high protein concentration and Kd ratio mean that only high affinity interactions can 
be determined accurately by ITC. Due to these limitations, although several promising 
TcTS inhibitor candidate have been developed, none of them have published 
thermodynamic data, since the best inhibitor against TcTS only have IC50 value in 
micromolar level, which is not equal but close to Kd. However, an expected ITC 
experiment require 50-10 of Protein concentration: Kd ratio (Duff et al., 2011), results 
in which the protein concentration is not easy to reach the ITC experimental 
requirements. 
 
Pure TcTS is only stable at concentrations up to 12 mg/ml (168.3 μM) in either Tris 
buffer or PBS, and it tends to aggregate in solution during ITC experiments (data not 
shown). ITC experiment was performed using NanoITC (TA instrument). Purified and 
degassed TcTS was injected into the sample cell, the ligand solution was loaded by 
syringe and titrated into the sample cell with 250rpm stirring. The temperature change 
for each titration was recorded and a 270 second gap was set between two titrations. 
The results were analysed by NanoAnalysis software (TA instrument) and thermal 
parameters of the interaction were calculated. Several α-aminophosphonate derivatives 
were tested in ITC assays but with most of them the full titration curve was not achieved 




15 μM) and high specificity, the saturation curve was successfully obtained in an ITC 
assay (Figure 3.16). 
 
Figure 3.15. A. Experimental data (up) and non-linear curve fitting (down) of ITC experiment, 
in which 5mM of compound 59 was titrated into 0.16 mM of purified TcTS. B. Thermodynamic 
parameters calculated from ITC experiment. C. A bar chart to present ΔG, ΔH, and –TΔS.    
 
The ITC result gave a binding constant Kd of compound 59 at 12 μM, which support 
the inhibition parameters (IC50 and Ki) obtained from kinetic assays, and suggest that 
the interaction between TcTS and compound 59 is a entropy driven spontaneous 
process, since entropy has higher contribution to the total binding energy than enthalpy. 
The ITC result also indicates a 1:1 binding ratio by the n value between TcTS and 
inhibitor. However, the interacting position and inhibition mechanisms are still unclear 





Kd (μM) 12.09±4.46 
ΔH(kJ/mol) -10.52±0.05 
ΔS(J/mol·K) 58.37 










3.8.1. Molecular docking is unsuccessful in its prediction of TcTS-inhibitor 
interaction 
 
The design of α-aminophosphonate compounds was based on the structure of TcTS 
substrates. However, it has been shown experimentally that they all show non-
competitive inhibition mechanisms, meaning that this class of compounds do not 
interact with TcTS at the catalytic pocket. Although molecular docking simulations 
shows that this class of compounds have high affinity to the catalytic site of TcTS, 
kinetics and thermodynamics results suggest that, in this case, the docking results are 
not reliable.  
 
Comparing the results of molecular docking and enzyme kinetics assays, it can be seen 
that molecular docking might not be a suitable technique to predict or investigate the 
binding of ligands when the binding site or mode of binding is unknown, and the affinity 
predicted by molecular docking cannot be as accurate as the experimental data. To 
increase accuracy of a rigid docking simulation, molecular docking is performed in a 
limited area, In the case of TcTS, no secondary binding sites, only the catalytic site, 
have been reported, hence the difficulty of predicting possible binding sites which have 
not been proved through experiments. More importantly, the macromolecule model in 
the molecular binding protocol used cannot perform major conformational changes, 
even conformational changes of Cα chains. For most docking programs, the flexibility 
of residues is limited to the side chain. Thus, interactions with ligands which may lead 
to conformational changes will be difficult to predict by molecular docking. 
Additionally, molecular docking does not consider the solvent environment of the 
macromolecule, this can also reduce the accuracy of prediction. 
 




TcTS and α-aminophosphonate compounds, it is still a useful tool in drug development. 
For cases in which the binding site of drug candidate is known, and the interaction does 
not lead to major conformational changes, such as most competitive inhibitors, 
molecular docking can be used to interpret the functions of different groups in drug 
candidates, to then improve their effect and specificity by rational modifications. Polar 
or charged substitutions on the 4’ position of the SA-mimic phenyl give a significant 
increase in inhibition and also enhance the solubility of the compound. However, only 
a phenyl group has been screened as the SA-mimic moiety in this study, multiple 
aromatic rings structure such as naphthalene or anthracene could be tested. 
 
3.8.2. Influence of R1 and R2 -phosphonate substitutions on the TcTS 
inhibition effect 
 
Although now known to be a non-competitive inhibitor, different substitutions in both 
R1 and R2 do still affect the inhibition, by some other mechanism than the initial design. 
Therefore, it is more suitable to describe the two moieties of the α-aminophosphonate 
compounds as the aldehyde (AL) moiety and the amine (AM) moiety, which are based 
on the reagent in synthesis, rather than “sialic acid moiety” and “lactose moiety” 
respectively. Although the kinetic results suggest a different mode of inhibition from 
original design, the screening results of both the sialic AL moiety and AM moiety still 
a structure-activity relationship that fitted the original model, for example, an 
anthracene at the amine moiety shows stronger inhibition than naphthalene compounds. 
Although the actual binding site of α-aminophosphonate compounds is not the catalytic 
site, this suggests they might have similar interactions.  
 
For the AM moiety, the screening in this study mainly focused on the type of aromatic 
group but not the modifications on these aromatic groups. Some characteristics can be 
drawn from the AM moiety screening. Firstly, direct linkage of aryl groups at the amino 
nitrogen gives stronger inhibition then linkage with extra carbon (compare between 




chiral center. And the increasing number of aromatic rings enhance the inhibition effect.  
In terms of the AL moiety, adequate modification of the benzene ring on AL group can 
be helpful for inhibition, for example, the introduction of nitro, carboxyl and acetamido 
group enhance the inhibition effect. However, the substitutes containing halogens in AL 
moiety gave limited improvement or even negative effect for the inhibition.   
 
3.8.3. Hypotheses of inhibition mechanism 
 
As a non-competitive inhibitor, the Km value between substrate and TcTS does not 
change when the α-aminophosphonate is bound. Therefore, the location of the allosteric 
binding site and the mechanism of how the α-aminophosphonates inhibit the activity of 
TcTS become important in further investigation and drug development. Two hypotheses 
come from the inhibition study and TcTS structure characteristics. Firstly, the binding 
of the inhibitor could stop hydrolysis progress by effecting key residues in the catalytic 
pocket. Non-competitive inhibition generally means that the Km value of substrate is 
not affected by inhibitor binding, but the catalytic process has been impacted (Su et al., 
2008). Except the catalytic site, no other binding sites on TcTS for substrate or inhibitor 
has been reported. It can be expected that α-aminophosphonate derivatives will not 
interact with residues which directly bind to substrates such as the arginine triad, Tyr342, 
Trp120, and Asp59, but it could limit the catalytic process by effecting other key 
residues, for example, locking Tyr119 in either the closed and open position.  
 
Secondly, the inhibition could be achieved by changing the rigidity of the catalytic site. 
The catalytic site, especially the lactose binding site of TcTS changes conformation to 
release the cleaved donor polysaccharide chains and accept the acceptor polysaccharide 










In short, α-aminophosphonate compounds inhibit TcTS, but show an unexpectedly non-
competitive manner and inhibit TcTS activity by influence of catalytic process rather 
than effect donor substrate binding, since it does not change the Km of MuNANA. It 
can be hypothesized that interaction between α-aminophosphonate and TcTS affect the 
conformation or rigidity of the catalytic site, result in eliminating either hydrolytic 
activity or catalytic product release. A structural study of TcTS-inhibitor complex 
































































Based on the published crystal structures of TcTS binding with its substrate sialyl-
lactose, α-aminophosphonates were designed and screened as selective TcTS inhibitors. 
However, through examining the mode of inhibition, all tested α-aminophosphonate 
candidates were shown to inhibit in a non-competitive manner, indicating that the 
inhibition of α-aminophosphonate follows an allosteric process. By biophysical and 
biochemical investigations alone, it is difficult to define the binding site and detailed 
inhibition mechanisms. Therefore, structural studies of TcTS in complex with inhibitors 
are important and necessary for investigation of inhibitory mechanisms and further drug 
development. 
 
This chapter describes structural studies of TcTS-inhibitor complexes, including α-
aminophosphonate compounds and published inhibitors such as DANA, lactitol and 
Rhein.  Since the α-aminophosphonate scaffold does not inhibit TcTS activity through 
mechanism-based inhibition, it is crucial to understand the binding position of this new 
type of inhibitor and investigate the inhibition mechanism based on the allosteric 
binding. Hitherto, no structure of non-competitive inhibitors in complex with TcTS has 
been reported and the detailed inhibition mechanisms of these compounds are still 
unclear. Our structure of a TcTS-aminophosphonate complex is the first reported 
structure of TcTS in complex with a non-competitive inhibitor, and a new binding site 
between the catalytic domain and lectin-like domain was identified by the crystal 
structure, which is critical in the investigation of TcTS mechanism and development of 
further improved inhibitors.  
 
The inter-domain allosteric binding site is formed by the movement of several residues, 
which then form a generally positively-charged binding pocket for the 
aminophosphonate inhibitors. To validate this novel binding site, two compounds 




with reduced inhibition effect, they bind to the same binding site as the anthracene 
compounds. Meanwhile, an anthraquinone fragment was also defined in the lactose-
binding site, and this binding was also validated by the crystal structure of TcTS soaked 
with Rhein, another known non-competitive anthraquinone inhibitor of TcTS. 
 
Further mutagenesis of residues, which interact with inhibitors in crystal structure, in 
the allosteric site was also examined. By truncating the side chains of three key 
arginines, the inhibition was lowered, but the overall activity was not greatly affected 
although the Km and kcat were slightly changed. Through bioinformatics studies of the 
catalytic site and allosteric site of TcTS, other trans-sialidase and sialidases were also 
studied to explore why α-aminophosphonate is a selective TcTS inhibitor. 
 
4.2. Auto induction procedure to increase the yield of TcTS 
expression 
 
Initially, expression and purification of recombinant TcTS was performed as described 
in Chapter 3, using IPTG induction and a two-step purification including His-trap and 
anion exchange chromatography. The purity after ion-exchange chromatography was 
adequate for high-purity assays, such as protein crystallography and ITC. However, the 
yield following IPTG induction was normally 3-4 mg pure TcTS per liter of E. coli 
culture. For crystallography, which requires larger amount of high-purity protein, IPTG 
induction alone was insufficient. 
 
Therefore, to increase the yield of protein purification, firstly TB media was tried as a 
replacement for LB media, an enrich media with additional nutrients and growth factors 
which potentially increase yield of E. coli (Tartof and Hobbs, 1987), but a similar yield 
of protein was obtained. Additionally, autoinduction was introduced as an alternative 
method to IPTG induction. After screening of different media, temperature and length 




the highest yield of 18-21 mg of pure protein per liter of E. coli culture after two-step 
purification.    
 
4.3. Crystallization of TcTS 
 
TcTS crystallization trials has been set either using robotic screening (Phoenix nano 
dispenser) of various conditions (JCSG, PEG screening from Molecular Dimensions), 
or manual screening based on the published conditions. Micro crystals grew from 
condition A (100mM Tris-HCl, 20% PEG 4000, 5% isopropanol, pH 7.5) after a few 
days (Figure 4.1 A). However, it was difficult to harvest single crystals and the 
microcrystals were not big enough for soaking and data collection. While, a few single 
crystals grew in condition B (100mM HEPES, 20% PEG 4000, 5% isopropanol, pH 
7.5), after few months (Figure 4.1 B), they still had the same problem with size since 
small crystals tend to dissolve when soaked with ligands which impacts the diffraction 
quality. However, the microcrystals were useful as seeds in condition B. After seeding, 
large single crystals, which are longer than 10nm and survived long soaking times were 
observed in the seeding drops (Figure 4.1 C, D, E) in a few weeks. 
 
Co-crystallization conditions were optimized using 24-well plates. Single crystals were 
grew after a few weeks （Figure 4.2 A, B. These crystals were flash-cooled and sent 
to the Diamond synchrotron (beam-line I04) where data were collected to 0.9Å (Figure 
4.2 C). Indexing of the data revealed a small P1 unit cell (unit cell dimensions: a = 9.90 
Å, b = 10.09 Å, c = 16.41 Å, α = 78.56°, β = 79.35°, γ = 79.62°) which would be very 
small for a protein, indeed the size of the unit cell is about the size of the compound 
alone. Analysis by ShelxC (Sheldrick, 2008) showed that the weight of the cell is 365Da, 
which is approximately the same as the ligand molecule (m.w. = 363 g/mol), however, 






Figure 4.1. Gallery of TcTS crystals: A. Microcrystals, B. Single crystal grown in condition 
highlighted by red arrows, C. Single crystal grown by macro seeding in condition A; D-E. 





Figure 4.2. (A): soaking crystal into compound 59. (B): A single crystal grew from co-
crystallization of TcTS with compound 59, in optimized condition. (C): Diffraction pattern of 





4.4. TcTS crystal structure in complex with naphthalene inhibitors 
 
In SAR screening, α-aminophosphonate compounds containing naphthalene gave a 
range of IC50 values from high micromolar to low millimolar levels, the compounds 
with 4’-nitrophenyl, 4’-acetamidophenyl and 4’-trifluromethylphenyl groups have the 
best IC50 of about 200μM, which are comparable to lactitol, the best commercially 
available TcTS inhibitor (Agusti et al., 2004). Although naphthalene compounds were 
not the best inhibitors in screening, it is still interesting to investigate the how the 
structure of TcTS interacts with this series of compounds to further understand the 
structure-mechanism relationship of α-aminophosphonate inhibitors. 
 
 
Figure 4.3 Structure of naphthalene compounds that soaked with TcTS crystals 
 
Single crystals of TcTS were soaked in crystallization solution (Condition B) 
containing TcTS and up to 10 mM of one of the compounds 51, 53 and 54 (Figure 4.3). 
A study of diffraction data from crystals soaked for different lengths of time by a project 
student Scott Gardner showed that positive difference peaks for soaked ligands started 
to appear in the electron density maps after 10 minutes soaking and crystals survived 
48 hours soaking (Gardner, MSc thesis, 2014), therefore the length of soaking in 
subsequent studies were generally 48 hours. Details of data collection (in-house and 
Diamond synchrotron source) and refinement are shown in table 4.1. In monoclinic 
crystals in complex with 51, positive peaks could be defined on the surface of the 
catalytic domain, at a distance of about 35 Å from the catalytic site. However, only the 
4’-trifluromethylphenyl moieties of compound 51 interacts with the catalytic domain 




surface. The naphthalene moiety bound to the lectin-like domain of a symmetry-related 
molecule (SRM) (Figure 4.4), but without significant interactions with any residues in 
the lectin like domain, only one hydrogen bound with the main chain of Lys543 and 
two hydrophobic interaction with the C-β of were found with the (Figure 4.5). The same 
binding position was also seen in the monoclinic crystal of TcTS soaked with compound 
54. The binding regions on both the catalytic and lectin-like domains are flexible loops, 
but the interaction between TcTS and these compounds do not change the conformation 
of these loops greatly when compared to a structure without inhibitors and it is at some 
distance from the active site. Therefore, in these structures, it is difficult to judge how 
this interaction affects the activity of TcTS. 
 
Table 4.1. X-ray data collection and model refinement statistics of TcTS crystal soaked with 
naphthalene compounds 
Crystal No. 1 2 3 4 






Protein TcTS TcTS TcTS TcTS 
Ligand soaked 51 54  54  53 
Soaking time (h) 48  48 48 72 
Ligand identified 51 54 54 N/A 
Data collection and processing statistics 
Wavelength (Å) 1.541 0.976 1.541 0.976 
Resolution (Å) 68.3-1.68 5.86-1.51 72.0-1.75 51.94-1.37 
Space Group P 1 21 1 P 1 21 1 P 21 21 21 P 1 21 1 
Unit cell dimensions 
a (Å) 54.09 54.29 60.90 54.5 
b (Å) 129.71 129.50 87.79 130.03 
c (Å) 59.32 54.44 120.56 54.62 
α (°) 90 90 90 90 
β (°) 108.5 107.87 90 107.63 
γ (°) 90 90 90 90 
No. observations 81996 108821 67854 161507 
Completeness (%) 89.9 (82.2) 95.41 (95.3) 92.1 (80.1) 99.8 (99.7) 
Ave. redundancy 4.68 (3.24) 3.29 (2.8) 4.12 (3.10) 6.4 (5.3) 
Rmergea  0.092 (0.482) 0.046 (0.841) 0.085(0.564) 0.052 (1.315) 





Reflections used  60306 98365 62482 82653 
Number of protein 
residues 
624 624 621 623 
Number of water 
molecules  
646 646 642 620 
Number of atoms  10445 10189 9972 10224 
Rfactor b 0.17 0.12 0.21 0.19 
Rfree c 0.22 0.14 0.25 0.19 
RMSD bond angle (°) 0.01 0.01 0.004 0.014 
RMSD bond length  1.071 1.181 0.707 1.457 
a
1 1
R ( ) / ( )
N N
merge hkl hkl hkl
hkl j hkl j
I I j I j
 
    
b R ( ) ( ) / ( )factor obs cal obs
hld hld
F hkl F hkl F hkl    
c Rfree was calculated as defined by Brunger for 5% of the total data(Brunger, 1992) 
*The calculation of Rmerge, Rfactor and Rfree in following tables of data collection and 
refinement will follow the same method. 
 
 
Interestingly, one of the crystals soaked with compound 54 crystallized in an 
orthorhombic space group (P 21 21 21) which has a different crystal packing from the 
monoclinic crystals. In this crystal form, the catalytic site was blocked by a symmetry 
related molecule, therefore, it not suitable for study of ligand binding especially for 
ligands that might bind to the catalytic site. However, by comparing the binding site of 
different crystal forms, it is possible to determine whether the interaction between 
ligand and protein is real or merely a structure bias resulting from the crystal packing. 
In the orthorhombic crystal structure of TcTS soaked with compound 54, electron 
density, which can be identified as the inhibitor molecule, can still be found between 
adjacent symmetry related molecules but in a different place to that seen in the 
monoclinic crystal structure. In the orthorhombic crystal structure, model of compound 
54 cannot be identified on the interface between the catalytic domain and the SRM 
lectin-like domain, but on the interface between lectin-like domain of two SRMs 




of naphthalene compounds on the interface between two SRMs are formed by crystal 
contact but not a real functional interaction.  
Figure 4.4. Inter-symmetry molecule binding position of compound 51 in monoclinic crystal 
(P1 21 1) crystal (A) and detailed binding site with 2mFo-DFc map (σ=1.0) (B). Inter-symmetry 
binding position of compound 54 in monoclinic crystal (P1 21 1) crystal (C) and detailed 
binding site with 2mFo-DFc map (σ=1.0) (D). Compound 54 soaked into a P 21 21 21 crystal 
between two symmetry related molecule, binding position of compound 54 is highlighted by 
red circle and catalytic is labeled as green star (E). Binding detail of compound 54 with 2mFo-






Figure 4.5. Details of interaction between compound 54 with TcTS in monoclinic (A) and 
orthorhombic (B) crystals.  
 
Having the crystal structures in two different space groups indicates that the binding 
site between two SRM is not a real binding pocket but results from coincidental 
proximity of appropriate residues across a crystal contact. In these crystals, 
naphthalene-based inhibitors tend to be reside in the gap between two SRM, without 
major interactions with any key residues in the catalytic activity. In addition, no 
significant positive peak can be found to identify inhibitor molecules in crystals soaked 






determine the effective binding site of naphthalene inhibitors. All naphthalene 
compound are weak inhibitors, since they have low affinity or lower stability when 
interacting with TcTS, which appears to result in electron density that is not possible to 
identify in the real binding site.  
 
4.5. The identification of a novel allosteric binding by crystal 
structure of TcTS complex with anthracene compounds 
 
Among the novel aminophosphonate inhibitors, anthracene compounds present the best 
inhibition effect with a range of IC50 from 0.2 mM to 0.015 mM. All this type of 
inhibitor show non-competitive inhibition suggesting that they might bind to an 
allosteric site rather than the catalytic site, but the interaction of the inhibitor affects the 
catalytic mechanism without an impact on Km value in present of inhibitor. The best 
candidate anthracene aminophosphonate inhibitors, compound 48, 59 or 61 (Figure 4.6), 
was added into the drops in which the TcTS crystal would be soaked for 48 hours. X-
ray diffraction data from all three crystals were collected at the synchrotron, and details 













Table 4.2. X-ray data collection and refinement statistics for crystals soaked with anthracene 
compounds 
Crystal No. 5 6 7 8 







Ligand soaked 48 48 59 61 
Length of soaking 48 hour 46 hour 48 hour 45 hour 
Ligand identified 48 48 59 61 
Data collection and processing statistics 
wavelength (Å) 1.541 0.979 0.976 0.979 
Resolution (Å) 65.06-1.69 54.26-1.31 48.19-1.39 51.72-1.43 
Space Group P 1 21 1 P 21 21 21 P 1 21 1 P 1 21 1 
Unit cell dimensions 
a (Å) 54.36 90.51 54.38 54.28 
b (Å) 130.11 119.37 129.72 129.48 
c (Å) 54.64 60.92 54.63 54.47 
α (°) 90 90 90 90 
β (°) 108.42 90 108.19 107.64 
γ (°) 90 90 90 90 
Number of. unique 
observations 
79536 147108 142388 126384 
Redundancy 4.47 (3.13) 8.66 (3.02) 4.84 (3.38) 6.40 (4.25) 
Completeness (%) 89.9 (81.1) 86.26 (78.5) 98.9 (90.7) 96.0 (67.2) 
Rmerge (%) 0.050 (0.176) 0.046 (0.798) 0.049 (0.737) 03042 (0.799) 
I/ σI 19.3 (5.1) 25.5 (1.5) 12.6 (1.2) 19.8 (1.4) 
Refinement  
Reflections used  53147 116324 142349 126340 
Number of protein 
residues  
624 627 625 627 
Number of water 
molecules  
594 913 714 650 
Number of atoms  
10258 11916 11237 11016 
R-factor   0.16 0.15 0.13 0.16 
R-free   0.20 0.17 0.16 0.18 
RMSD bond 
length (Å) 
0.018 0.008 0.007 0.004 
RMSD bond angle 
(°)  




In the crystal structure soaked with anthracene compounds, a novel binding site was 
identified between the catalytic domain and lectin-like domain (crystal 5), and the 
distance of the anthracene compound binding site is about 30 Å from the catalytic 
pocket (Figure 4.7 A).  
 
An orthorhombic crystal soaked with compound 48 (crystal 6) verified the position of 
this binding site (Figure 4.7 B), although they still have several minor differences. In 
monoclinic structures, the compound 48 binds to TcTS in only one conformation, but 
in orthorhombic crystal, a dual conformation can be identified from the electron density 
map (Figure 4.7 D), apart from the first conformation which is the same as the 
orthorhombic structure and other anthracene compounds (Figure 4.8A). However, a 
second conformation occurs in which the anthracene has a 90° rotation, and the phenyl 
group place different from the first one but still has cation-π iteration with Arg577 
(Figure 4.8B).  
 
Furthermore, in the orthorhombic crystal structure, a second binding site on the surface 
of the α-helix between the catalytic domain and lectin-like domain can be determined 
(Figure 4.7 E). It is possible that it is a crystal artifact since the same interaction cannot 
be found in either complexes of compound 48 with TcTS in different crystal forms or 
crystal soaked with different anthracene compounds. However, it might really has weak 
interaction because the soaked compound shows some interactions with residues on the 
helix, including the salt bridge between Ser380/Arg437 with phosphate group, and 
cation-π interaction between Arg437 and the anthracene group (Figure 4.8C). 
Furthermore, ITC analysis of anthracene compound binding indicated that the binding 
ratio between TcTS and this type of compound could be either 1:1 or 1:2 (ITC, 
n=1.3±0.25). Moreover, in both of two crystal forms the helix which links catalytic and 
the lectin-like domain is exposed to the solvent, result in the helical binding site is not 
affect by the symmetry related molecules. The helix binding site, thus, could be a real 
but weak binding site, it is because although the ligand shows interaction with residues 















Figure 4.7. Binding location of compound 48 in monoclinic crystal (A) and orthorhombic 
crystal form (B). 2mFo-DFc maps (σ=0.9) of compound 48 in monoclinic structure (C) and 






Figure 4.8. Interaction details of (A) First conformation, (B) second conformation of 
compound 48 at inter-domain allosteric binding site and (C) helix binding site of compound 
48. Ligands are present in green, catalytic domain residues are in blue and lectin-like domain 




Compound 59 (IC50 = 15μl) was the best inhibitor in the SAR screening of α-
aminophosphonate derivatives, followed by the compound 61 (IC50 = 23μl).  Crystal 
structures of these compounds soaked into TcTS (crystal 7, 8) showed that both bind 
to the inter-domain allosteric binding site identified by crystal structures of complexes 
with compound 48 (Figure 4.9). Thus, the anthracene compound soaks indicated that 
α-aminophosphonate derivatives, at least anthracene compounds, bind to TcTS in this 
novel binding site and it could be a potential target site for rational drug design of TcTS 
inhibitors. 
 
Since anthracene compounds bind to the novel binding site in between two domains of 
TcTS, the interaction between ligand and TcTS is mediated by residues both from the 
catalytic domain (Arg249, Leu252, Arg272) and the lectin-like domain (Arg577, 
Thr578) (Figure 4.5). In all the structures with anthracene compounds bound, Arg249 
and Leu252 clamp the anthracene moiety through cation-π interactions and 
hydrophobic interactions respectively. The phosphate group binds to Arg272 from 
catalytic domain, and Arg577 and Thr578 from the lectin-like domain. The amino 
nitrogen does not have direct interaction with TcTS but interacts with Thr578 via a 
water bridge. Compared with the non-liganded structure (Figure 4.9A), several residues 
in the inter-domains binding site change their conformation to interact with anthracene 
compounds. In the former TcTS structure, the side chain of Arg249 points towards to 
Tyr248, but on inhibitor binding a conformation change happens to form the cation- π 
interactionwith the inhibitor. Arg577 is s a flexible residue, which has often been 
truncated in non-liganded crystal structures (Buschiazzo. et al., 2002).  
 
Arg577 also undergoes significant movement to form a cation- π interaction with the 
phenyl group whilst also binding the phosphate group. In the interaction with 
aminophosphonate molecules, Arg249 and Arg577 act as a closing door to hold the 
inhibitor molecules into the binding site. As noted above, as well as with Arg577, the 
phosphate group of anthracene compounds also interacts with Arg272, the side-chain 




binding of aminophosphonate compounds result in fitting of binding site geometry 
might trigger the rotation of Arg272.  
 
No structural data has been published in previous studies about the interaction of TcTS 
and either non-competitive or mixed inhibitors. Therefore, although numbers of non-
competitive or mixed inhibitors have been developed based on structure mimicry of 
TcTS substrates, the allosteric binding site is still unknown. 
 
Figure 4.9 Interaction details, compound 59 (B) and 61 (D). Residues from catalytic domain 
and lectin-like domain are presented in green and orange respectively. Ligand molecules are in 





The inter-domain binding site is located about 35 Å from the catalytic pocket. Therefore, 
whether it is a functional binding site and how this interaction will affect TcTS activity 
is important to understand for the next stage of study. The catalytic site in the crystal 
structures of anthracene inhibitors also shows several positive difference density peaks. 
However, they only models of components in mother liquor such as water, glycerol, 
PEG or PEG fragments fit into these, not the soaked inhibitor (Figure 4.10).  
 
 
Figure 4.10. 2mFo-DFc maps (blue, σ=1.5) and Fo-Fc map (Green for positive and red for 
















4.6. Validation of the allosteric binding site by introducing 
anthraquinone compounds 
 
Crystal structures have indicated an allosteric binding site for TcTS interacting with α-
aminophosphonate derivatives. However, when compounds with other aromatic groups 
such as naphthalene or phenyl at the “lactose-mimic” moiety were soaked into TcTS 
crystals, the binding position of ligand could not be identified due to the low protein-
ligand affinity. Therefore, an anthraquinone group was introduced to validate the new 
binding site. Although anthraquinone derivatives have been shown to be decent 
inhibitors against TcTS, which has the range of IC50s from lower millimolar level to 
micro molar level, and show non-competitive inhibition (Arioka et al., 2010), the 
binding site and the inhibitory mechanism is still unclear.   
 
Two compounds, compound 62 and 63, containing anthraquinone group on the amino 
side of the inhibitor, were designed and synthesized (Figure 4.11). Inhibition screening 
results showed that anthraquinone compounds can inhibit TcTS activity more strongly 
than naphthalene or bi-aryl compounds but more weakly than anthracene compounds. 
Compound 62 with a phenyl group on the phosphate side has an IC50 of 94 μM and the 
IC50 of compound 63, with a 4-accetamidophenyl group on the phosphate side is 79 μM 
(Figure 4.12 A, B; Table 4.3). Not surprisingly, they still show non-competitive 
inhibition against TcTS （Figure 4.12 C, D） 
 










Table 4.3. Inhibition and kinetics result of compound 62 and 63 
Compound LogIC50TcTS 







Compound 62 -1.024 0.027 0.094 - - 




































































Concentration of compound 63

































In X-ray data collected from crystals soaked with compound 63 for 48 hours (Crystal 
9), the compound can only be partially identified and built in the positive difference 
density at the inter-domain binding site (occupancy = 72%), and cannot be built in other 
positive difference map peaks. This crystal soaking result shows that compound 62 
might still bind to the inter-domain binding site but the low occupancy and poor electron 
density map reflect the weaker affinity and lowered stability of the complex shown 
experimentally.  
 
When compound 63 was soaked into TcTS crystals, the subsequent diffraction data 
revealed better density for the ligand in the inter-domain allosteric binding site since it 
is of higher affinity than 62. Looking at the details of the binding (Figure 4.13 D), the 
interaction between anthraquinone compounds and TcTS is the same as for anthracene 
compounds. The phenyl group close to the phosphate still interacted with Arg577 
through cation-π interaction, and the phosphate group interact with Arg577, Thr578 and 
Arg272. The anthraquinone group appears in between Arg249 and Leu252. However, 
in anthracene compound soaked structures, the cation center of the Arg249 is around 
3.6-3.8 Å above the middle and the outer ring of the anthracene, however, in 
anthraquinone compounds, Arg249 only has cation-π interaction with the outer ring 
since the conformation changes.  
 
In crystal structures of either naphthalene or anthracene compounds, there is no 
inhibitor bound to the catalytic site. However, electron density which fits the structure 
of an anthraquinone fragment has been defined in the structure soaked with compound 
63 (Figure 4.13 C). The anthraquinone fragment undergoes π-π stacking with both 
Tyr119 and Trp312, and is located in a similar place as the lactose fragment in the SAL 







Table 4.4. X-ray data collection and refinement statistics for TcTS crystals soaked with 
anthraquinone compounds 
Crystal No. 9 10 
Detector In-house Diamond beamline I04 
Protein TcTS 
Ligand soaked 62 63 
Ligand identified 62 63 
Data collection and processing statistics 
wavelength (Å) 1.541 0.979 
Resolution (Å) 65.06-1.69 52.24-1.58 
Space Group P 1 21 1 P 1 21 1 
Unit cell dimensions 
a (Å) 54.36 54.39 
b (Å) 130.11 129.82 
c (Å) 54.64 54.88 
α (°) 90 90 
β (°) 108.42 107.83 
γ (°) 90 90 
Number of unique observations 79536 91114 
Redundancy 8.84 (4.47) 6.84 (4.47) 
Completeness (%) 89.9 (81.1) 92.2 
Rmerge (%) 0.050 (0.176) 0.048(0.035-1.011) 
I/ σI 19.3 (5.1) 19.2(1.2) 
Refinement statistics 
Reflections used  53147 91076 
Number of protein residues 624 623 
Number of water molecules  594 320 
Number of atoms 11356 10043 
R-factor  0.16 0.18 
R-free  0.20 0.23 
RMSD bond length (Å) 0.018 0.014 






Figure 4.13. 2Fo-mFc map of compound 62 (A) and 63 (B) in the allosteric site. 2Fo-mFc map 
of anthraquinone fragment of compound 63 in lactose binding site (σ = 0.9). C: Details of 
interaction between compound 62 at the allosteric site. D. Details of iterations of anthraquinone 
in the lactose binding site, superimpose with SAL (PDB: 1S0I).    
 
 






4.7. Crystal structure of published inhibitors (DANA, lactitol, rhein) 
 
As well as the α-aminophosphonates, other published inhibitors were also soaked into 
TcTS crystals and their X-ray crystal structures determined, including DANA, lactitol, 
and rhein. DANA was the first defined inhibitor against TcTS, although it only shows 
extremely weak inhibition (Vandekerckhove et al. 1992). It was reported that after 
soaking in DANA for short time, TcTS crystals were destroyed as the result of active 
site conformation changes (Buschiazzo et al. 2002). In this study, we show that in the 
monoclinic crystal form, the crystal survived after 48 hours soaking and provided high 
resolution (1.7Å) and high completeness diffraction data (table 4.5).  
 
Table 4.5. X-ray data collection and refinement parameters of DANA, lactitol and rhein soaked 
into TcTS crystals 
Crystal No. 11 12 13 
X-ray source In-house In-house 
Diamond beamline 
I03 
Protein TcTS TcTS TcTS 
Ligand soaked DANA Lactitol Rhein 
Length of soaking(hours) 48 48 48 
Ligand identified DANA N/A Rhein 
Data collection and processing statistics 
X-ray wavelength (Å) 1.541 1.741 0.979 
Resolution (Å) 1.69 (54.23-1.69) 1.78 (54.23-1.78) 1.59 (64.82-1.59) 
Space Group P1 21 1 P1 21 1 P1 21 1 
Unit cell dimensions 
a (Å) 54.38 54.32 54.52 
b (Å) 130.18 130.02 129.65 
c (Å) 54.62 54.65 54.82 
α (°) 90 90 90 
β (°) 108.54 107.33 107.43 
γ (°) 90 90 90 
Unique Number of. 
reflections 
75397 76644 96484 
Redundancy 4.22 (2.93) 4.84 (2.66) 6.32 (2.86) 
Completeness (%) 93.8 (79.3) 88.7 (65.3) 99.22 
Rmerge (%) 0.095 (0.232) 0.092 (0.365) 0.0964 





Reflections used  74684 71738 96444 
Number of protein residues 624 623 623 
Number of water molecules  633 656 634 
Number of atoms  10276 10150 10055 
Rfactor  0.16 0.16 0.21 
Rfree   0.18 0.19 0.24 
RMSD bond length (Å) 0.005 0.019 0.010 
RMSD bond angle (°) 0.787 1.491 1.037 
 
 
When compared to the published crystal structure of TcTS with DANA, when DANA 
is soaked into the crystals for a long time, the structure shows similar interaction 
between the enzyme and ligand, indicated that binding of DANA is stable in the 
catalytic site and not affected by the time of interaction. Unlike in the structures from 
crystals soaked with α-aminophosphonate compounds, in the DANA binding structure 
Tyr119 is present with 100% occupancy in the “open” conformation, and interact with 
oxygen O9 at the glycerol side chain (Figure 4.14). Although DANA is only a weak 
inhibitor of TcTS, the (2Fo-mFc) electron density surrounding the DANA is much 
better defined and appears in higher occupancy then the stronger inhibitors such as α-
aminophosphonate and rhein (occ.DANA=0.93 and occ.Rhein=0.76). This phenomenon 
could be explained by DANA buried inside the catalytic pocket that has higher 
conformational stability than the allosteric binding site of the α-aminophosphonates, or 
the lactose-binding site where Rhein binds, which are on the surface of the enzyme and 





Figure 4.14. Crystal structure of DANA interacts with the TcTS catalytic site, with 2mFo-DFc 
map of DANA molecule (σ=0.9, occ. = 0.93). Hydrogen bonds are present by blue dash and 
salt bridge by in yellow dash. 
 
Lactitol is the only molecule on the market that can inhibit TcTS with an IC50 lower 
than 1mM (Agusti, Paris et al. 2004), and it has been applied in research into TcTS 
mechanism and functions (Mucci, Risso et al. 2006). However, there is still no crystal 
structure available for lactitol bound to TcTS, though it is thought to interact with TcTS 
in a similar manner to lactose binding. A TcTS crystal was soaked with a solution with 
up to 10mM lactitol for 48 hr, and 1.7 Å diffraction data was obtained from the in-house 
X-ray system. After molecular replacement and several rounds of refinement, lactitol 
was able to be identifed at the lactose-binding site (Figure 4.15), indicating that lactitol 
binds to TcTS similarly to lactose. However, the weak occupancy (occ.=73.2%) 
suggests lactitol is a weak binder to TcTS, but it still can bind to the lactose binding site 
without presence of a sialic acid donor. In the lactitol-soaked structure, Tyr119 has 
moved to the parallel conformation, which indicates the formation of the lactose 
binding site, the cyclic ring of lactitol appearing in the stacking position between 
Tyr119 and Trp312 but it did not have strong interactions, shown by the long distances 






Figure 4.15. Detail of interaction of lactitol at the TcTS lactose binding site, with 2mFo-DFc 
map of lactitol molecule (σ=0.7, occ. = 0.73). Hydrogen bonds are present by blue dash and 
π- π stacking is shown by green dash. 
 
Rhein is an anthraquinone compound which was identified in 2010 by Arioka et, al. 
that can inhibit TcTS activity more strongly than DANA and lactitol (IC50=17μM) and 
it also shows non-competitive inhibition. (Arioka et al. 2010). However, the binding 
site of anthraquinone compound is still undefined.  
 
The crystal structure of TcTS in complex with anthraquinone-aminophosphonate above 
(Section 4.3.5) showed that as well as the binding in the inter-domain allosteric binding 
site, positive difference electron density was also defined in the lactose binding site 
between Tyr119 and Trp312 (Figure 4.16) into which an anthraquinone fragment could 
be built. To investigate whether anthraquinone compounds can bind to the lactose-
binding sites, a TcTS crystal was soaked in solution (condition B) containing 
0.18mg/ml TcTS and 0.2mM of rhein. As expected, following data collection and 
structure solution, positive difference map peaks can be identified in the lactose binding 






Compared to the anthraquinone-aminophosphonate compound, the interaction between 
rhein and TcTS lactose binding site shows stronger π- π stacking, and all three of the 
aromatic rings are stacked with either Tyr119 or Trp312, and this could be the reason 
that rhein exhibits stronger inhibition of TcTS than anthraquinone-aminophosphonate 
compounds. In addition, since the lactose binding site for SA transfer activity is unique 
to trypanosoma trans-sialidase rather than other sialidases, it may explain the selectivity 
of anthraquinone scaffold.  
 
 
Figure 4.16. Crystal structure of rhein interaction at the TcTS lactose-binding site, with 2mFo-
DFc map on rhein molecule (σ=0.9, occ.=0.86). Superimposed with anthraquinone fragment of 
compound 63 at the catalytic site (pink). Hydrogen bond is present by blue dash, salt bridge by 










4.8. Binding of α-aminophosphonate affects the conformation of the 
catalytic site 
 
As non-competitive inhibitors, it can be observed from the crystal structures that α-
aminophosphonate derivatives bind to TcTS at an allosteric pocket between the 
catalytic and lectin-like domains. Therefore, it is important to explain the inhibitory 
mechanism of this allosteric binding. The allosteric site location is about 35 Å from the 
catalytic site and several residues in the catalytic domain, such as Arg249, Leu252 and 
Arg27, participate in the interaction with aminophosphonate compounds. However, 
these residues have not been recorded to be involved in the TcTS catalytic activity. 
Therefore, the effect of the allosteric binding on the catalytic activity or even the 
catalytic site structure cannot be directly estimated from existing reports. At the 
catalytic site, it can be identified that Tyr119, appears in the conformation that stacks 
with Trp312, which known as the “closed position”.  
 
Tyr119 has been shown to be a critical residue for the transfer activity of TcTS, loss of 
Tyr119 will significantly impact both hydrolysis and transfer activity (Paris et al., 2001), 
and gain of tyrosine in the same position in T. rangeli sialidase leads to this enzyme 
acquiring the ability to transfer sialic acid (Paris et al., 2005). Generally, Tyr119 is 
rotated towards the catalytic pocket in empty structures or in an intermediate state 
interacting with sialic acid, which are regarded as the “open” conformation. The Tyr119 
stacking conformation, also known as the “closed” conformation, normally occurs in 
secondary ligand binding, for example, binding with donor or acceptor oligosaccharides 
(Amaya et al., 2004; Buschiazzo. et al., 2002; Watts et al., 2006). However, the closed 
conformation also occurs in empty TcTS structures without ligand binding, indicating 
the high flexibility of Tyr119 (Buschiazzo. et al., 2002; Telford, 2014).  
 
To investigate whether the binding of allosteric inhibitor triggers the closed 




into a TcTS crystal was performed. X-ray data collection and refinement information is 
given in Table 4.6 
 
Table 4.6. X-ray data collection and refinement of TcTS crystal soaked with compound 48 and 
DANA 
Crystal No. 14 
Detector Diamond beamline I02 
Protein TcTS 
Ligand soaked DANA+48 
Length of soaking(hr) 48hr 
Ligand identified DANA, 48 
Data collection parameters 
X-ray wavelength (Å) 0.979 
Resolution (Å) 51.56-1.23 
Space Group P1 21 1 
Unit cell dimensions  
a (Å) 54.27 
b (Å) 129.58 
c (Å) 54.31 
α (°) 90 
β (°) 108.3 
γ (°) 90 
Number of unique reflections 189537 
Redundancy  
Completeness (%) 91.36 (86.45) 
Rmerge (%) 0.044 (0.031-1.190) 
I/ σI  
Refinement parameters 
Reflections used  180253 
Number of protein residues  626 
Number of water molecules  724 
Number of atoms  10788 
R-factor   0.1532 
R-free   0.1684 
RMSD bond length (Å) 0.017 





The previous DANA-soaked crystal structure (Section 4.3.6) showed that DANA is a 
good catalytic site binder although it is only an extremely weak inhibitor against TcTS. 
In the co-soaked structure with both DANA and compound 48, compound 48 was 
identified at the inter-domain binding site, and DANA in the catalytic pocket (Figure 
4.17 A) where it is bound in the same position as in the TcTS-DANA complex structure 
(Figure 4.17 B). This indicates that binding of α-aminophosphonate compounds will 
not impact the assessment and interaction of substrate or other catalytic site binder. 
However, in the co-soaked TcTS structure, Tyr119 presents a dual conformation that 
has a ratio between open and closed occupancies of 3:7. This result shows that the 
allosteric binding of α-aminophosphonate inhibitor tends to change the conformation 
of Tyr119 from the open to closed state (Figure 4.18), that is an important step of lactose 
binding site formation. The lack of a positive difference map peak at the lactose-binding 
site stacking between Tyr119 and Trp312, means that the “closure” of Tyr119 might not 
because of lactose site occupancy. Although the Tyr119 still has a higher occupancy at 
open than the closed position, this may be due to DANA and the α-aminophosphonate 
compounds not being strong inhibitors. Therefore, it can be postulated that a possible 
inhibitory mechanism of the α-aminophosphonate compounds in the allosteric site is a 
result of the conformational change of Tyr119 and formation of stable lactose binding 
site, result in lactose binding without donor substrate and prevent it from release. 
 
Figure 4.17 (A): The allosteric site showing the model of compound 48 in the DANA/48 co-





site of TcTS in the co-soaked structure with f DANA and the dual conformations of Tyr119 
surrounded by the 2Fo-DFc map (σ=1.0). 
 
 
Figure 4.18 Structure alignment of the catalytic pockets of the co-soaked crystal with DANA 
and compound 48 (Blue, crystal 14) and that of the DANA soaked TcTS crystal (Yellow, 
crystal 11). 
 
4.9. Mutagenesis study on the TcTS allosteric binding site 
 
As known from crystal structures of TcTS in complex with α-aminophosphonate, it can 
be hypothesed that the interaction at the inter-domains allosteric binding site could 
change the conformation of the catalytic site, leading to inhibition. Since the residues 
in the allosteric binding site are distant from the catalytic site, they will not be directly 
involved in the catalytic activity, but they might also control the catalytic activity 





To investigate the effect of allosteric binding site on catalytic activity, site-directed 
mutagenesis on the three arginine residues at the allosteric site was performed. As 
shown in the crystal structures (Figure 4.9), the most important residues interacting with 
aminophosphonate compounds are three arginines, Arg249, Arg272 in the catalytic 
domain and Arg577 in the lectin-like domain. As seen in Figure 4.19, the overall 
activity was not eliminated by any of the mutations, showing that none of these three 
residues is critical for TcTS activity. The turnover number, which is represented by kcat. 
has slightly reduced in all three mutations from 4.2 s-1 to 3.9 s-1. Surprisingly, even the 
interaction with α-aminophosphonate inhibitor did not change the Km of substrate but 
mutation of any of the inhibitor-binding residues may decrease the substrate affinity, 
with an increasing Km from 0.15mM to 0.24-0.25mM. The kinetic results indicate that 
the allosteric binding site could have a function in TcTS activity and may be involved 
in substrate recognition.  
 
 





















Table 4.7 Kinetic parameters of TcTS mutations compared to wild type TcTS 
 
TcTSR249A TcTSR272A TcTSR577A TcTS 
kcat (s-1) 3.95 3.92 3.94 4.18 
Km (mM) 0.25 0.24 0.24 0.16 
kcat/Km 15.99 16.36 16.40 26.87 
 
4.10. Sequence alignment study of allosteric binding site 
 
The variation of TcTS between different strain is the main reason why TcTS cannot be 
a potential vaccine target (Rosenberg et al., 2016). To investigate whether the α-
aminophosphonate compounds could be a broad-spectrum inhibitor or a strain specific 
inhibitor against TcTS, multiple sequence alignments (MSA) were undertaken to 
compare TcTS protein sequences within different isoforms. The proteome of the T. cruzi 
CL brener strain has been intensively studied (Sodre et al., 2009), thus, sequences of 
TcTS isoform can be obtained from the CL brener strain for MSA study. The similarity 
between TcTS isoforms from CL brener strain and the query sequence (Q6966) is 
shown in table 4.8, sequence XP_807431.1 has the highest identity and the sequence 
XP_80548.1 has the lowest identity, which is 77%. 
 
The MSA result (Figure 4.12, full alignment in Appendix 8.7) shows that most inhibitor 
binding residues are conserved across TcTS isoforms, suggesting that the allosteric 
binding site interacting with α-aminophosphonate compounds is generally conserved 
among different TcTS strains. However, Arg249 only occur in two different isoforms 
and is replaced by alanine and threonine in others. Interestingly, in the isoforms 
containing Arg249, residue 248 is tyrosine (XP_807308.1 and XP_807593.1), however 
if residue 249 is alanine, polar residues, such as arginine appear at residue 248, which 






Table 4.8. The sequence accession codes of TcTS from CL brener strain and statistics of 





Figure 4.20. The inter-domain binding site region of MSA result of different TcTS isoform. 
Key residues at the inter-domain binding site are highlighted in green and catalytic site residues 








4.11. Discussion  
 
4.11.1. TcTS crystal structure shows the non-competitive inhibition of α-
aminophosphonate compounds   
 
Acquiring a protein-ligand complex is the critical step for structure-based drug design 
and development. For TcTS, although numbers of potential types of inhibitor have been 
identified, the lack of a structure-function relationship study will limit further 
development of these inhibitor, especially for inhibitors which do not bind to the known 
binding sites. The case of the α-aminophosphonate and other examples above shows 
that although compounds may be designed based on the substrate of an enzyme, they 
may not bind to the enzyme competitively. Fortunately, the α-aminophosphonates can 
still interact with TcTS and inhibit its activity in a non-competitive manner. The crystal 
structures of TcTS-aminophosphonate complexes can attest the non-competitive 
inhibition through the novel inter-domain binding site and lack of electron density for 
inhibitors in the catalytic site. Through kinetic assays (chapter 3) it has been shown that 
the binding of an α-aminophosphonate compound does not affect the binding Km of the 
donor substrate; this has also been proved by the co-soaked TcTS structure showing 
both the aminophosphonate inhibitor and DANA bound. In general, allosteric binding 
is accompanied by significant conformation change of the acceptor (Luque and Freire, 
2000). However, from the soaking experiments to obtain crystals of TcTS in complex 
with aminophosphonate inhibitors, it is clear that, no major conformational change 
occurs in the overall structure of TcTS, and looking at the structure, even the catalytic 
site is almost the same as the unliganded structure. Therefore, it is difficult to explain 
the inhibition mechanism based on inhibitor soaking structures.  
 
An anthraquinone group was introduced at the AM moiety to validate the allosteric 




compound, and have lower occupancy in the crystal structure. This can be explained by 
the introduction of two C=O bonds changing the electrostatic distribution which 
weakens the cation-pi interaction with Tyr249 (Figure 4.21).  
 
 
Figure 4.21. Electrostatic distribution of anthracene and anthraquinone (generated by UCSF 
Chimera) with positive charges in blue, negative in red 
 
Through allosteric binding, the inhibition mechanism of aminophosphonate inhibitors 
could be attributed to three possible reasons: (1). Binding of an aminophosphonate 
inhibitor could change the conformation at the active site. (2). although the interaction 
of this type of inhibitor cannot block the substrate binding, it could inhibit the release 
of catalytic product by increasing the rigidity and stability of the active site. (3). the 
inter-domain binding site has a function in the catalytic activity such as substrate 
recognition.  
 
From crystal structure of TcTS-aminophosphonate complexes, no significant 
conformation change can be observed in the catalytic pocket except the Tyr119, which 
flips to the “closed” position. However, since Tyr119 is present in a dual conformation 
in non-liganded structure, it is still not possible to decide whether the closed 
conformation is result of inhibitor binding. Thus, the addition of DANA to the crystal 
soaking was performed since DANA is known to be a good active site binder and can 
trigger the rotation of Tyr119 to the open position. Comparison of the DANA-soaked 
and aminophosphonate-soaked TcTS structures showed that although the binding of 




can still partially trigger the formation of the closed conformation, which is critical for 
lactose binding.   
 
In addition, the anthracene or anthraquinone moiety of aminophosphonate compounds 
interact with a loop which contain several important residues in TcTS activity, for 
example Asp247 (neighboring residues 248 and 249 involved in aminophosphonate 
binding) interacts with Trp312 via a water bridge, which could trigger the conformation 
change of Trp312 away from Tyr119 (Figure 4.22). Mutation of Asp247 will 
significantly reduce TcTS activity (Oliveira et al., 2014). In unliganded TcTS structures, 
this loop is exposed to the solvent and tends to have high flexibility to affect the 
movements of Trp312. By interacting with aminophosphonate inhibitors, this loop 
might become more stable and the conformational changes of Trp312 could be 
restricted, which will affect the binding and release of substrates.    
 
Figure 4.22. A: final frame of the MD simulation of binary complex TS3-SL. B: crystal 
structure of intermediate complex of TcTSD59A-SAL (Oliveira et al., 2014).  
 
The R249A mutation did not eliminate or significantly reduce TcTS catalytic activity, 
but the Km and kcat for MuNANA substrate were slightly different in the mutant enzyme. 
However, this result is insufficient to show that the inter-domain binding site is critical 






4.11.2. Inhibitors probing lactose binding site show non-competitive inhibition 
 
The anthraquinone derivatives are good inhibitors for the trans-sialidase, but after 
incorporation into aminophosphonates, the performance of anthraquinone seems 
weaker than the anthracene they replaced. The reason could firstly be attributed to the 
weaker cation-π interaction between anthraquinone compounds and TcTS. Rather than 
being parallel with the aromatic group as in the example of anthracene compound 
binding, the Arg249 is attracted to the oxygen in the anthraquinone group and loses the 
optimal distance and angle to from the strong cation-π interaction (Marshall et al., 2009). 
Another reason could be that multiple binding sites weaken the interaction at the inter-
domain binding site, since an anthraquinone fragment can be found in the lactose 
binding site and the rest of compound seems placed outside the catalytic site, suggesting 
that around the catalytic site, the only stable interactions can be made by the 
anthraquinone fragment.  
 
The less modified anthraquinone derivatives also show very weak inhibition. For 
example, Dantron (Figure 4.23A) has the IC50 against TcTS at 0.71 mM, but the 
addition of a carboxyl group at C2 (rhein, Figure 4.23B) improves the IC50 value to 
0.014 mM (Arioka et al., 2010), and the carboxyl group also has great contribution to 
interactions based on the crystal structure (Figure 4.16). Thus, it can be expected that 
the anthraquinone fragments at the aminophosphonate compounds (Figure 4.23C) 
might act weakly as a anthraquinone inhibitor that interacts with the lactose binding 
site. The weaker inhibition at both the inter-domain binding site and lactose binding 
site results in weaker inhibition of anthraquinone aminophosphonate compounds 






Figure 4.23. Structure of (A) Dantron, (B) Rhein and (C) anthraquinone fragment of 
compound 62 which identified in the lactose binding site. 
 
Either in published anthraquinone derivatives (Arioka et al., 2010) and anthraquinone-
aminophosphonate compounds are non-competitive with MuNANA, and interact with 
the lactose-binding site, which is part of the catalytic pocket. These results suggest that 
that when the lactose-binding site is occupied by anthraquinone, the donor substrate can 
still access to the SA binding site. Comparing with the position of anthraquinone and 
DANA/SA binding (Figure 4.24), it can be seen that after interacting with 
anthraquinone at the lactose-binding site, it might still have enough space for donor 
sialiyl substrate to bind to the SA pocket and be hydrolyzed, but the anthraquinone will 
block the binding of acceptor substrate. That could be an explanation for the non-
competitive inhibition for the lactose site binder.  
 
Figure 4.24. Binding of anthraquinone in the lactose binding site, superimposed with crystal 
structure with DANA binds with the SA binding site. Rhein is shown as green stick, 
anthraquinone fragment of compound 62 is pink stick, and DANA is molecule is present as 




Both structure and kinetics studies suggest that the lactose binding site of TcTS is 
formed by donor substrate interaction, that can explain why lactose derivatives or other 
acceptor substrates can only interact with the lactose binding site whilst the catalytic 
pocket is occupied by sialic acid (Buschiazzo. et al., 2002). Agusti et al suggested that 
lactitol inhibits TcTS activity as a poor acceptor substrate but also a good lactose-site 
binder (Agusti et al., 2004). When TcTS crystals are soaked in a high concentration of 
lactitol, it can be identified in the catalytic site, although with a low occupancy. But at 
the lactose binding site of crystal structure soaked with lactose, no lactose molecules 
could not be identified (Buschiazzo. et al., 2002), suggesting that lactitol has higher 
affinity than lactose and is able to bind to TcTS without donor substrate being present. 
 
The crystal structure of TcTS in complex with rhein suggests that rhein or other 
anthraquinone compounds interact with the lactose binding site without binding of 
sialic acid, similarly crystal structures of TcTS in complex with anthraquinone-
aminophosphonate compounds also indicated that the anthraquinone moiety can bind 
to the lactose binding site. However, due to the effect of the phosphonate and phenyl 
groups on the aminophosphonate compound, only two rings of the anthraquinone stack 
with Tyr119 and Trp312, and all three aromatic rings show π- π stacking with lactose 
binding site residues, which induces a stronger interaction with the lactose binding site 
than anthraquinone-aminophosphonate compounds.    
 
As a known non-competitive inhibitor, binding of anthraquinone derivatives, would not 
affect the binding TcTS substrates, even though the lactose-binding site has been 
occupied. It suggests that it might have extra binding site for the oligosaccharide moiety 
of the donor sialyl oligosaccharides. That could be an experimental evidence to support 
the hypothesis that the TcTS mechanism is not a traditional ping-pong but a mixture of 









Using structural biology approaches, the high-resolution structures of TcTS in complex 
with different ligands have been determined. The structural studies revealed a novel 
binding site between the catalytic domain and lectin-like domain. Crystal structures also 
suggest lactitol and anthraquinone bind to the lactose-binding site, providing new 
understanding of TcTS inhibition mechanisms that the lactose site binding of inhibitors 
can be also non-competitive to the donor substrate. It can also correlate the relationship 
between ligand affinity and identification of ligand in crystal structures, weak inhibitors 


























Chapter 5. Interpreting lactose binding: evaluation of the 
















5.1.  Prelude 
 
Despite their design based on the structure of the TcTS substrate, α-aminophosphonate 
compounds have been determined to be non-competitive inhibitors and it was shown to 
bind to an allosteric binding site between the catalytic and the lectin-like domain due 
to the determination of the crystal structure of TcTS-inhibitor complex. However, the 
mechanisms of inhibition of the allosteric binding are still unclear. The information 
deduced from the crystal structures also needs confirmation using other biophysical or 
biochemical approaches.  
 
The detailed mechanisms of TcTS, especially the binding of the acceptor lactose and 
the transfer activity, are still controversial (Damager et al., 2008; Oliveira et al., 2014). 
In our studies, formation of the lactose binding site is achieved in by interacting with 
α-aminophosphonate in the TcTS-inhibitor complex structures, therefore, lactose 
binding can be used to investigate the mechanisms of inhibition by α-
aminophosphonate derivatives. Additionally, lactose binding behavior is also useful in 
understanding the mechanisms of TcTS catalytic activity. 
 
This chapter describes the investigation of lactose binding to TcTS in the presence of 
inhibitor, using enzyme kinetics, structural biology, and thermodynamic assays. These 
studies interpret the influence of lactose on TcTS catalytic activity, and its effects in 
present of α-aminophosphonate. The crystal structure of TcTS co-soaked with both 
inhibitor and lactose suggests that the formation of lactose binding site through α-
aminophosphonate binding truly occurs, and this result is also confirmed by the 
thermodynamic studies. Altogether, the mechanism of TcTS inhibition by α-
aminophosphonates can be attributed to formation of the lactose binding site, and 
induction of a stable interaction with lactose or other acceptor oligosaccharides. In 
addition, binding of the α-aminophosphonate also limits the release of catalytic product 




5.2. Effect of lactose on kinetics and inhibition 
 
In the TcTS catalytic activity, lactose or other oligosaccharides play an important role 
as acceptor substrates or as part of donor substrates. Therefore, the influence of lactose 
is critical in any investigation of TcTS inhibition. In this study, MuNANA was used as 
the substrate to detect TcTS hydrolysis activity since the catalytic product 4-Mu is 
neither an inhibitor of TcTS nor the acceptor substrate, thus only hydrolysis activity 
would be detected. In the presence of lactose, the kinetics characteristics of the 
hydrolysis activity might be affected due to the interposition of acceptor substrate and 
transfer activity.  
 
In the same reaction system, both the Km and kcat of MuNANA were significantly 
increased when high concentrations of lactose (5mM) were added into the reaction 
mixture, indicating that in the presence of acceptor substrates, the Km of MuNANA is 
reduced whilst the turnover number has increased (Table 5.1). This can be explained 
since with the addition of acceptor substrates, TcTS shows trans-sialidase activity, an 
extra step of sialyation onto lactose occurs that influences the interaction with SA, 
inducing the reduction of Km of donor substrate. Moreover, because of the attack on the 
TcTS-SA intermediate by lactose, the SA moiety becomes easier to release from the 
catalytic pocket through sialylation activity, the turnover time is reduced and the 
turnover number of TcTS then increases from about 3.8 ± 0.3 s-1 to 7.6 ± 0.2 s-1. 
Additionally, the kcat/Km ratio did not show significant changes, suggesting that the 
























- 0.15 3.6 24.0 0.048 0.035 
+ 0.34 7.8 22.9 0.042 0.032 
53 
- 0.15 4.2 28.0 0.23 0.20 
+ 0.31 7.5 24.2 0.21 0.24 
 
 




of IC50 determination of compound 53; C, D. Non-linear fitting and Lineweaver-Burk plot of 
TcTS kinetics in the presence of compound 48 in different concentrations. E, F. Non-linear 
fitting and Linewaver-Burk plot of TcTS kinetics in the presence of compound 53 in different 
concentrations. 
 
Inhibition assays without lactose show that the inhibition of α-aminophosphonate 
follows non-competitive behavior, suggesting that the interaction between TcTS and 
this type of compound would not affect the binding of substrates, MuNANA in this case. 
The allosteric binding site which is observed in crystal structures indicates that α-
aminophosphonates do not interact with either the SA or lactose binding sites. Therefore, 
the influence of lactose binding in the presence of inhibitors has been investigated in 
this study.  
 
Both IC50 and inhibition assays were performed with 5 mM of lactose, which is much 
higher than the Km value of lactose in the presence of SA (0.79 mM, using MuNANA 
as donor substrate) (Wilbrink, M. H. et al., 2014), to prevent depletion of lactose during 
the assay. The IC50 of both detected inhibitors show slightly reductions in the presence 
of lactose but these are not significant, indicating that binding of lactose has no or 
limited influence on the binding and inhibition of TcTS by α-aminophosphonate 
compounds. The addition of an acceptor substrate did not change the mode of inhibition, 
and the inhibition constant Ki of both compounds investigated was unchanged.  
 
These results support that, from an enzymatic point of view, α-aminophosphonates do 
not bind to the catalytic site, nor to the lactose moiety directly. Additionally, the addition 
of inhibitor does not influence the binding of lactose, both the Km and kcat value still 
increase when inhibitor interacts with TcTS. However, the kinetic assay was based on 
the fluorescence released from the hydrolysis product 4-Mu. Thus, the donor substrate, 
which can trigger the lactose binding site formation, is crucial for the kinetic assay. 
However, it is still unclear whether the inhibitor can induce lactose binding site 




especially in the sialyation step, cannot be determined in this assay. Therefore, further 
investigations were carried out to determine whether lactose binding with TcTS in the 
presence of the α-aminophosphonate inhibitors can be informative in the interpretion 
of the inhibition mechanisms. 
 
5.3. Crystal structure of lactose bound to TcTS 
 
A single crystal of TcTS was grown as described in Chapter 4, then transferred to 
crystallization solution (condition B, chapter 4.3.2) containing 18 mg/ml purified TcTS 
and 5 mM compound 48 and incubated at room temperature for 16-20 hours. The 
soaked crystal was then transferred to crystallization solution (condition B) containing 
18 mg/ml purified TcTS, 5 mM compound 48 and 10 mM lactose. Crystal soaking with 
lactose was also performed in condition B with 10 mM of lactose, i.e. without inhibitor. 
The soaking crystals were incubated at room temperature for 12 hours, then cryo-cooled 
using by liquid nitrogen. X-ray diffraction data collection was performed using 
synchrotron radiation (Diamond Light source, UK).   
 
In the presence of lactose, the hydrolysis efficiency of TcTS is maintained at the same 
level with the increase of kcat and decrease of Km. The presence of lactose cannot change 
either the effect or mode of inhibition of α-aminophosphonates. In crystal structures of 
TcTS soaked with α-aminophosphonate compounds, the formation of lactose binding 
site was observed. Structure and surface plasmon resonance (SPR) studies show that 
lactose only binds to TcTS in the presence of bound sialic acid or its derivatives, 
suggesting that the lactose binding site only forms when the sialic acid binding pocket 
is occupied (Buschiazzo. et al., 2002). Therefore, whether the interaction of α-
aminophosphonate compounds can induce the lactose binding site formation and allow 
lactose binding without the presence of sialic acid or other donor substrates is critical 
in interpreting the mechanisms of inhibition and the mechanisms of the TcTS catalytic 




to the “closed” position, which indicates the formation of the second binding site that 
allows either donor or acceptor oligosaccharides to bind. The TcTS crystal structure 
with DANA and compound 48 (4.3.7) also indicates that Tyr119 can still rotate toward 
the sialic acid binding pocket when it is occupied by sialic acid or its derivatives, but 
the binding of aminophosphonate compounds tend to retain the conformation of Tyr119 
in the closed state. Therefore, whether binding of aminophosphonate inhibitors can 
trigger lactose binding in the lactose binding site is crucial to interpreting the inhibitory 
mechanism of aminophosphonate derivatives.  
 
Soaking of TcTS crystals in lactose solution without SA or other donor substrates had 
no electron density for lactose in the lactose-binding site (Buschiazzo. et al., 2002), this 
same result was obtained in our lab after the crystal had been soaked in 10 mM lactose 
for as long as 72 hours (data not shown). Nevertheless, using high resolution data (1.4 
Å, table 5.2) from a TcTS crystal co-soaked with both compound 48 (5mM) and lactose 



















Table 5.2 Data collection and refinement of TcTS crystal soaked with compound 48 and lactose 
(crystal structure 15) 
Crystal No. 15 
Beamline Diamond beamline i03 
Protein TcTS 
Ligand soaked 
10 mM Lactose 
5 mM compound 48 
Length of soaking (hours) 48 
Ligand identified Lactose and compound 48 
X-ray data collection 
X-ray wavelength (Å) 0.976 
Resolution (Å) 51.28-1.37 
Space Group P1 21 1 
Unit cell dimensions 
a (Å) 51.28 
b (Å) 128.76 
c (Å) 54.06 
α (°) 90 
β (°) 108.45 
γ (°) 90 
No. unique reflections 189537 
Redundancy 6.7 (5.9) 
Completeness (%) 93.0 (60.7) 
Rmerge (%) 0.046 (1.017) 
Refinement  
Reflections used  135949 
Number of protein residues  625 
Number of water molecules  689 
Number of atoms  10934 
R-factor   0.16 
R-free   0.17 
RMSD bond length (Å) 0.005 




Since TcTS has low affinity for lactose even in the presence of sialic acid (Km = 0.79 
mM), a higher concentration of lactose was used in the crystal soaking to enhance 
lactose binding (Vandekerckhove et al., 1992). As reported previously (Buschiazzo. et 
al., 2002), a TcTS crystal structure soaked with lactose alone failed to define any lactose 
molecules or fragments. However, in the co-soaked crystal structure of TcTS with both 
lactose and compound 48, after molecular replacement and a few cycles of refinement, 
both of the soaked ligands can be identified interacting with TcTS (Figure 5.2). Electron 
density map peaks which fit compound 48 can be found in the inter-domain allosteric 
binding site as described before, and the lactose molecule can also be identified in the 
lactose binding site. After refinement, the electron density map for the lactose is still 
poorer than that of the inhibitor ligand, with an occupancy of 78%, which is slightly 
lower than either the protein (occ. = 1) or the inhibitor compound 48 (occ. = 0.83), 
suggesting that either lactose has a weaker binding with the lactose binding site, which 
tends to be formed by the interaction between TcTS and the inhibitor, or that the 
conformation of lactose has a lower certainty.   
 
 
Figure 5.2. The electron density map (2Fo-mFc map contoured at σ = 0.8) of lactose and 
compound 48 (in cyan and grey stick form respectively) bound in the TcTS crystal structure 
(shown in cartoon representation, the catalytic domain in grey, lectin in orange). 
 





same as that seen in the crystal structure after soaking with inhibitor alone. Looking at 
the conformation in the catalytic site, Tyr119 has rotated to the closed position, and the 
lactose is found between Tyr119 and Trp312. When the TcTS crystal structure 
complexed with lactose only (PDB: 1MS9) (Buschiazzo. et al., 2002) is superimposed, 
the position of lactose in crystal structure 15 is highly similar (Figure 5.1 B). The 
binding position of lactose presents that only glucose part of lactose shows stacking 
with Tyr119 and Trp312, and the distance from center of cyclic center of glucose to the 
stacking residues is 5.1 Å to Tyr119 and 4.1 Å to Trp312.  
 
Figure 5.3. A. Detailed interactions of compound 48 with TcTS at the allosteric site. B. Details 






the lactose molecule seen in the crystal structure of TcTS bound with DANA and lactose (PDB: 
1MS9) shown in grey bonds following superimposition of the two structures. 
 
Therefore, considering the electronic distribution on either galactose and glucose 
(Martinez and Iverson, 2012), the lactose molecule may have a weak π-π interaction 
with both Tyr119 and Trp312. Apart from the weak π-π interaction, the main 
contribution to the interaction between lactose and TcTS is through hydrogen bonds, 
several key residues in catalytic site, such as Asp59, Tyr342 and the arginine triad are 
all interact with lactose. The average distance of the hydrogen bonds between lactose 
and binding residues is 3.8 Å, indicating that the hydrogen bonding in this interaction 
is weak (Jeffrey and Jeffrey, 1997). Both weak π-π interaction and weak hydrogen 
bonding result in an overall weak interaction between lactose and the lactose binding 
site, this finding could explain the low affinity of lactose to TcTS catalytic site even in 
the presence of sialic acid. It can also be conjectured that lactose derivatives are difficult 
to develop as a potential inhibitor due to the weak affinity of TcTS for lactose in the 
binding site. In contrast, the anthraquinone compound could be a potential inhibitor 
probing the lactose-binding site of TcTS due to the stronger interactions, since the 
distance from aromatic centers of anthraquinone to either Tyr119 or Trp312 is less than 
4Å, which is shorter than lactose (4 - 5 Å). 
 
Consequently, the crystal structure shows that binding of the α-aminophosphonate 
compounds induces lactose binding site formation independent of the SA binding site 
occupation. And stable lactose binding in the lactose-binding site occurs in a crystal 
soaked with the α-aminophosphonate inhibitor, but not in the absence of inhibitor. This 
finding suggests that the inhibition of this new class of inhibitors could be achieved 
through affecting the conformation of the catalytic site. By interaction with α-
aminophosphonates, the lactose site has increased stability and this interrupts the 






5.4. Thermodynamic study of lactose binding to TcTS 
 
The crystal structure suggested that lactose bound in the presence of an α-
aminophosphonate. To investigate the interaction of secondary substrate (lactose in this 
case) in the presence of inhibitor, a thermodynamics study was introduced. ITC was 
used as the technique to determine the temperature changes of lactose binding to the 
enzyme-inhibitor complex. In inhibition assays and the ITC study, the inhibition 
constants IC50, Ki and the binding constant Kd were all detected. Therefore, for this ITC 
assay, the enzyme was pre-incubated with 0.5 mM of the inhibitor compound 59, which 
is more than 10 times the concentration given by the inhibition constant (Ki = 0.014 
mM) to insure the interaction between TcTS and inhibitor was saturated before the 
titration of lactose began.  
 
Site directed mutagenesis of D59A was performed following the standard protocol. The 
primer pair TcTSD59AF and TcTSD59AR (Appendix 8.5) were purchased from Invitrogen, 
UK. The PCR reaction was performed using pfu DNA polymerase (source). The PCR 
product was cleaned using a QIAquick PCR purification kit (Thermo Scientific) and 
digested using Fastdigest DpnI restriction enzyme (Thermo Scientific). The digested 
PCR product was then transferred to NEB5α and plated onto LB agar plates. Single 
colonies were picked and amplified by overnight incubation in LB (with appropriate 
antibiotics), and the plasmids were extracted by GeneJET plasmid miniprep kit 
(Thermo Scientific). The insert sequence was determined by DNA sequencing (Source 
bioscience).  
 
Thermodynamic studies of TcTS interacting with lactose were performed in a Nano-
ITC (TA instrument, USA). Purified TcTS was concentrated to 0.16 mM, then dialysed 
against ITC experiment buffer (Appendix 8.2). Sialic acid (10 μl from 50 mM stock in 
ITC buffer), inhibitor compound 59 (10 μl from 20 mM stock in ITC buffer) or ITC 
buffer (10 μl) were added into 190 μl dialyzed TcTS and preincubated at 25°C for 30 




collected using NanoRun (TA instrument) and thermodynamic parameters were 
processed using NanoAnalysis (TA instrument). 
 
A previous study achieved the binding of lactose in the presence of sialic acid using a 
mutated TcTSD59N, which resulted in stable binding of lactose by eliminating catalytic 
activity (Buschiazzo. et al., 2002). In TcTSD59A the TcTS catalytic site has lost a key 
residue due to the truncation of the Asp59 side chain which plays a vital role in the 
cleavage of the donor substrate and linkage of the sialyl moiety to the acceptor 
substrates. Unsurprisingly, this mutation eliminated major hydrolysis activity of TcTS. 
Surface plasmon resonance (SPR) indicated that the binding of sialic acid or other donor 
sialyl-oligosaccharides induces the formation of the lactose binding site. The lactose 
binding experiment was measured by ITC to compare the lactose binding to TcTS in 
the presence of lactose and sialic acid then lactose would be titrated into TcTS pre-
incubated into compound 59, in order to investigate the interaction between lactose and 
TcTS-inhibitor complex.  
 
ITC results of mutated TcTSD59N (Figure 5.4) shows that lactose can bind to TcTSD59N 
in complex with sialic acid and inhibitor compound 59, with a similar range of heat 
generation increase (approximately 1.8-0.4μJ/mol) as TcTS (1-0.2 μJ/mol), indicated 
that stronger interaction occurs in TcTSD59N than TcTS. Crystal structures suggest that 
lactose binds to the catalytic site mainly by stacking with Tyr119 and Trp312, however, 
all the ITC experiments using either TcTS or TcTSD59N suggest that the interaction of 
lactose is driven by enthalpy rather than entropy, meaning that hydrogen bonds and van 






Figure. 5.4. Titration pattern (upper panels) of ITC experiment and fitted curve (lower): A. lactose 
was titrated into TcTSD59N, B. lactose was titrated into TcTSD59N plus sialic acid; C. lactose was 




Wide type TcTS failed to achieve saturation with low concentration of lactose, either in 
case of only TcTS or with the addition of sialic acid or inhibitor, since lactose bind 
weakly to TcTS even in the presence of donor substrate (MuNANA, Km= 0.79 mM) 
(Wilbrink, M. H. et al., 2014), and an ITC assay needs high substrate concentration and 
Kd ratio (c value) to achieve a proper situation curve (100>c>10) (Turnbull and Daranas, 
2003). However, when the concentration of TcTS was increased to 0.25mM, and was 
then titrated by 50mM lactose, it presented a significant saturation process (figure 5.5), 
whilst the lactose titrated into native TcTS showed a much lower level of heat 
generation, suggesting that without the presence of inhibitor, lactose tends not to 





However, the reaction parameters between lactose and TcTS are unable to be 
determined by ITC because the heat generated by the transfer sialic acid activity might 
disrupt the signal generated by lactose binding. Additionally, the c value (c=MKdn, 
where M is starting concentration of protein, Kd is the binding constant and n is the 
stoichiometry parameter) (Duff, et al., 2011) of the wild type TcTS titration by lactose 
is lower than 0.5, which will strongly impact the veracity of stoichiometry and entropy 
changes. The ITC gave a binding constant (Kd) of lactose binding in the presence of 
inhibitor is 0.46mM, which is similar to the kinetic constant (Km) of transfer-lactose 
activity. These results indicate that lactose can interact with TcTS. 
Figure. 5.5. Titration pattern of ITC experiment (upper panel), and fitted curve (lower): Blue: 
50 mM lactose titrated into 0.15 mM TcTS preincubated with 2 mM compound 59. Green 50 







Lactose plays a crucial role in TcTS catalytic activity as an acceptor substrate, thus it is 
important to evaluate TcTS activity and inhibition in the presence of lactose. In kinetics 
studies, addition of lactose did not change the overall catalytic efficiency but influenced 
the kinetics parameters such as Km and kcat. The changes of kinetics parameter induced 
by lactose were not affected by α-aminophosphonate inhibitors, illustrating that this 
type of inhibitor is neither competitive against donor structure nor acceptor substrate in 
the interaction with TcTS, supporting the crystallographic data that it binds to a novel 
allosteric site but not in the catalytic pocket.    
 
In the crystal structure soaked with both inhibitor and lactose, the hypothesis of lactose 
binding site formation has been proved and supported by lactose binding determination 
in both structural and thermodynamic studies. With induction of lactose-binding site 
formation, the Km of lactose binding is unchanged compared to the lactose-binding site 
formation induced by DANA. Thus, as observed from the crystal structures, the 
formation of the lactose binding site, which is triggered by either sialic acid or allosteric 
inhibitors would have similar effect on lactose binding site formation. The presence of 
α-aminophosphonate did not change the Km between donor substrate, in this case 
MuNANA, and the TcTS catalytic site but did reduce the turnover number (kcat) of the 
hydrolysis activity, with or without lactose. It illustrates that with α-aminophosphonate 
bound, donor substrates can still interact with the SA binding site, and the most probable 
inhibitory mechanism is to abolish the catalytic process or prevent substrate release.   
 
This structure characteristic is also proved by thermodynamic studies. In the presence 
of an α-aminophosphonate compound, lactose shows a significant interaction with the 
TcTS protein and this interaction tends to be saturated with increasing lactose 
concentration, suggesting that the binding between lactose and TcTS-inhibitor complex 




inhibitor binding, but also suggest that the lactose binding is stable, which may explain 


















































6.1. Future development of a potential TcTS inhibitor based on the 
inter-domain allosteric site 
 
The discovery of a TcTS inhibitor has been a great challenge for rational drug design 
due to its complex catalytic site structure and mechanisms. During the last decade, 
numerous strategies have been applied to the design of potential TcTS inhibitors, 
including modification of natural substrates, and high-throughput screening of the 
databases of known compounds. Unfortunately, unlike other sialidases which can be 
inhibited by substrate analogues, TcTS cannot be inhibited strongly by substrate-related 
compounds, especially SA analogues. This failing can be attributed to the unique 
structure of the TcTS catalytic site which has an extra hydrophobic “gate” (Tyr119 and 
Trp312), which might affect the recognition and interaction with inhibitor molecules. 
In addition, the dual-substrate catalytic mechanism is another possible reason to explain 
the weak inhibition of SA-related inhibitors. Due to TcTS’s sialylation activity, many 
SA analogues, such as DANA, can be used as a donor substrate which will be released 
from the catalytic site through attack by either water or an acceptor molecule 
(Buschiazzo. et al., 2002). Interestingly, after broad range screening among different 
small molecule databanks, the most potent inhibitors targeting TcTS were both 
compounds which are not related to substrates. And numbers of compounds inhibit 
TcTS activity in a non-competitive manner, which suggests the existance of an extra 
binding site apart from the catalytic pocket.   
 
This study describes α-aminophosphonate derivatives as a new type of TcTS inhibitor, 
which were designed by mimicries and simplification of the natural substrates of TcTS. 
Nevertheless, the inhibition mechanism assays went contrary to our initial plans and 
suggested non-competitive inhibition. And further kinetics results, including inhibitor 
removal and time-dependent experiments, supported this result that the inhibition 
triggered by α-aminophosphonate corresponds was both non-competitive and a non-




competitive and non-covalent binding and indicate a novel allosteric site located 
approximately 30 Å from the catalytic pocket (Figure 7.1). The electrostatic 
characteristics of this allosteric site show that this binding site between the two domains 
of TcTS is mainly positively-charged, which is adequate for the binding of phosphonic 
acid compounds. None of the catalytic residues are involved in the allosteric binding 
site, indicating that the inhibition is by an indirect mechanism. And no major 
conformation change occurs, the interaction at the allosteric site only induces 
rearrangement of several residues like a closing door.  
 
Figure 6.1. The catalytic site and allosteric binding site of TcTS, presented in a surface 
representation with electrostatic colorings, the positively charged residues are in blue and 
negatively charged residues are in red. Catalytic site is highlighted by a solid red circle. The 
allosteric binding site is circled by a red dashed line, in which the phosphonate binding area is 
highlighted by a green circle and aromatic binding areas by brown circles.   
 
The allosteric binding has three contributing parts (Figure 6.1, Table 6.1), the multiple-
rings aromatic group stacking (Arg249, Leu252), benzene ring interaction (Arg577), 




structural studies including those in this thesis about ligand binding to TcTS, 
phosphonate compounds are the only molecules that can be identified in this allosteric 
site, suggesting that the phosphate group is the core of the allosteric interaction. 
Moreover, the geometry of the phosphate moiety indicates that it possibly fits better 
with a tetrahedral acidic structure such as phosphate or sulfonate groups (Figure 6.2). 
In further potential inhibitor design and screening, this hypothesis could be investigated 
with different substitutions for this moiety. 
 
Table 6.1 Polar and hydrophobic interactions between TcTS and α-aminophosphonates 










48, 59, 61 Anthracene Cation-π interaction 3.3 
62, 63 Anthraquinone Hydrogen bond 3.4 
Leu252 
48, 59, 61 Anthracene Hydrophobic 
interaction 
3.5-4.0 





*All  Phosphate 








Hydrogen bond 2.5-3.0 




*All Phenyl Cation-π interaction 3.0-3.5 
59, 63 Acetamido O Hydrogen bond 2.8-3.2 
61 Hydroxyl O Salt bridge 3.8 





Figure 6.2. 2D view of the interaction between compound 59 and TcTS at the allosteric binding 
site, hydrogen bond is presented as purple lines, salt bridges as purple dashed lines, and the 
cation-π interaction is shown as orange lines. Generated by LeView (Caboche, 2013). 
 
Aminosulfonate (64) is able to be synthesized as a replacement of phosphonate to form 
the corresponding sulfonate compounds (Mauro, 2010). Based on the phenyl-phenyl 
compound, the synthesis of a phenyl-naphthalene compound (65) was attempted by an 
undergraduate project student, but it failed to purify by column chromatography. 
Nevertheless, the impure sample still gave an IC50 of 0.06 mM (data not shown), which 
is similar to the phenyl-anthracene aminophosphonate compound (48, IC50 = 0.045 
mM). This attempt suggests that aminosulfonate compounds could also be a potential 
type of inhibitor against TcTS. It can be seen that the nitrogen at the amino group only 
interacts with solvent but not with any residue of TcTS in the allosteric binding site, 
indicating that the amino group might not contribute to the ligand affinity and inhibition 
process. Therefore, replacing the amino-nitrogen by a carbon ion could be beneficial to 
the chemical stability of the compounds. Looking at phosphonate compounds, 
phenylphosphonic acid (66) has been reported as a human prostatic acid phosphatase 
inhibitor (Schwender et al., 1996), so further modifications can be achieved through a 




been reported which can be used as the basic skeleton for further modifications (Enders 
et al., 2002). 
 
Based on structural studies and previous research, the phosphate group could be 
considered as a possible reason for the non-catalytic-pocket binding since all 
phosphonate inhibitors against TcTS are non-competitive inhibitors. Another strategy 
in molecular mimicry could be replacement of the phosphate group by a carboxyl group 
which would maintains the negatively charged substitutent seen in SA. Both the amino 
acid derivative (68) and a compound that replaced the nitrogen with a carbon (69) have 
been reported to be synthesized (Juhl et al., 2017; Sathe et al., 2013).  
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The mechanism of the allosteric inhibition by α-aminophosphonates can be attributed 
to the formation of the lactose-binding site and induction of lactose binding without the 
presence of SA substrates. However, the detailed molecular mechanisms that trigger 
conformation change of the catalytic site indirectly need further investigation. 
Molecular dynamics (MD) simulation will be a powerful tool to probe the effect on key 
residues at the catalytic site after interacting with α-aminophosphonates. Further 
biochemical and biophysical techniques such as mutagenesis, kinetics studies, 
structural studies, etc. would favor the interpreting of the molecular mechanisms of this 
allosteric inhibition accomplished with computer-assisted approaches. 
 
6.2. Future inhibitor development based on catalytic site 
 
The catalytic site is the most important site for TcTS activity, as well as for potential 
inhibitor design. In our XRC study of the known inhibitor Rhein, to our surprise we 
found that the inhibitor molecule interacts with the lactose binding site, a part of the 
catalytic site. This finding suggests that lactose-site binding might not affect the 
interaction between TcTS and its donor substrate. The hydrophobicity distribution of 
the TcTS catalytic site (Figure 6.4) shows that the areas on both the top and the bottom 
of the SA binding pocket are hydrophilic, which favors SA interaction. In the closed 
conformation, the hydrophilic area above the SA binding pocket is reduced and covered 
behind the “closed door” formed by Tyr119 and Trp312, Therefore, the hydrophilic area 
below the SA pocket could be important for SA binding. For example, the mutagenesis 





Figure 6.4. The surfaces of the open (A) and closed (B) conformation of the TcTS catalytic 
pocket, colourd by hydrophobicity (image generated by Chimera). Blue is hydrophilic, white is 
hydrophobic, and tan is maximum hydrophobic. The lactose binding site is formed by Tyr119 
and Trp312, the SA binding site is circled by purple dashed line. 
 
Additionally, the soaked crystal structures show that both naphthalene and anthracene 
do not interact with the catalytic site, and that anthraquinone and lactitol and other 
lactose derivatives, are lactose site binders, which can be applied to future drug 
discovery as useful fragments. In terms of the SA binding site, in all soaked crystal 
structures, it appears that the phenyl-phosphonate cannot bind to the catalytic site like 
SA and its derivatives. But fragment-based drug design by Telford indicated that proline 
could be a potential SA-site binder (Telford, 2014). Therefore, future structural based 
drug design could be measured based on these findings. For example, the compound 
that combines proline and anthraquinone (70) could be a potential inhibitor which binds 
to both the SA pocket and lactose binding site, the synthesis could be based on that of 
the known compounds 2-(phenylmethyl)-L-Proline (71) (Sutar and Joshi, 2013) and 2-


















Figure 6.5 Structure of Proline-based predicted TcTS inhibitors. 
 
In the interaction between α-aminophosphonate compounds and the TcTS inter-domain 
allosteric site, the replacement of the glycosidic bond oxygen by a nitrogen did not 
utilise its function and did not even have any interaction in the allosteric binding. 
However, in structure-based design based on catalytic site binding fragments, the 
nitrogen linkage between SA-mimic moiety and lactose-mimic moiety can still be 
expected to interact with Asp59 through acidic-basic interactions. SA and SA 
derivatives are not good inhibitors of TcTS, but SA-1-N- compounds might have a 
better inhibition effect since it would also interact with the lactose-binding site based 
on SA substrate recognition. For example, with simple alteration of the glycosidic bond 
into an amino bond on SAL (73) it is possible to achieve catalytic site binding without 
hydrolysis activity, inducing TcTS inactivation. Aromatic groups, for instance, 4-
nitrophenyl (74, Vibrio cholera neuraminidase inhibitor) (Khorlin et al., 1970) and 
anthraquinone (75), can be attached to SA by an N-link for a π-π interaction with the 



















Figure 6.6 Structure of predicted TcTS inhibitors based on SA. 
 
 
6.3. Future directions for the investigation of TcTS catalytic 
mechanisms  
 
Through the investigation of TcTS-inhibitor complex structure and inhibitory 
mechanisms, useful information would be provided for further research into the 
inhibition, catalytic mechanisms, and even further applications of the biosynthesis 
activity of TcTS. Firstly, TcTS is currently only a potential therapeutic target against 
Chagas disease because of the lack of strong and specific inhibitor. α-
Aminophosphonates are potential inhibitors but still need improved inhibition effect 
and specificity. In vivo pharmacokinetics study and cytotoxicity studies should be 
measured especially as these are non-natural compounds. Fortunately, the crystal 
structures of TcTS-inhibitor complex have been solved making future rational 











































After intensive research for more than a decade, the catalytic process of TcTS is 
basically understood. However, there are still several unsolved questions regarding 
detailed mechanisms and biological roles. One of the key arguments about the catalytic 
mechanism is whether the two-step reaction follows a classical ping-pong mechanism 
or a ternary-complex mechanism. In the classical ping-pong mechanism, the binding of 
the acceptor substrate in the lactose binding site occurs after the release of the 
hydrolysis product (Damager et al., 2008). However, after the release of the hydrolysis 
product glycans, the TcTS-SA complex could be attacked by solvent rather than 
accepter glycans, resulting in a low efficiency of SA transfer activity (Oliveira et al., 
2014). Therefore, a ternary complex of TcTS, donor substrates and acceptor substrates 
could prevent miss-attack by solvents. In our crystal structure studies, anthraquinone 
derivatives, a type of non-competitive inhibitor of TcTS, was identified in the lactose 
binding site, illustrating the possibility of the ternary complex formation.  
 
Another question for the sequential catalytic process is that it could lead to the re-
sialylation of donor glycans, which will also result in low efficiency. From enzyme 
kinetics, it is reported that TcTS shows selectivity for the acceptor, for example, using 
MuNANA as the SA donor, TcTS has higher affinity towards 3’-galactosyl-lactose than 
lactose (Wilbrink, Maarten H et al., 2014). However, in the case of TcTS activity in 
vivo, when host sialyl-glycans are structurally similar to T. cruzi mucin glycans, how 
TcTS prevents transfer inaccurately to host glycans and hydrolysis of T. cruzi sialyl 
mucin glycans is still unclear. The channel between catalytic site and the inter-domain 
allosteric site is a potential binding site for longer glycan chains since multiple polar 
small molecules such as glycerol or PEG derivatives bind (Figure 6.7), indicating that 
this area may have some function in substrate recognition. Thus, the future studies about 
TcTS catalytic details could focus on two major aspects, the first being the intermediate 
ternary complex, and the second the substrate recognition. A better understanding of 
the TcTS mechanism could favour future drug candidate development, in order to 
develop an effective chemical therapy against Chagas disease. And the interpretation 




products using TcTS as a catalyst.  
 
Figure 6.7. Overview of crystal structure of TcTS soaked with lactose and compound 48. 
Catalytic domain residues are shown in blue and lectin-like domain in orange. Compound 48 is 


























































7.1.1. Chemicals, reagents and solvents. 
 
Table 7.1. List of chemicals, solvent and their suppliers. 
Chemical Supplier 
1 kb plus DNA ladder Invitrogen 





2-O- (4-methylumbelliferyl) -a-D-N-acetylneuraminic acid carbosynth 
2-Propanol Sigma-Aldrich 
3,5-Bis(trifluoromethyl)benzaldehyde Sigma-Aldrich 
36.5% formaldehyde solution Sigma-Aldrich 
4-(Trifluoromethyl)benzaldehyde Sigma-Aldrich 
4-Acetamidobenzaldehyde Sigma-Aldrich 





4-Nitrobenzaldehyde  Sigma-Aldrich 
4-Nitrobenzamide  Sigma-Aldrich 
6X DNA loading dye Thermo scientific 
Acrylamide 40% solution Fisher scientific 
Agarose, electrophoresis grade Melford 
Ampicillin Sigma-Aldrich 




Bovine Serum Albumin (BSA) Sigma-Aldrich 
Brilliant Blue R-250 Fisher scientific 
Bromophenol Blue Sigma-Aldrich 
Bromotrimethylsilane purum Sigma-Aldrich 
Calcium chloride Sigma-Aldrich 





Dimethyl phosphite Sigma-Aldrich 
Dimethyl sulfoxide (DMSO) Sigma-Aldrich 
EDTA- disodium salt Sigma-Aldrich 
Ethidium bromide Sigma-Aldrich 
Ethylenediaminetetraacetic acid (EDTA) Sigma-Aldrich 
Fast digest DpnI restriction enzyme       Thermo scientific 
Glycerol Fisher scientific 
Glycine Fisher scientific 
HEPES Sigma-Aldrich 
Kanamycin sulfate Sigma-Aldrich 
Lactose anhydrous carbosynth 
LB-Agar miller Fisher scientific 
Magnesium chloride Fluca 
Magnesium sulfate Sigma-Aldrich 
N-Acetyl-2,3-dehydro-2-deoxyneuraminic acid(DANA) Sigma-Aldrich 





Nickel sulfate Sigma-Aldrich 
PEG 4000 Sigma-Aldrich 
Pfu DNA Polymerase Agilent 
Phosphate buffer saline tablets Oxoid 
Phusion DNA Polymerases Thermo scientific 
Polyethylene glycol (PEG) 3350 Sigma-Aldrich 
Potassium sulfate Sigma-Aldrich 
RNAse A solution Promega 
Sodium acetate Sigma-Aldrich 
Sodium chloride Fisher scientific 
Sodium dodecyl sulphate (SDS)   Sigma-Aldrich 
Sodium hydrogen carbonate Fisher scientific 
T4 DNA ligase New England Biolabs 
T4 DNA ligase 10X buffer New England Biolabs 
Tetramethylethylenediamine (TEMED) Sigma-Aldrich 






Triton X-100 BDH laboratory 
Trizma base Fisher scientific 
Tryptone BD 
Xhol I restriction enzyme New England Biolabs 
Yeast extract  BD  
Solvent Supplier 
Acetone HPLC grade Fisher 
Dichloromethane  Fisher 
Ethanol  Fisher 
Ethyl acetate Fisher 
Ethyl ether Fisher 
Methanol  Fisher 
Petroleum ether  Fisher 
Toluene  Fisher 





7.1.2. Plasmids, cell strains and media 
 
7.1.2.1. Expression plasmids 
 
The plasmid TcTS-pTrcHisA encoding recombinant TcTS truncated to contain only the 
catalytic and lectin-like domains with 7 mutations (Asn58Phe, Ser495Lys, Val496Gly, 
Glu520Lys, Asp593Gly, Ile597Asp, and His599Arg) on the surface of protein  
(performed to produce a crystallizable TcTS construct (Buschiazzo. et al., 2002)) was 
provided as a gift from the Prof. P. Alzari group (Pasteur Institute, Paris, France). None 
of these mutations directly involve in catalytic progress, although Asn58Phe is close to 
the catalytic site, and the mutations will not affect TcTS activity. The pTrcHisA 
(ampicillin resistance, Appendix 8.1) expression plasmid is designed for effective 
expression of recombinant protein controlled by the pTrc (lac) promotor (Li et al., 
1984), and contains a 6- histidine tag on the N-terminus...  
 
Plasmid SpCBM-pHisTEV was provided as a gift from Prof. G. Taylor group 
(University of St. Andrews, UK). pHisTEV vector (kanamycin resistance, Appendix 
8.1), which is modified from the pET21d expression vector, is used for expression of 
N-terminal His-tagged protein with the tag cleavable with TEV protease. 
 
7.1.2.2. Cell strains 
 
The E. coli strains XL-Gold Ultra and XL-Blue (Agilent) chemically competent cells 
were used for TcTS molecular cloning experiments. For mutagenesis experiments and 
cloning of SpCBMcat recombinant protein, E. coli strain NEB5α (NEB, UK) was 
applied. The E. coli strain BL21 (DE3) (NEB) chemically competent cells were used 








E. coli cells were cultured in autoclaved sterilized luria-bertani broth (LB, recipe given 
in Appendix table 8.2.), which is a nutritionally-rich medium. All components were 
weighed and dissolved into 900ml distilled water then autoclaved and stored at room 
temperature or 4°C for longer storage. Antibiotic stock solutions (100mg/ml ampicillin 
or 50mg/ml kanamycin) were added to the medium at a dilution of 1/1000 (v/v) prior 
to the cell culture. Transformed competent cells were spread onto LB agar plates 
containing 2% agar powder in LB media. The LB agar solution was autoclaved and 
allow to cool down to 45°C before adding the antibiotic solutions, the media was poured 
into 90mm Petri dishes with 10ml per dish. The LB agar plates were sealed and stored 
at 4°C.  
 
TB based auto-induction medium (TBAIM) was used to express proteins cloned into 
pTrc vectors where protein expression is controlled by trc promotor. Like LB medium, 
TB medium also contain tryptone, and yeast extract, but it also has additional 0.5% of 
glycerol, and 10x TB salt which contains 0.17M KH2PO4 and 0.7M K2HPO4, which 
would prepared and autoclaved separately (Appendix 8.2). After cooling down, 100ml 
of 10x TB salt solution was added to 900ml TB medium and the appropriate antibiotics 
added before cell culture.    
 
After transformation, E. coli cells were recovered in super optimal medium with 
catabolite repression (SOC, Appendix 8.2). SOC media is a rich media with multiple 













Chemical reagents were purchased from Sigma-Aldrich unless specifically stated. 
Anhydrous solvents were purchased from Sigma-Aldrich and used without further 
purification. All other solvents were purchased from Fisher Scientific. Analytical thin 
layer chromatography (TLC) was carried out on Merck aluminium backed TLC plates 
silica gel 60 F254 (0.25 mm thickness), viewed using UV light of wavelength 254 nm 
or stained with potassium permanganate solution or para-anisaldehyde stain. Silica gel 
chromatography was performed on silica gel 60 Å (200-400 mesh) from Sigma-Aldrich. 
Standard work-up is referring to diluting the reaction residue in appropriate organic 
solvent (mentioned), washing with an aqueous saturated sodium bicarbonate solution, 
followed by washing with brine. The organic phases were then combined and dried over 
anhydrous magnesium sulphate, filtered and the filtrate concentrated in vacuo. 
Preparative reverse phase chromatography (C-18) was performed using a VersaFlash 
hand held column (23 x 110 mm) from Supelco. Melting points were obtained using a 
Thermo Fisher IA9000 digital melting point apparatus. 1H, 13C and 31P NMR spectra 
were recorded using Bruker Advance III (400 and 500 MHz) spectrometers with 
acquisition frequencies of 400 or 500 MHz for 1H; 101 or 125 MHz for 13C; and 162 
MHz for 31P. Deuterated solvents were purchased from Cambridge Isotope Laboratories. 
The NMR chemical shifts δ are recorded in parts per million (ppm) with reference to 
tetramethylsilane for 1H and 13C and phosphoric acid for 31P NMR spectroscopy. The 
multiplicities are assigned as a singlet (s), doublet (d), triplet (t), quartet (q), doublet of 
doublets (dd), doublet of doublet of doublets (ddd), doublet of triplets (dt), triplet of 
doublets (td), broad (br) and multiplet (m). High resolution mass spectrometry was 






7.2.2. Synthesis of protected aminophosphonate 
 
 
S41. Dimethyl (phenyl (phenylamino) methyl) phosphonate 
A mixture of benzaldehyde (0.48 mL, 4.7 mmol) and analine (0.45 mL, 4.7 mmol, 1.0 
equiv.) were dissolved in dimethyl phosphite (5 mL, 10.0 equiv. v/v) and the resultant 
solution subjected to microwave heating (90 W) for 5 minutes. The reaction mixture 
then subjected to a standard work-up (DCM) and purified by column chromatography 
(35 % EtOAc/petroleum ether) to give the protected aminophosphonate S41 as a white 
solid (1.02 g, 75 %). Spectroscopic data (1H and 13C NMR) was consistent with that 
reported in the literature (Tajbakhsh et al., 2008).  1H NMR (400 MHz, CDCl3): δ 7.48 
– 7.40 (m, 2H, Ar), 7.35 – 7.26 (m, 2H, Ar), 7.26 – 7.19 (m, 1H, Ar), 7.12 – 7.00 (m, 
2H, Ar), 6.66 (t, J = 7.3Hz, 1H, Ar), 6.60 – 6.53 (m, 2H, Ar), 4.81-4.70(m, 2H, NH, P-
CH ), 3.71 (d, J = 10.6 Hz, 3H, OMe), 3.43 (d, J = 10.6 Hz, 3H, OMe).13C NMR (100.6 
MHz, CDCl3): δ 146.16, 129.13, 128.65, 127.98, 127.76, 118.48, 113.85, 55.68 (d, J = 
151.3 Hz, P-CH), 53.75, 53.69. 31P NMR (161.93 MHz, CDCl3): δ 24.96. HRMS (ESI): 
Calculated for C15H19NO3P (M+H)+: m/z = 292.1024, found m/z = 292.1066. 




S42. Dimethyl ((naphthalen-1-ylamino) (phenyl) methyl) phosphonate 














(0.14 g, 4.7 mmol, 1 equiv.) were dissolved in dimethyl phosphite (5 mL, 10.0 equiv. 
v/v) and the resultant solution subjected to microwave heating (90 W) for 5 minutes. 
The reaction mixture then subjected to a standard work-up (DCM) and purified by 
column chromatography (60 % EtOAc/petrol) to give the protected aminophosphonate 
S42 as a white solid (1.36 g, 85 %). Spectroscopic data (1H and 13C NMR) was 
consistent with that reported in the literature (Mu et al., 2006). 1H NMR (400 MHz, 
CDCl3):  δ 8.06-8.03 (m, 1H, Ar), 7.79 (d, J = 8.0Hz, 1H, Ar), 7.56 – 7.45 (m, 4H, 
Ar), 7.38 – 7.22 (m, 4H, Ar), 7.19-7.16 (m, 1H, Ar), 6.49 – 6.37 (m, 1H, Ar), 5.49 (s, 
1H, NH), 3.80 (d, J = 10.6 Hz, 3H, OMe), 3.53 (d, J = 10.6 Hz, 3H, OMe). 13C NMR 
(101 MHz, CDCl3) δ 141.05, 135.25, 134.20, 128.72, 128.62, 128.07, 127.58, 126.13, 
125.85, 125.11, 123.88, 119.97, 118.69, 106.54, 55.87 (d, J = 151.0 Hz, P-CH), 53.85, 
58.81. 31P NMR (162 MHz, CDCl3): δ 24.94. HRMS (ESI) calculated for C19H21NO3P 






S44. Dimethyl (([1,1'-biphenyl]-3-ylamino)(phenyl)methyl)phosphonate 
A mixture of benzaldehyde (0.48, 4.7 mmol, 1.0 equiv.) and 3-Aminobiphenyl (0.79 g, 
4.7 mmol, 1.0 equiv.) were dissolved in dimethylphosphite (5 mL, 10.0 equiv. v/v) and 
the resultant solution subjected to microwave heating (90 W) for 7 minutes. The 
reaction mixture then subjected to a standard work-up (DCM) and purified by column 
chromatography (32 % EtOAc/petrol) to give the protected aminophosphonate (S44) as 
a white solid (1.34 g, 84 %). Spectroscopic data: 1H NMR (400 MHz, CDCl3) δ 7.50 – 
7.43 (m, 2H, Ar), 7.43 – 7.37 (m, 2H, Ar), 7.36 – 7.27 (m, 4H, Ar), 7.27 – 7.24 (m, 1H, 
Ar), 7.23 – 7.18 (m, 1H, Ar), 7.11 (t, J = 7.8 Hz, 1H, Ar), 6.89-6.86 (m, 1H, Ar), 6.79 









Hz, 1H, P-CH), 3.72 (d, J = 10.7 Hz, 3H, OMe), 3.43 (d, J = 10.6 Hz, 3H, OMe). 13C 
NMR (101 MHz, CDCl3) δ 146.42, 135.56, 129.49, 128.70, 128.52, 128.03, 127.79, 
127.73, 127.11, 126.96, 117.57, 112.81, 112.67, 55.71 (d, J = 151.4 Hz, P-CH), 53.76, 
53.69.  31P NMR (162 MHz, CDCl3): δ 24.88. HRMS (ESI) calculated for 
C21H24N2O4P [M+H]+: 368.1414. Found: 368.1415. Calculated for C21H23N2O4PNa 




S45. Dimethyl (([1,1'-biphenyl]-2-ylamino) (phenyl) methyl) phosphonate 
A mixture of benzaldehyde (0.48 ml, 4.7 mmol, 1.0 equiv.) and 2-aminobiphenyl (0.79 
g, 4.7 mmol, 1.0 equiv.) were dissolved in dimethyl phosphite (5 mL, 10.0 equiv. v/v) 
and the resultant solution subjected to microwave heating (90 W) for 5 minutes. The 
reaction mixture then subjected to a standard work-up (DCM) and purified by column 
chromatography (30 % EtOAc/petrol) to give the protected aminophosphonate (S45) as 
a white solid (1.3 g, 76.4 %). Spectroscopic data: 1H NMR (400 MHz, CDCl3): δ 7.53 
– 7.44 (m, 4H, Ar), 7.40-7.38 (m, 3H, Ar), 7.37 – 7.31 (m, 2H, Ar), 7.31 – 7.27 (m, 1H, 
Ar), 7.14 – 7.09 (m, 2H, Ar), 6.79 (t, J = 7.4Hz, 1H, Ar), 6.64 – 6.46 (m, 1H, Ar), 4.99 
(s, 1H NH), 4.80 (br. d, J = 24.2 Hz, 1H, P-CH), 3.62 (d, J = 10.6 Hz, 3H, OMe), 3.47 
(d, J = 10.6 Hz, 3H, OMe). 13C NMR (100.6 MHz, CDCl3): δ 143.14, 138.88, 135.61, 
130.25, 129.18, 128.92, 128.78, 128.62, 127.96, 127.62, 127.50, 118.28, 111.89, 56.13 
(d, J = 150.8 Hz, P-CH), 53.69, 53.52. 31P NMR (162 MHz, CDCl3): δ 24.51. HRMS 
(ESI) calculated for C21H24N2O4P [M+H]+: 367.1337. Found: 368.1414. Calculated for 












S48. Dimethyl ((anthracen-1-ylamino) (phenyl) methyl) phosphonate 
A mixture of benzaldehyde (0.48 g, 4.7 mmol, 1.0 equiv.) and 1-aminoanthracene (0.91 
g, 4.7 mmol 1.0 equiv.) were dissolved in dimethyl phosphite (5 mL, 10.0 equiv. v/v) 
and the resultant solution subjected to microwave heating (90 W) for 9 minutes. The 
reaction mixture then subjected to a standard work-up (DCM) and purified by column 
chromatography (80 % EtOAc/petrol) to give the protected aminophosphonate (S48) as 
a brown solid (1.1 g, 87 %). Spectrocopic data:  1H NMR (400 MHz, CDCl3): δ 8.59 
(s, 1H, Ar), 8.36 (s, 1H, Ar), 8.16 – 8.08 (m, 1H, Ar), 8.02 – 7.94 (m, 1H, Ar), 7.61 – 
7.53 (m, 2H, Ar), 7.53 – 7.44 (m, 2H, Ar), 7.44 – 7.24 (m, 4H, Ar), 7.20 – 7.10 (m, 1H, 
Ar), 6.40 – 6.33 (m, 1H, Ar), 5.70 (s, 1H, NH), 5.06 (d, J = 23.9 Hz, 1H, P-CH) 3.85 
(d, J = 10.7 Hz, 3H, OMe), 3.54 (d, J = 10.5 Hz, 3H, OMe). 13C NMR (100.6MHz, 
CDCl3): δ 140.63, 135.17, 132.34, 131.57, 131.05, 128.75, 128.44, 128.10, 127.70, 
127.63, 127.58, 126.71, 125.61, 125.27, 123.81, 118.89, 118.63, 104.51, 55.83 (d, J = 
151.4 Hz, P-CH), 53.97, 53.91. 31P NMR (162 MHz, CDCl3): δ 24.94. HRMS (ESI) 




S50. Dimethyl ((4-chlorophenyl) (naphthalen-1-ylamino) methyl) phosphonate 
A mixture of 4-Chlorobenzaldehyde (0.5g, 4.7mmol, 1.0 equiv.) and 1-naphthylamine 
(0.672g, 4.7mmol, 1.0 equiv.) were dissolved in dimethyl phosphite (5 ml, 10.0 equiv. 
v/v) and the resultant solution subjected to microwave heating (90 W) for 5 minutes.  















column chromatography (70% EtOAc/PetEther) to give compound S50 at white solid. 
Yield: 0.98g (87%). Spectroscopic data: 1H-NMR (400MHz, CDCl3): δ 8.02-7.99 (m, 
1H, H-Ar), 7.81-7.77 (m, 1H, H-Ar), 7.55-7.44 (m, 4H, H-Ar), 7.33-7.30(m, 2H, H-Ar), 
7.27 (d, 1H, J=8.4Hz, H-Ar), 7.19-7.15 (t, 1H, J=16Hz, H-Ar), 6.36 (d, 1H, J=7.2Hz, 
H-Ar), 5.42 (s, 1H, N-H), 4.98(d, 1H, J=24Hz, P-CH),3.82 (d, 3H,, J=10.8Hz, OMe), 
3.62 (d, 3H, J=10.8Hz, OMe). 13C NMR (100.6MHz, CDCl3): δ 140.83, 140.69, 134.21, 
133.93, 133.89, 128.96, 128.93, 128.85, 128.68, 126.04, 125.96, 125.84, 123.85, 119.87, 
119.02, 106.59, 56.09 (d, J = 150.3 Hz, P-CH), 54.59, 54.08. 31P-NMR (161.93MHz, 
CDCl3): δ 24.10. HRMS: Calculated for [C19H21ClNO3P]: m/z=375.0869, found [M+H] 





S51. Dimethyl((naphthalen-1-ylamino) (4-(trifluoro-methyl) phenyl) methyl) phos-
phonate 
A mixture of 4-(Trifluoromethyl) benzaldehyde (0.5g, 2.87 mmol, 1.0 equiv.) and 1-
naphthylamine (0.41g, 2.8 mmol, 1.0 equiv.) were dissolved in dimethyl phosphite (5 
ml, 10.0 equiv.) and the resultant solution subjected to microwave heating (90 W) for 7 
minutes. The reaction mixture then subjected to a standard work-up (DCM) and purified 
by column chromatography (70% EtOAc/PetEther) to give compound S51 at white 
solid. Yield: 0.65g (55.5%). Spectroscopic data: 1H-NMR (400MHz, CDCl3): δ 8.23 (d, 
2H, J=6.6Hz, H-Ar), 7.96 (s, 1H, H-Ar), 7.82 (d, 2H, J=6.3Hz, H-Ar,), 7.71-7.52 (m, 
4H, H-Ar), 7.24-7.15 (m, 2H, H-Ar), 6.34 (q, 1H, H-Ar, J=8.2Hz), 5.53 (s, 1H, N-H), 
5.08(d, 1H, P-CH, J=21.6Hz),3.85 (d, 3H, OMe, J=10.8Hz), 3.69 (d, 3H, OMe, 
J=10.2Hz). 13C NMR (100.6MHz, CDCl3): δ 141.85, 140.66, 140.16, 139.28, 135.37, 










120.07, 117.04, 58.31 (d, J = 153.3 Hz, P-CH), 53.97, 53.67, 31P-NMR (161.93MHz, 
CDCl3): δ 24.60. HRMS: Calculated for [C20H20F3NO3P]: m/z=409.1124, 




S52.Dimethyl ((3,5-bis(trifluoromethyl) phenyl) (naphthalen-1-ylamino) methyl) 
phos-phonate 
A mixture of 3,5-Bis(trifluoromethyl)benzaldehyde (0.5g, 2.06 mmol, 1.0 equiv.) and 
1-naphthylamine (0.295g, 2.06 mmol, 1.0 equiv.) were dissolved in dimethyl phosphite 
(5ml, 10 equiv.) and the resultant solution subjected to microwave heating (90 W) for 
7 minutes. The reaction mixture then subjected to a standard work-up (DCM) and 
purified by column chromatography (80% EtOAc/PetEther) to give compound S52 at 
white solid. Yield: 0.82g (83.6%). Spectroscopic data: 1H-NMR (400MHz, CDCl3): δ 
8.04 (t, 3H, J=17.6Hz, H-Ar), 7.83 (t, 2H, J=8.2Hz, H-Ar), 7.58-7.50 (m, 2H, H-Ar), 
7.32 (d, 1H, H-Ar, J=8.4Hz), 7.21 (t, 1H, J=16Hz), 6.29 (d, 1H, J=5.6Hz, H-Ar), 5.48 
(s, 1H, NH), 5.08(d, 1H, J=24.4Hz, P-CH), 3.85 (d, 3H, OMe, J=10.8Hz), 3.69 (d, 3H, 
J=10.8Hz, OMe). 13C NMR (100.6MHz, CDCl3): δ 142.65, 140.15, 140.06, 137.18, 
133.27, 131.56, 128.95, 128.58 (d, C-Ar, J=2.4Hz), 127.87, 126.23, 126.17, 125.37, 
125.07, 124.76, 122.36, 121.83, 120.05, 116.04, 56.35 (d, J = 153.3 Hz, P-CH), 54.07, 
53.97, 31P-NMR (161.93MHz, CDCl3): δ 24.23. HRMS: Calculated for 
[C21H19F6NO3P]: m/z=477.1007, found [M+H]+ =478.1019.14. Calculated for 














S53. Dimethyl ((4-acetamidophenyl) (naphthalen-1ylamino) methyl) phosphonate 
A mixture of 4-Acetamidobenzaldehyde (0.5g, 3.06 mmol, 1.0 equiv.) and 1-
naphthylamine (0.437g, 3.06 mmol, 1.0 equiv.) were dissolved in dimethyl phosphite 
(5ml, 10 equiv.) and the resultant solution subjected to microwave heating (90 W) for 
8 minutes. The reaction mixture then subjected to a standard work-up (DCM) and 
purified by column chromatography (70% EtOAc/petrol) to give compound S53 at 
white solid. Yield: 1.31g (72%). Spectroscopic data: 1H-NMR (400MHz, CDCl3): δ 
8.00 (d, 1H, J=6.4Hz, H-Ar), 7.83-7.71 (m, 1H, H-Ar), 7.53-7.71 (m, 6H, H-Ar),7.25 
(d, 1H, J=8Hz, H-Ar), 7.18-7.14 (t, 1H, J=16Hz, H-Ar), 6.41 (d, 1H, J=6Hz, H-Ar), 
5.39 (s, 1H, N-H), 4.97(d, 1H, J=20Hz, P-CH),3.81 (d, 3H, J=10.4Hz, OMe), 3.57 (d, 
3H, J=9.6Hz, OMe), 2.15(s, 3H, Ac-NH). 13C NMR (100.6MHz, CDCl3): δ 163.63, 
141.15, 141.06, 138.28, 134.37, 130.65, 128.85, 128.38, 128.07, 126.33, 126.07, 
125.37, 124.06, 123.33, 120.05, 119.04, 55.55 (d, J = 150.5 Hz, P-CH) 54.23, 54.07, 
29.86, 24.63. 31P-NMR (161.93MHz, CDCl3): δ 24.71. HRMS: Calculated for 
[C21H24N2O4P]: m/z=398.14, found [M+H]+=399.14. Calculated for 




S54. Dimethyl ((naphthalen-1-ylamino) (4-nitrophenyl) methyl) phosphonate 
A mixture of 4-Nitrobenzaldehyde (0.5g, 3.3 mmol) and 1-naphthylamine (0.473g, 3.3 
mmol) were dissolved in dimethyl phosphite (5ml, 10 equiv.) and the resultant solution 















subjected to a standard work-up (DCM) and purified by column chromatography (85% 
EtOAc/PetEther) to give compound S54 at yellow solid. Yield: 0.92g (72%). 
Spectroscopic data: 1H-NMR (400MHz, CDCl3): δ 8.20 (d, 2H, J=6.8Hz, H-Ar), 8.01 
(d, 1H, J=6.4Hz, H-Ar), 7.85 (d, 2H, J=5.8Hz, H-Ar), 7.71-7.68 （t, 2H, J=8.8, H-Ar）, 
7.57-7.49 (m, 2H, H-Ar), 7.27 (d, 1H, J=7.2Hz, H-Ar), 7.17-7.13（t, 1H, J=16, H-Ar）, 
6.27 (d, 1H, J=7.6Hz, H-Ar), 5.46 (s, 1H, NH), 5.10(d, 1H, J=24.8Hz, P-CH),3.92 (d, 
3H, J=10.2Hz, OMe), 3.68 (d, 3H, J=9.9Hz, OMe). 13C NMR (100.6MHz, CDCl3): δ 
143.63, 143.28, 140.06, 134.32, 128.77, 128.43, 128.38, 126.16, 125.91, 125.49, 
123.92, 123.88, 123.84, 119.75, 119.53, 106.60, 55.41 (d, J = 150.5 Hz, P-CH) 54.21, 
53.93. 31P-NMR (161.93MHz, CDCl3): δ 23.20. HRMS: Calculated for [C19H20N2O5P]: 
m/z=386.1099, Found [M+H]+=387.1109. Calculated for [C19H19N2O5PNa] m/z= 




S57. Dimethyl ((anthracen-1-ylamino) (4- (trifluoromethyl) phenyl) methyl) phos-
phonate 
A mixture of 4-(Trifluoromethyl) benzaldehyde (0.5g, 2.8 mmol, 1.0 equiv.) and 1-
naphthylamine (0.54g, 2.8 mmol, 1.0 equiv.) were dissolved in dimethyl phosphite (6 
ml, 10.0 equiv.) and the resultant solution subjected to microwave heating (90 W) for 9 
minutes. The reaction mixture then subjected to a standard work-up (DCM) and purified 
by column chromatography (90% EtOAc/PetEther) to give compound S57 at brown 
solid. Yield: 0.32g (21%). Spectroscopic data: 1H-NMR (400MHz, CDCl3): δ 8.37 (s, 
1H, H-Ar), 8.37 (s, 1H, H-Ar), 8.14 (d, 2H, J=8.8Hz, H-Ar), 8.03-7.88 (m, 3H, H-Ar), 
7.68 (s, 1H, H-Ar), 7.55-7.51 (m, 3H, H-Ar), 7.18 (d, 1H, J=7.6Hz, H-Ar), 6.34 (d, 1H, 









OMe), 3.31 (d, 3H, J=10.6Hz, OMe). 13C NMR (100.6MHz, CDCl3): δ 142.38, 139.64, 
137.53, 133.46, 132.04, 131.94, 131.62, 128.80, 128.04, 127.34, 126.80, 126.37, 
125.48, 125.15, 125.04, 123.47, 122.23, 117.73, 116.82, 106.89, 56.53 (d, J = 150.3 Hz, 
P-CH), 54.37, 54.25. 31P-NMR (161.93MHz, CDCl3): δ 24.34. HRMS: Calculated for 
[C24H21F3NO3P]: m/z=459.1289, Found [M+H]+ =460.1275. Calculated for 




S58. Dimethyl ((anthracen-1-ylamino) (3,5-bis (trifluoromethyl) phenyl) methyl) 
phosphonate 
A mixture of 3,5-Bis(trifluoromethyl)benzaldehyde (0.5g, 2.06 mmol, 1.0 equiv.) and 
1-naphthylamine (0.397g, 2.06 mmol, 1.0 equiv.) were dissolved in dimethyl phosphite 
(6.5 ml, 10.0 equiv.) and the resultant solution subjected to microwave heating (90 W) 
for 7 minutes. The reaction mixture then subjected to a standard work-up (DCM) and 
purified by column chromatography (90% EtOAc/PetEther) to give compound S58 at 
brown solid. Yield: 0.83g (75.6%). Spectroscopic data: 1H-NMR (400MHz, CDCl3): δ 
8.57 (s, 1H, H-Ar), 8.39 (s, 1H, H-Ar), 8.14 (t, 2H, J=9.2Hz, H-Ar), 8.04 (q, 2H, 
J=20.8H,z H-Ar), 7.84 (s, 1H, H-Ar), 7.52-7.47 (m, 3H, H-Ar), 7.20 (t, 1H, H-Ar, 
J=16Hz), 6.22 (d, 1H, J=8.6Hz, H-Ar), 5.72 (q, 1H, J=16.8Hz, NH), 5.17(d, 1H, 
J=24Hz, P-CH) 3.89 (d, 3H, J=10.6Hz, OMe), 3.35 (d, 3H, J=10.8Hz, OMe). 13C NMR 
(100.6MHz, CDCl3): δ 140.18, 140.04, 138.93, 132.26, 131.94, 131.74, 131.19, 128.40, 
127.79, 127.64, 127.00, 125.88, 125.58, 125.25, 124.44, 123.60, 122.219, 121.73, 
119.93, 118.52, 104.59, 55.82 (d, J = 150.5 Hz, P-CH), 54.93, 54.35. 31P-NMR 
(161.93MHz, CDCl3): δ 22.54. HRMS: Calculated for [C25H20F6NO3P]: m/z=527.1163, 












S59. Dimethyl ((4-acetamidophenyl) (anthracen-1-ylamino) methyl) phosphonate 
A mixture of 4-acetamidobenzaldehyde (0.5 g, 3.07 mmol, 1.0 equiv.) and 1-
aminoanthracene (0.59 g, 3.07 mmol, 1.0 equiv.) were dissolved in dimethyl phosphite 
(5 mL, 10.0 equiv. w/v) and the resultant solution subjected to microwave heating (90 
W) for 8 minutes. The reaction mixture then subjected to a standard work-up and 
purified by column chromatography (2 % MeOH/EtOAc) to give the protected 
aminophosphonate (S59) as a brown solid (0.36 g, 43 %). Spectrocopic data: 1H-NMR 
(400MHz, CDCl3): δ 8.55 (s, 1H, Ar), 8.35 (s, 1H, Ar), 8.15 – 8.06 (m, 1H, Ar), 8.03 – 
7.92 (m, 1H, Ar), 7.48 (d, J = 9.6 Hz, 6H, Ar), 7.41 (d, J = 8.5 Hz, 1H, Ar), 7.18 – 7.12 
(m, 1H, Ar), 6.33 (d, J = 7.3 Hz, 1H, Ar), 5.61 (s, 1H, NH), 5.02 (d, J = 23.7 Hz, 1H, 
P-CH), 3.85 (d, J = 10.6 Hz, 3H, OMe), 3.57 (d, J = 10.6 Hz, 3H, OMe). 13C NMR 
(101MHz, CDCl3): δ 168.24, 140.48, 137.94, 132.30, 131.56, 131.03, 130.61, 128.41, 
128.23, 127.71, 126.75, 125.61, 125.31, 123.80, 119.95, 119.01, 118.54, 104.69, 55.31 
(d, J = 152.3 Hz), 54.01, 53.95, 24.51. 31P-NMR (161.93MHz, CDCl3): δ 24.75. HRMS 
(ESI): Calculated for C25H26N2O4P [M+H]+: 449.1552. Found [M+H]+: 449.1713. 




S60. methyl 4-((anthracen-1-ylamino) (dimethoxyphosphoryl) methyl) benzoate 
A mixture of benzaldehyde (0.5 g, 3.05 mmol, 1.0 equiv.) and 1-aminoanthracene (0.59 
g, 3.05 mmol, 1.0 equiv.) were dissolved in dimethyl phosphite (3 mL, 10.0 equiv. w/v) 














reaction mixture then subjected to a standard work-up and purified by column 
chromatography (90 % EtOAc/petrol) to give the protected aminophosphonate (S8) as 
a brown solid (0.99 g, 72 %). Spectroscopic data: 1H NMR (400 MHz, CDCl3) δ 8.58 
(d, J = 1.1 Hz, 1H, Ar), 8.36 (s, 1H, Ar), 8.15 – 8.07 (m, 1H, Ar), 8.07 – 8.00 (m, 2H, 
Ar), 8.00 – 7.94 (m, 1H, Ar), 7.68 – 7.61 (m, 2H, Ar), 7.53 – 7.45 (m, 2H, Ar), 7.42 (d, 
J = 8.7 Hz, 1H, Ar), 7.18 – 7.10 (m, 1H, Ar), 6.35 – 6.16 (m, 1H, Ar), 5.70 (s, 1H, NH), 
5.11 (d, J = 24.4 Hz, 1H, P-CH), 3.89 (s, 3H, COOMe), 3.86 (d, J = 10.7 Hz, 3H, OMe), 
3.60 (d, J = 10.7 Hz, 3H,  OMe).  13C NMR (101 MHz, CDCl3) δ 166.60, 140.74, 
140.44, 132.30, 131.64, 131.11, 130.01, 129.98, 128.41, 127.73, 127.62, 126.81, 125.70, 
125.40, 123.76, 119.28, 118.56, 104.64, 55.95 (d, J = 149.8 Hz), 54.08, 53.99, 52.05. 
31P NMR (162 MHz, CDCl3) δ 24.10. HRMS (ESI): Calculated for C25H25NO5P 
[M+H]+: 450.1392. Found [M+H]+: 450.1436. Calculated for C25H24NO5PNa [M+Na]+: 





S62. Dimethyl (((9,10-dioxo-9,10-dihydroanthracen-1-yl) amino) (phenyl) methyl) 
phosphonate 
A mixture of benzaldehyde (0.48 ml, 4.7 mmol, 1 equiv.) and 1-aminoanthraquinone 
(1.05 g, 4.7 mmol) were dissolved in dimethyl phosphite (5 mL, 10 equiv. w/v) and the 
resultant solution subjected to microwave heating (90 W) for 8 minutes. The reaction 
mixture then subjected to a standard work-up and purified by column chromatography 
(85% EtOAc/petrol) to give the protected aminophosphonate (S62) as a red solid (1.35 
g, 89%). Spectroscopic data: 1H NMR (400 MHz, CDCl3) δ 10.73 (t, J = 8.8 Hz, 1H, 
NH), 8.43 – 8.31 (m, 1H, Ar), 8.29 – 8.18 (m, 1H, Ar), 7.80-7.70 (m, 2H, Ar), 7.68 – 










Ar), 5.04 (d, J = 31.1 Hz, 1H,P-CH), 3.76 (d, J = 10.7 Hz, 3H, OMe), 3.69 (d, J = 10.7 
Hz, 3H, OMe). 13C NMR (101 MHz, CDCl3) δ 1 185.63, 183.41, 150.09, 135.23, 
134.68, 134.64, 133.98, 133.24, 132.91, 128.86, 128.32, 127.69, 127.64, 127.02, 
126.70, 118.36, 116.86, 114.61, 55.03 (d, J = 152.6 Hz), 54.17, 53.95. 31P NMR (162 
MHz, CDCl3) δ 23.12. HRMS (ESI): Calculated for C23H20NO5P [M+H]+: 479.1294. 







S63. Dimethyl (((9,10-dioxo-9,10-dihydroanthracen-1-yl) amino) (phenyl) methyl) 
phosphonate 
A mixture of 4-acetamidobenzaldehyde (0.5 g, 163.19 mmol, 1 equiv.) and 1-amino-
9,10-anthraquinone (0.68 g, 3.06 mmol, 1 equiv.) were dissolved in dimethyl phosphite 
(5 mL, 10 equiv. w/v) and the resultant solution subjected to microwave heating (90 W) 
for 5 minutes. The reaction gives the protected aminophosphonate (S63) as a red solid 
which is insoluble in most solvent and only partly soluble in DMSO. The product was 
sequentially washed by large volume of dichloromethane, petroleum ether, ethyl acetate, 
methanol and water, then dried and stored at -20°C for next step of reaction. 
Spectroscopic data: HRMS (ESI): Calculated for C25H23N2O6P [M+H]+: . Found 














7.2.3. Synthesis of de-protected aminophosphonic acid 
 
 
41. (phenyl(phenylamino)methyl) phosphonic acid 
TMSBr (0.22 mL, 1.71 mmol, 5.0 equiv.) was added dropwise to a solution of the 
aminophosphonate S41 (100 mg, 0.34 mmol, 1.0 equiv.) in anhydrous DCM (2 mL) at 
0°C and the mixture held at this temperature for 30 minutes. The solution was then 
allowed to warm to room temperature and concentrated in vacuo. The resultant residue 
was then diluted with water (2.5 mL), neutralized (aq. 1 M NaOH) and purified by C-
18 reverse phase chromatography (35 % MeOH/H2O) to give the phosphonic acid 
compound 41 as a white solid (84 mg, 94 %). Spectroscopic data (1H and 13C NMR) 
was consistent with that reported in the literature (Ryabukhin et al., 2014). 1H NMR 
(400 MHz, CD3OD):  δ 7.54 (d, J = 8.0 Hz, 2H, Ar), 7.23 (t, J = 7.6 Hz, 2H, Ar), 7.10 
(t, J = 7.3 Hz, 1H, Ar), 7.03 – 6.89 (m, 2H, Ar), 6.60 – 6.44 (m, 3H, Ar), 4.49 (d, J = 
21.6 Hz, 1H，P-CH). 13C NMR (100.6 MHz, CD3OD): δ 150.25, 144.04, 129.62, 129.15, 
128.62, 126.46, 117.34, 114.74, 60.64 (d, J = 130.3 Hz). 31P NMR (161.93 MHz, 
CD3OD): δ 15.46. HRMS (ESI): Calculated for C13H14NO3P (M-H)-: m/z = 262.0633, 




42. ((naphthalen-1-ylamino) (phenyl) methyl) phosphonic acid 
TMSBr (0.16mL, 0.88 mmol, 3.0 equiv.) was added dropwise to a solution of the 
aminophosphonate S42 (100 mg, 0.29 mmol, 1.0 equiv.) in anhydrous DCM/DMF (3 














was then allowed to warm to room temperature and concentrated in vacuo. The resultant 
residue was then diluted with water (2.5 mL), neutralized (aq. 1 M NaOH) and purified 
by C-18 reverse phase chromatography (40% MeOH/H2O) to give the phosphonic acid 
compound 42 as a white solid (74.5 mg, 82 %). 1H NMR (400 MHz, CD3OD): δ 8.37 
– 8.29 (m, 1H, Ar), 7.73 – 7.62 (m, 1H, Ar), 7.57 (d, J = 8.1 Hz, 2H, Ar), 7.48 – 7.30 
(m, 2H, Ar), 7.19 (t, J = 7.6 Hz, 2H, Ar), 7.11 – 6.93 (m, 3H, Ar), 6.26 (d, J = 7.3 Hz, 
1H, Ar), 4.64 (d, J = 21.3 Hz, 1H, P-CH). 13C NMR (100.6 MHz, CD3OD): δ 145.19, 
143.55, 135.87, 129.13, 129.07, 128.60, 127.42, 126.46, 126.24, 125.27, 124.96, 
122.25, 116.77, 106.31, 60.57 (d, J = 130.6 Hz). 31P NMR (162 MHz, CD3OD): δ 15.74. 





44. (([1,1'-biphenyl]-3-ylamino)(phenyl)methyl)phosphonic acid 
TMSBr (0.16 mL, 1.23 mmol, 4.5 equiv.) was added dropwise to a solution of the 
aminophosphonate S44 (100 mg, 0.27 mmol, 1.0 equiv.) in anhydrous DCM (2 mL) at 
0°C and the mixture held at this temperature for 30 minutes. The solution was then 
allowed to warm to room temperature and concentrated in vacuo. The resultant residue 
was then diluted with water (2.5 mL), neutralized (aq. 1 M NaOH) and purified by C-
18 reverse phase chromatography (25 % MeOH/H2O) to give the phosphonic acid 
compound 44 as a white solid (68 mg, 74 %). Spectrocopic data: 1H NMR (400 MHz, 
Methanol-d4) δ 7.57 (d, J = 7.9 Hz, 2H, Ar), 7.43 – 7.36 (m, 2H, Ar), 7.30 (t, J = 7.5 
Hz, 2H, Ar), 7.23 (q, J = 7.5 Hz, 3H, Ar), 7.09 (t, J = 7.3 Hz, 1H, Ar), 7.02 (t, J = 7.8 
Hz, 1H, Ar), 6.78 (s, 1H, Ar), 6.75 – 6.70 (m, 1H, Ar), 6.53 (d, J = 7.9Hz, 1H, Ar), 4.54 
(d, J = 21.5 Hz, 1H, P-CH). 13C NMR (101 MHz, CD3OD) δ 150.62, 144.09, 143.43, 














45. (([1,1'-biphenyl]-2-ylamino) (phenyl)methyl)phosphonic acid 
TMSBr (0.16 mL, 1.23 mmol, 4.5 equiv.) was added dropwise to a solution of the 
aminophosphonate S45 (100 mg, 0.27 mmol, 1.0 equiv.) in anhydrous DCM (2 mL) at 
0°C and the mixture held at this temperature for 30 minutes. The solution was then 
allowed to warm to room temperature and concentrated in vacuo. The resultant residue 
was then diluted with water (2.5 mL), neutralized (aq. 1 M NaOH) and purified by C-
18 reverse phase chromatography (20% MeOH/H2O) to give the phosphonic acid 
compound 45 as a white solid (78.6 mg, 86 %). 1H NMR (400 MHz, CD3OD): δ 7.61 
– 7.54 (m, 2H, Ar), 7.53 – 7.42 (m, 4H, Ar), 7.35 – 7.27 (m, 1H, Ar), 7.22 (t, J = 7.6 
Hz, 2H, Ar), 7.08 (t, J = 7.2 Hz, 1H, Ar), 6.98 – 6.86 (m, 2H, Ar), 6.56 (t, J = 7.4Hz, 
1H, Ar), 6.46 (d, J = 8.4 Hz, 1H, Ar), 4.51 (d, J = 21.8 Hz, 1H, P-CH).13C NMR (100.6 
MHz, CD3OD): δ 146.57, 144.08, 141.77, 131.25, 130.51, 129.99, 129.29, 129.05, 
128.65, 127.88, 126.49, 117.18, 113.26, 60.63 (d, J = 130.9 Hz). 31P NMR (162 MHz, 














48. ((anthracen-1-ylamino) (phenyl)methyl) phosphonic acid 
TMSBr (0.289 mL, 2.19 mmol, 8.0 equiv.) was added dropwise to a solution of the 
aminophosphonate S48 (100 mg, 0.26 mmol, 1.0 equiv.) in anhydrous DCM/DMF (3 
mL, 2:1) at 0°C and the mixture held at this temperature for 30 minutes. The solution 
was then allowed to warm to room temperature and concentrated in vacuo. The resultant 
residue was then diluted with water (2.5 mL), neutralized (aq. 1 M NaOH) and purified 
by C-18 reverse phase chromatography (60 % MeOH/H2O) to give the phosphonic acid 
compound 48 as a yellow solid (68 mg, 74 %). Spectroscopic data. 1H NMR (400 MHz, 
CD3OD): δ 9.00 (s, 1H, Ar), 8.23 (s, 1H, Ar), 8.18 – 8.08 (m, 1H, Ar), 7.98 – 7.87 (m, 
1H, Ar), 7.69 – 7.57 (m, 2H, Ar), 7.48 – 7.34 (m, 2H, Ar), 7.25 – 7.12 (m, 3H, Ar), 7.11 
– 6.99 (m, 2H, Ar), 6.16 (d, J = 7.4 Hz, 1H, Ar), 4.69 (d, J = 21.0 Hz, 1H, P-CH). 13C 
NMR (100.6 MHz, CD3OD): δ 142.94, 140.92, 134.37, 132.87, 132.19, 129.79, 129.16, 
128.57, 127.48, 126.57, 126.31, 126.17, 125.51, 125.37, 121.12, 116.50, 113.43, 103.68, 
60.76 (d, J = 129.8 Hz, P-C). 31P NMR (162 MHz, CD3OD): δ 15.57. HRMS (ESI) 




50. ((4-Chlorophenyl) (naphthalen-1-ylamino) methyl) phosphonic acid 
TMSBr (0.158 mL, 1.21 mmol, 4.5 equiv.) was added dropwise to a solution of the 
aminophosphonate S50 (100 mg, 0.27 mmol, 1.0 equiv.) in anhydrous DCM/DMF (3 















was then allowed to warm to room temperature and concentrated in vacuo. The resultant 
residue was then diluted with water (2.5 mL), neutralized (aq. 1 M NaOH) and purified 
by C-18 reverse phase chromatography (60 % MeOH/H2O) to give the phosphonic acid 
compound 50 as a white solid (78.3mg, 79%). Spectroscopic data: 1H-NMR (400 MHz, 
CD3OD): δ 8.33 (d, 1H, J = 8.6Hz, H-Ar), 7.68-7.66 (m, 1H, H-Ar), 7.55-7.53 (m, 1H, 
H-Ar), 7.43-7.36 (m, 1H, H-Ar), 7.17 (d, 1H, J = 8.4Hz, H-Ar), 7.06-6.99 (m, 2H, H-
Ar), 6.2 (q, 1H, J = 8.0Hz, H-Ar), 4.79 (d, 1H, J = 21.2Hz, P-CH). 13C NMR (100.6 
MHz, CD3OD: δ 146.76, 147.94, 146.89, 144.98, 144.01, 132.43, 129.74, 129.50, 
129.15, 126.64, 126.52, 125.37, 122.91, 122.40, 116.59, 106.32, 60.78 (d, J = 130.4 Hz, 
P-C). 31P-NMR (CD3OD, 161.93 MHz): δ 16.54. HRMS: [C17H15ClNO3P]: m/z = 




51. ((Naphthalen-1-ylamino) (4-(trifluoromethyl)phenyl) methyl) phosphonic acid 
TMSBr (0.182 mL, 1.22 mmol, 5 equiv.) was added dropwise to a solution of the 
aminophosphonate S51 (100 mg, 0.244 mmol, 1.0 equiv.) in anhydrous DCM/DMF (3 
mL, 2:1) at 0°C and the mixture held at this temperature for 30 minutes. The solution 
was then allowed to warm to room temperature and concentrated in vacuo. The resultant 
residue was then diluted with water (2.5 mL), neutralized (aq. 1 M NaOH) and purified 
by C-18 reverse phase chromatography (80 % MeOH/H2O) to give the phosphonic acid 
compound 51 as a white solid (62.5 mg, 64.4 %). Spectroscopic data: 1H-NMR (400 
MHz, CD3OD): δ 8.35 (d, 1H, J = 8.4Hz, H-Ar) 7.65 (d, 1H, J = 7.6Hz, H-Ar,), 7.23 
(d, 1H, J = 7.6Hz, H-Ar), 7.63-7.39 (m, 4H, H-Ar), 7.08-6.95 (m, 3H, H-Ar), 6.38 (d, 
J = 8.2Hz, H-Ar), 4.82 (d, 1H, J = 24.1Hz, P-CH). 13C NMR (100.6 MHz, CD3OD): 
149.08, 145.05, 135.919, 129.43, 129.39, 129.17, 128.59, 128.30, 127.63, 127.40, 










P-C). 31P-NMR (161.93 MHz, CD3OD): δ 17.53. HRMS: [C18H15F3NO3P]: m/z = 




52. ((3,5-bis(trifluoromethyl) phenyl) (naphthalen-1-ylamino) methyl) phosphonic 
acid 
TMSBr (0.092 mL, 0.73 mmol, 3.5 equiv.) was added dropwise to a solution of the 
aminophosphonate S52 (100 mg, 0.21 mmol, 1.0 equiv.) in anhydrous DCM/DMF (3 
mL, 2:1) at 0°C and the mixture held at this temperature for 30 minutes. The solution 
was then allowed to warm to room temperature and concentrated in vacuo. The resultant 
residue was then diluted with water (2.5 mL), neutralized (aq. 1 M NaOH) and purified 
by C-18 reverse phase chromatography (80 % MeOH/H2O) to give the phosphonic acid 
compound 52 as a white solid (38.3 mg, 39.5 %). Spectroscopic data: 1H-NMR (400 
MHz, CD3OD): δ 8.39 (d, 1H, J = 8.0Hz, H-Ar), 8.18 (s, 1H, H-Ar), 7.72 (d, 1H, J = 
8.0Hz, H-Ar), 7.63 (s, 1H, H-Ar), 7.48-7.39 (m, 2H, H-Ar), 7.07 (q, 2H, J = 11.2Hz, 
H-Ar) 6.15 (q, 1H, J = 8.4Hz, H-Ar), 4.77 (d, 1H, J = 20.0Hz, P-CH), 13C NMR (100.6 
MHz, CD3OD): 148.35, 148.30, 144.79, 135.94, 131.82, 131.47, 131.15, 129.32, 
129.20, 127.34, 126.75, 126.74, 126.52, 125.28, 124.09, 122.27, 122.07, 117.54, 105.93, 
61.43 (d, J = 129.9 Hz, P-C). 31P-NMR (161.93 MHz, CD3OD): δ 13.53. HRMS: 














53. ((4-Acetamidophenyl) (naphthalen-1-ylamino) methyl) phosphonic acid 
TMSBr (0.08 mL, 0.62 mmol, 2.5 equiv.) was added dropwise to a solution of the 
aminophosphonate S53 (100 mg, 0.25 mmol, 1.0 equiv.) in anhydrous DCM/DMF (3 
mL, 2:1) at 0°C and the mixture held at this temperature for 30 minutes. The solution 
was then allowed to warm to room temperature and concentrated in vacuo. The resultant 
residue was then diluted with water (2.5 mL), neutralized (aq. 1 M NaOH) and purified 
by C-18 reverse phase chromatography (80 % MeOH/H2O) to give the phosphonic acid 
compound 53 as a white solid (86 mg, 93.5 %). Spectroscopic data: 1H-NMR (400 
MHz, CD3OD): δ 8.34 (d, 1H, J = 8.4Hz, H-Ar), 7.67 (d, 1H, J = 10.4Hz, H-Ar), 7.54-
7.51 (m, 2H, H-Ar), 7.41-7.33 (m, 4H, H-Ar), 7.04-6.95 (m, 2H, H-Ar), 6.26 (d, 1H, J 
= 7.6Hz, H-Ar), 4.63 (d, 1H, J = 20.8Hz, P-CH), 2.063 (s, 3H, Me). 13C NMR (100.6 
MHz, CD3OD): δ 171.41, 145.16, 139.97, 137.05, 135.76, 129.19, 129.15, 129.04, 
127.33, 126.17, 125.16, 122.17, 121.02, 116.70, 106.25, 60.77(d, J = 129.6 Hz, P-C), 
23.61. 31P-NMR (161.93 MHz, CD3OD): δ 15.01. HRMS: [C19H19N2O4P]: m/z = 




54. ((Naphthalen-1-ylamino) (4-nitrophenyl) methyl) phosphonic acid 
TMSBr (0.148 mL, 1.125 mmol, 4.5 equiv.) was added dropwise to a solution of the 
aminophosphonate S54 (100 mg, 0.25 mmol, 1.0 equiv.) in anhydrous DCM/DMF (3 
mL, 2:1) at 0°C and the mixture held at this temperature for 30 minutes. The solution 
















residue was then diluted with water (2.5 mL), neutralized (aq. 1 M NaOH) and purified 
by C-18 reverse phase chromatography (50 % MeOH/H2O) to give the phosphonic acid 
compound 54 as a yellow solid (54.4 mg, 59.3 %). Spectroscopic data: 1H-NMR (400 
MHz, CD3OD): δ 8.37 (d, 1H, J = 8.4Hz, H-Ar), 8.091 (d, 1H, J = 8.8Hz, H-Ar), 7.79 
(d, 2H, J = 8.4Hz, H-Ar), 7.69 (d, 1H, J = 8.0Hz, H-Ar), 7.49-7.38 (m, 2H, H-Ar), 7.032 
(d, 2H, J = 4.0Hz, H-Ar), 6.18 (t, 1H, J = 8.0Hz, H-Ar), 4.79 (d, 1H, J = 21.2Hz, P-
CH). 13C NMR (100.6 MHz, CD3OD): δ 153.26, 147.42, 147.39, 144.81, 144.69, 
135.93, 129.74, 129.70, 129.25, 127.34, 126.56, 125.27, 123.91, 122.20, 117.49, 106.22, 
61.68 (d, J = 130.1 Hz, P-C). 31P-NMR (161.93 MHz, CD3OD): δ 14.04. HRMS: 




57. ((Anthracen-1-ylamino) (4-(trifluoromethyl)phenyl)methyl)phosphonic acid 
TMSBr (0.128 mL, 0.95 mmol, 5.0 equiv.) was added dropwise to a solution of the 
aminophosphonate S57 (90 mg, 0.19 mmol, 1.0 equiv.) in anhydrous DCM/DMF (3 
mL, 2:1) at 0°C and the mixture held at this temperature for 30 minutes. The solution 
was then allowed to warm to room temperature and concentrated in vacuo. The resultant 
residue was then diluted with water (2.5 mL), neutralized (aq. 1 M NaOH) and purified 
by C-18 reverse phase chromatography (75 % MeOH/H2O) to give the phosphonic acid 
compound 57 as a yellow solid (55.3mg, 56.4 %). Spectroscopic data: 1H-NMR (400 
MHz, CD3OD): δ 9.02 (s, 1H, H-Ar), 8.23 (s, 1H, H-Ar), 8.15 (t, 1H, J = 8.0 Hz, H-
Ar), 7.91(t, 1H, J = 5.6 Hz, H-Ar), 7.81 (d, 2H, J = 8.1Hz, H-Ar), 7.51-7.39 (m, 4H, H-
Ar), 7.20 (d, 2H, J = 8.8Hz, H-Ar), 7.08 (t, 1H, J = 16 Hz, H-Ar), 6.143 (d, 2H, J = 
7.2Hz, H-Ar), 4.82 (d, 1H, J = 21.2Hz, P-CH). 13C NMR (100.6 MHz, CD3OD): δ 
148.74, 144.61, 134.23, 132.87, 132.20, 129.64, 129.34, 129.30, 128.60, 128.32, 










61.35 (d, J = 129.6 Hz, P-C), 31P-NMR (161.93 MHz, CD3OD): δ 14.70. HRMS: 




58. ((Anthracen-1-ylamino) (3,5-bis (trifluoromethyl) phenyl) methyl) phosphonic 
acid 
TMSBr (0.075 mL, 0.57 mmol, 3.0 equiv.) was added dropwise to a solution of the 
aminophosphonate S58 (100 mg, 0.19 mmol, 1.0 equiv.) in anhydrous DCM/DMF (3 
mL, 2:1) at 0°C and the mixture held at this temperature for 30 minutes. The solution 
was then allowed to warm to room temperature and concentrated in vacuo. The resultant 
residue was then diluted with water (2.5 mL), neutralized (aq. 1 M NaOH) and purified 
by C-18 reverse phase chromatography (80 % MeOH/H2O) to give the phosphonic acid 
compound 58 as a yellow solid (62.4 mg, 63.1 %). Spectroscopic data: 1H-NMR (400 
MHz, CD3OD): δ 9.02 (s, 1H, H-Ar), 8.28-8.14 (m, 4H, H-Ar), 7.96(t, 1H, H-Ar, J = 
9.2Hz), 7.64 (s, 1H, H-Ar), 7.44-7.42 (m, 2H, H-Ar), 7.25 (d, 2H, J = 8.8Hz, H-Ar), 
7.06 (t, 1H, J = 8.0Hz, H-Ar), 6.07 (d, 1H, J = 8.1 Hz, H-Ar), 4.83 (d, 1H, J = 20.8Hz, 
P-CH). 13C NMR (100.6 MHz, CD3OD): δ 147.97, 144.40, 143.69, 137.54, 134.29, 
133.05, 132.38, 129.82, 129.36, 128.65, 127.21, 126.85, 126.39, 125.65, 125.37, 
122.65, 121.97, 121.08, 121.19, 117.64, 116.36, 103.59, 61.01 (d, J = 129.6 Hz, P-C). 
31P-NMR (161.93 MHz, CD3OD): δ 17.76. HRMS: [C23H16F6NO3P]: m/z = 499.0802, 
















59. ((4-acetamidophenyl) (anthracen-1-ylamino) methyl) phosphonic acid 
TMSBr (0.115 mL, 0.88 mmol, 4 equiv.) was added dropwise to a solution of the 
aminophosphonate S59 (100 mg, 0.22 mmol) in anhydrous DCM/DMF (3 mL, 2:1) at 
0°C and the mixture held at this temperature for 30 minutes. The solution was then 
allowed to warm to room temperature and concentrated in vacuo. The resultant residue 
was then diluted with water (2.5 mL), neutralized (aq. 1 M NaOH) and purified by C-
18 reverse phase chromatography (35 % MeOH/H2O) to give the phosphonic acid 
compound 59 as a yellow solid (40 mg, 41%). Spectrocopic data: 1H-NMR (400 MHz, 
CD3OD): δ 9.00 (s, 1H, Ar), 8.22 (s, 1H, Ar), 8.16 – 8.08 (m, 1H, Ar), 7.93 – 7.85 (m, 
1H, Ar), 7.63 – 7.54 (m, 2H, Ar), 7.45 – 7.31 (m, 4H, Ar), 7.16 (d, J = 8.4 Hz, 1H, Ar), 
7.05 (t, J = 7.9 Hz, 1H, Ar), 6.20 (d, J = 7.4 Hz, 1H, Ar), 4.69 (d, J = 20.9 Hz, 1H), 2.06 
(s, 3H, Me). 13C NMR (100.6 MHz, CD3OD): 171.52, 144.94, 140.01, 137.19, 134.33, 
132.89, 132.23, 129.72, 129.29, 128.67, 127.44, 126.77, 126.28, 125.52, 121.17, 
121.00, 116.88, 103.96, 60.36 (d, J = 129.8 Hz), 23.75. 31P-NMR (CD3OD, 161.93 




60. ((anthracen-1-ylamino) (4-(methoxycarbonyl)phenyl) methyl) phosphonic acid 
TMSBr (0.19 mL, 1.45 mmol, 6.5 equiv.) was added dropwise to a solution of the 
















0°C and the mixture held at this temperature for 30 minutes. The solution was then 
allowed to warm to room temperature and concentrated in vacuo. The resultant residue 
was then diluted with water (2.5 mL). Methyl group in methyl ester is removed by 
adding 0.2ml 5M NaOH at 0°C and allowed to warm up to room temperature after 10 
minutes. The reaction stops after 5 hours then purified by C-18 reverse phase 
chromatography (10% MeOH/H2O) to give the phosphonic acid compound 8 as a 
yellow solid (68 mg, 76%). Spectroscopic data: 1H NMR (400 MHz, D2O) δ 8.99 (s, 
1H, Ar), 8.18 (t, J = 5.1 Hz, 2H, Ar), 7.88 – 7.75 (m, 3H, Ar), 7.62 (d, J = 7.9 Hz, 2H, 
Ar), 7.51 – 7.41 (m, 2H, Ar), 7.16 (d, J = 8.7 Hz, 1H, Ar), 7.12 – 7.03 (m, 1H, Ar), 6.32 
(d, J = 7.3 Hz, 1H, Ar), 4.75 (d, J = 6.9 Hz, 1H, P-CH). 13C NMR (101 MHz, D2O) δ 
175.84, 145.22, 142.97, 134.08, 132.26, 130.69, 128.64, 128.54, 127.54, 127.48, 
127.44, 126.46, 126.17, 125.99, 125.42, 119.66, 116.57, 102.80, 58.80 (d, J = 128.4 
Hz). 31P NMR (162 MHz, Deuterium Oxide) δ 14.93. HRMS (ESI): Calculated for 




61. 4-((anthracen-1-ylamino)(phosphono)methyl)benzoic acid 
TMSBr (0.19 mL, 1.45 mmol, 6.5 equiv.) was added dropwise to a solution of the 
aminophosphonate S7 (100 mg, 0.22 mmol) in anhydrous DCM/DMF (3 mL, 2:1) at 
0°C and the mixture held at this temperature for 30 minutes. The solution was then 
allowed to warm to room temperature and concentrated in vacuo. The resultant residue 
was then diluted with water (2.5 mL). Methyl group in methyl ester is removed by 
adding 0.2ml 5M NaOH at 0°C and allowed to warm up to room temperature after 10 
minutes. The reaction stops after 5 hours then purified by C-18 reverse phase 










yellow solid (68 mg, 76%). Spectroscopic data: 1H NMR (400 MHz, D2O) δ 8.99 (s, 
1H, Ar), 8.18 (t, J = 5.1 Hz, 2H, Ar), 7.88 – 7.75 (m, 3H, Ar), 7.62 (d, J = 7.9 Hz, 2H, 
Ar), 7.51 – 7.41 (m, 2H, Ar), 7.16 (d, J = 8.7 Hz, 1H, Ar), 7.12 – 7.03 (m, 1H, Ar), 6.32 
(d, J = 7.3 Hz, 1H, Ar), 4.75 (d, J = 6.9 Hz, 1H, P-CH). 13C NMR (101 MHz, D2O) δ 
175.84, 145.22, 142.97, 134.08, 132.26, 130.69, 128.64, 128.54, 127.54, 127.48, 
127.44, 126.46, 126.17, 125.99, 125.42, 119.66, 116.57, 102.80, 58.80 (d, J = 128.4 
Hz). 31P NMR (162 MHz, Deuterium Oxide) δ 14.93. HRMS (ESI): Calculated for 




62. (((9,10-dioxo-9,10-dihydroanthracen-1-yl) amino) (phenyl)methyl) phosphonic 
acid 
MSBr (0.155 mL, 1.19 mmol, 5 equiv.) was added dropwise to a solution of the 
aminophosphonate S62 (100 mg, 0.237 mmol) in anhydrous DCM/DMF (3 mL, 2:1) at 
0°C and the mixture held at this temperature for 30 minutes. The solution was then 
allowed to warm to room temperature and concentrated in vacuo. The resultant residue 
was then diluted with water (2.5 mL), neutralized (aq. 1 M NaOH) and purified by C-
18 reverse phase chromatography (20% MeOH/H2O) to give the phosphonic acid 
compound 62 as a purple solid (89 mg, 95%). Spectroscopic data: 1H NMR (400 MHz, 
D2O) δ 7.87 (s, 1H, Ar), 7.57 (s, 2H, Ar), 7.43 (s, 3H, Ar), 7.37 (s, 1H, Ar), 7.16 (d, J = 
7.7 Hz, 1H, Ar), 6.98 (d, J = 7.6 Hz, 1H, Ar), 6.86 (d, J = 7.3 Hz, 2H, Ar), 4.68 (s, 1H, 
P-CH). 13C NMR (101 MHz, D2O) δ 185.01, 184.87, 140.92, 135.29, 134.67, 133.29, 
131.68, 128.29, 128.02, 126.73, 126.21, 120.33, 116.27, 112.52, 57.71 (d, J = 131.9 
Hz).  31P NMR (162 MHz, D2O) δ 14.21. HRMS (ESI): Calculated for C21H16NO5P 






63.((4-acetamidophenyl) ((9,10-dioxo-9,10-dihydroanthracen-1yl) amino) methyl) 
phosphonic acid 
TMSBr (0.115 mL, 0.88 mmol, 4 equiv.) was added dropwise to a solution of the 
aminophosphonate S63 (100 mg, 0.22 mmol) in anhydrous DCM/DMF (3 mL, 2:1) at 
0°C and the mixture held at this temperature for 30 minutes. The solution was then 
allowed to warm to room temperature and concentrated in vacuo. The resultant residue 
was then diluted with water (2.5 mL), neutralized (aq. 1 M NaOH) and purified by C-
18 reverse phase chromatography (35 % MeOH/H2O) to give the phosphonic acid 
compound 63 as a yellow solid (40 mg, 41%). Spectroscopic data: 1H-NMR (400 MHz, 
CD3OD): δ 9.00 (s, 1H, Ar), 8.22 (s, 1H, Ar), 8.16 – 8.08 (m, 1H, Ar), 7.93 – 7.85 (m, 
1H, Ar), 7.63 – 7.54 (m, 2H, Ar), 7.45 – 7.31 (m, 4H, Ar), 7.16 (d, J = 8.4 Hz, 1H, Ar), 
7.05 (t, J = 7.9 Hz, 1H, Ar), 6.20 (d, J = 7.4 Hz, 1H, Ar), 4.69 (d, J = 20.9 Hz, 1H), 2.06 
(s, 3H, Me). 13C NMR (100.6 MHz, CD3OD): 171.52, 144.94, 140.01, 137.19, 134.33, 
132.89, 132.23, 129.72, 129.29, 128.67, 127.44, 126.77, 126.28, 125.52, 121.17, 
121.00, 116.88, 103.96, 60.36 (d, J = 129.8 Hz), 23.75. 31P-NMR (CD3OD, 161.93 
MHz): δ 15.27. HRMS (ESI): Calculated for C23H21N2O4P [M-H]-: 419.1161. Found: 
419.1184.  
 
7.2.4. Downstream protocols of chemical synthesis 
 
7.2.4.1. Thin layer chromatography 
 
Thin layer chromatography (TLC) was used in different steps of organic synthesis to 




fractions eluted from columns. TLC can be used to monitor the progress of reaction, 
identify the compound percentage from a mixture, or determine the purity of substances. 
TLC is performed on a silica coated foil plate (Sigma), with the sample spotted onto 
the plate using a capillary. After application of the sample, the TLC plate was placed in 
a mobile phase (solvent or solvent mixture), Different analytes ascend the plate at 
different rates to achieve the separation (Vogel and Furniss, 1989).  
 
The separation of components can be observed by UV light (wavelength 254 nm). The 
TLC plate was then stained by Potassium Permanganate solution (1.5g KMnO4, 10g 
K2CO3, and 1.25mL 10% NaOH, dissolved in 200mL water) or p-anisaldehyde stain 
(135 mL of absolute ethanol, 5 mL of concentrated sulfuric acid, 1.5 mL of glacial acetic 
acid, 3.7 mL of p-anisaldehyde) so that after drying, the spots of analytes would be 
visible.  
 
7.2.4.2. Purification of small molecule compounds 
 
All synthesized small molecule compounds were purified using column 
chromatography, which is a fundamental method to purify individual compounds from 
a mixture. For compounds which have high solubility in organic solvent, the columns 
use silica gel as the stationary phase, the ratio between the silica gel and the analyte is 
around 30:1. The solvent system of mobile phase was determined by TLC beforehand. 
Silica gel was mixed with the starting solvent or solvent mixture then placed into the 
column with cotton wool and silicon dioxide on the bottom. For liquid analyte mixtures, 
the sample was loaded directly on the top of packed silica gel, the analyte mixture in 
solid phase would be dissolved by the minimum volume of the starting solvent or 
solvent mix before loading onto the packed column. For analytes that were insoluble in 
starting solvent, the sample was dissolved completely in appropriate solvent(s) and 
mixed with silica gel. The sample-silica gel mixture was then dried gently using a rotary 
evaporator and loaded on the column carefully. After loading, elution from the column 




spectrometry (MS) (Burke, Germany), and pure fractions were collected in a round 
bottom flask and dried through a rotary evaporator then a high vacuum pump.  
 
Compounds with high polarity or high aqueous solubility were purified by Reversed-
phase chromatography using SNAP C18 prepacked cartridges (Biotage, Sweden), an 
octadecyl carbon chain (C18) bond silica based column. Typically, the mobile phase of 
a reversed phase column used a mixture of water and methanol. Firstly, the column was 
washed with 400ml of methanol and prepared by running 100ml of distill water through 
it. The sample was dissolved in the minimum volume of water (1-2ml) and loaded onto 
the column by syringe. The mobile phase had a gradient of methanol concentration. 
Fractions were analysed by TLC and MS, pure fractions were collected and dried using 
a dry ice bath rotary evaporator, and water was removed by freeze drying (Biobase, 
Germany). 
 




7.3.1.1. Molecular docking 
 
Molecular docking is one of the most widely used virtual screening techniques for drug 
discovery. By computationally docking the small molecule candidate to a potential 
binding site of the macromolecule acceptor, the potential binding position and binding 
energy can be predicted and evaluated. Although many limitations still exist, for 
example, rigid docking does not normally consider the flexibility of a protein structure 
and nor the solvent system, docking is still a useful tool for drug development. In this 
study, we perform molecular docking of α-aminophosphonate compounds into the 
catalytic pocket of TcTS, predict the binding energy and bound structures, which can 





A protein model of TcTS was first prepared by AutoDockTools (Morris et al., 2009) 
using an unliganded TcTS model (PDB: 1MS3), all hydrogens were added to the model 
and the docking grid box was limited to the catalytic site, and Tyr119 and Trp312 were 
set to be flexible residues. Three-dimensional models of ligands were built using Phenix 
eLbow (Moriarty et al., 2009) or JLigand (Lebedev et al., 2012), based on the SMILE 
string and/or on a 2D model built by PerkinElmer Chemdraw.  
 
Molecular docking experiments can be run using AutoDock Vina (Trott and Olson, 
2010) after the preparation of both the ligand and protein models, AutoDock Vina will 
screen the possible binding positions and calculate the predicted binding energy as the 
docking score. At the end of the process, the top 10 high ranked positions will be listed 
and the binding model presented by PyMol (Janson et al., 2016).  
 
7.3.1.2. Multiple sequence alignment 
 
Bioinformatics methods were applied to examine the allosteric binding site by 
comparing different strains of TcTS, and to evaluate the uniqueness of the allosteric 
binding site among different sialidases in order to evaluate the specificity of 
aminophosphonate. Initially, TcTS sequence from different strains were obtained from 
GenBank (https://www.ncbi.nlm.nih.gov/genbank/). Sequence alignment in each strain 
and among different strains were performed by Expresso, a protein sequence alignment 
server using structural information (Armougom et al., 2006). The conservation of 
residues in the catalytic and allosteric sites was presented by ESPript 









7.3.2. Cloning and transformation 
 
7.3.2.1. Transformation  
 
Vectors containing inserts which encode recombinant proteins were transformed to 
appropriate cell lines for amplitude or expression. Plasmids were first transformed into 
the cloning cell line NEB5α. The transformation experiments followed a typical heat 
shock transformation protocol (van der Rest et al., 1999), All plasmids were dissolved 
in distilled water, and diluted to around 125 ng/μl (DNA concentration was detected by 
spectrometer). Chemical competent cells (10 μl) were thawed on ice for 10min. 1-5μl 
of plasmid was added into the competent cell and mixed gently before incubation on 
ice for 30mins. The pre-incubated transformation mixture of NEB5α was placed in a 
42℃ water bath for exactly 30 seconds and transferred onto ice immediately. After 
transformation, 900 μl of SOC media was added into the reaction mixture and recover 
at 37℃ for 1 hr with 180-200 rpm shaking. Then 100-500 μl recovered culture was 
spread on a LB agar plate (containing appropriate antibiotics) and incubate at 37℃ 
overnight to obtain the single colonies.  
  
1-5 single colonies of NEB5α were picked and grown overnight in 15ml LB media 
contacting 1mM ampicillin. Cells were harvested by centrifugation (8500g, 10min), 
and the amplified plasmid extracted using a GeneJET plasmid miniprep kit (Thermal 
scientific, UK). 10μl of extracted plasmid was sent for sequencing by SourceBioscience, 
UK.  
 
After the sequences were confirmed, the plasmids were transformed into the expression 
cell line BL21 (DE3), parameters were chosen following the advice of the 







7.3.2.2. Site directed mutagenesis 
 
Site directed mutagenesis was performed following a general protocol (Weiner et al., 
1994). The E. coli strain containing the gene sequence of the recombinant protein was 
first resuscitated overnight in 15ml LB media with appropriate antibiotics. The plasmid 
DNA was extracted using a GeneJET Plasmid Miniprep Kit (Thermo Fisher Scientific). 
DNA primers with the mutated site mismatch were designed using the QuickChange 
primer design program (access from http://www.genomics.agilent.com 
/primerDesignProgram.jsp) and synthesized by Invitrogen, UK. The Polymerase chain 
reaction (PCR) mixture was prepared in a thin wall PCR tube using the recipe shown 
in Table 2.2 and mixed gently. The PCR mixture was then placed in the PCR machine 
(MJ Research), and the reaction was run as shown in table 2.3.   
 
Table 7.2. PCR mix of mutagenesis using Pfu polymerase 
10X Pfu Buffer with MgSO4 5 μl (0.2 mM of each) 
 dNTP Mix, 10 mM  1 μl (0.2 mM of each) 
Forward primer  1.0 μM 
Reverse primer  1.0 μM 
Template DNA 1μg 
Pfu DNA Polymerase  1.25-2.5 U 








Table 7.3. Cycling parameters for the site-directed mutagenesis PCR reaction 
Segment  Cycles  Temperature Time  
1 1 95°C  30 seconds  
2 12–18  
95°C  30 seconds  
55°C  1 minute  
68°C  1 minute/kb of plasmid length*  
 
PCR products were examined by DNA gel electrophoresis. In next step, Methylated 
and hemimethylated DNA was removed by DpnI digestion. A digestion reaction mix 
was prepared on ice, the reaction mix then transferred into a 37°C water bath for 30min 
and chilled on ice. Transformation was performed by the heat-shock method 
immediately after the digest reaction was finished. The result of mutagenesis was 
examined by DNA sequencing (Source Bioscience, UK). 
 
Based on the crystal structure, a novel allosteric site was found through aminophosphate 
inhibitor binding. To interpret the authenticity of our observation from the soaked 
crystal structure, site direct mutagenesis of residues around the allosteric site was 
performed. Three mutations, R249A, R275A, R577A were performed through a 
standard site-direct mutagenesis protocol (Liu and Naismith, 2008). Alanine was 
chosen to remove the side chain of these three Arginines while maintaining the stability 
of the C-α chains. Another mutagenesis, D59A was generated to interpret lactose 
binding with and without inhibitors. 
 
The method relies on two complement PCR primers, which incorporate both the 
selection site and the desired single base substitutions at the mutant site. Forward and 
Reverse primers of all four mutations (Appendix 8.5) were designed with a single 




















Table 7.5. Reaction mix of dpnI digestion 
Components Volume 
Water 15 μl 
10X FastDigest or 10X FastDigest 
Green Buffer  
2 μl 
PCR product 2 μl (up to 1 μg) 
FastDigest dpnI  1 μl 
Total  20μl 
 
7.3.3. Expression and purification of recombinant protein 
 
7.3.3.1. Expression of recombinant protein by IPTG induction 
 
This section describes the expression of recombinant protein via IPTG induction, for 




coli strain and spread on agar plates with appropriate antibiotics (1 μM ampicillin for 
TcTS and 1 μM kanamycin for SpNA), a single colony was picked and grown at 37°C 
overnight in 15 ml of LB medium with addition of appropriate antibiotic in a 
temperature-controlled shaking incubator. The overnight primary culture was used to 
incubate a larger scale secondary LB culture (250-1000mL) to which had been added 
the appropriate antibiotics (1 μM ampicillin for TcTS and 1 μM kanamycin for SpNA). 
Cells were grown at 37°C with shaking at between 180 to 200 rpm. The induction of 
over-expression of the recombinant protein was achieved by adding isopropyl 
thiogalactoside (IPTG) during the exponential phase of bacterial growth (OD600 = 0.6-
0.8) and incubate at 25°C for 12-16 hr with 180 to 200 rpm shaking.  
 
7.3.3.2. Auto induction  
 
Instead of IPTG induction, recombinant protein from vectors that contain genes that 
relate to sugar metabolism, for example T7 and pTrc promoter, underwent auto-
induction. The primary culture was the same as IPTG induction. The secondary culture 
was started by adding 5ml of primary culture into 1L TB media with appropriate 
antibiotics and incubated at 37°C with 200rpm shaking for 2 hours, then the temperature 
was lowered to 16°C and incubation continued for 48-60 hours.  
 
7.3.3.3. Harvest and lysis of cells 
 
Induced cells were harvested by centrifugation at 4°C, 8,000 g for 30 minutes and stored 
at -80°C. To lyse the cells, a cell pellet was thawed and re-suspended in His A buffer 
(table 7.6). The cell suspension then lysed using a cell disruptor (Branson, USA) for 6 
cycles (10sec per cycle with 10min gap between cycles). The solution was centrifuged 







7.3.3.4. Protein purification 
 
All recombinant proteins in this study are His-tagged, thus the most common method 
for protein purification is Ni-affinity chromatography and further purification was 
achieved through ion exchange chromatography. The columns used for each method 
and the buffers are listed in table 7.6. All purifications were performed using a ÄKTA  
purifier protein purification system (GE Healthcare) 
 
Table 7.6. Methods, columns and buffers used in protein purification 
Protein TcTS/TcTSmut SpNA 
Method Nickel affinity chromatography 
Column His-trap FF 1ml/5ml (GE Healthcare) 
Buffer 
Binding buffer (His A): 50mM Tris, 500mM NaCl, 
20mM Imidazole, pH 7.4 
Elution buffer (His B): 50mM Tris, 500mM NaCl, 
500mM Imidazole, pH 7.4 
Method Anion-exchange chromatography 
Column Hi-trap Q FF 1ml/5ml (GE Healthcare) 
Buffer 
Binding buffer (Anion A): 50mM Tris, pH 9 
Elution buffer (Anion B): 50mM Tris, 500mM NaCl, pH 
9 
Method Gel filtration 
Column Superdex 200 10/300 GL (GE Healthcare) 





7.3.3.5. Buffer exchange 
 
Four buffer-exchanging methods were used in this study. Amicon-Ultra (Merck 
Millipore) centrifugal filters were used to enrich purified protein, several cycles of 
spinning dilutions-enrichment were repeated utilizing the replacement buffer, until an 
equivalent of 1000× dilution (4 cycles of 25× dilution) of the original buffer was 
attained. Alternatively, protein sample were buffer exchanged by PD-10 gravitational 
desalting column (GE-Healthcare). Briefly, a PD-10 gravitational column was pre-
equilibrated with 25ml of replacement buffer. Up to 2.5 ml of protein sample was loaded 
on the top of the column. When the protein sample had been fully absorbed by the 
column, 3.5 ml of replacement buffer was added then 3.5ml of protein solution was 
eluted in the desired buffer. For small volumes of protein, protein desalting spin 
columns (10,000Da cut off, Thermo Scientific) were used. The spin column was first 
equilibrated with replacement buffer through 3 wash cycles (400 μl per cycle), and the 
excess liquid was removed by 1 min centrifugation at 1500 g. The protein sample was 
then placed on the center of the resin bed and the column was placed above a new 
collection tube, after which the column was spun at 1500 g for 2 minutes to collect the 
buffer-exchanged sample. 
 
To exchange the buffer more completely, classical dialysis was performed by using 
Slide-A-Lyzer™ G2 Dialysis Cassettes (10,000Da cut off, Thermo Scientific). Dialysis 
cassettes were first prepared by soaking in the replacement buffer or ddH2O for 2 min. 
Samples were added into the cassette by pipetting or using a syringe with a needle, 
followed by removal of excess air in the cassette. The cassette was placed in a 
replacement buffer of 200× higher volume than protein sample. The dialysis process 
was performed at 4°C in a cold room with gentle stirring, the dialysis buffer was 







7.3.3.6. Concentrator and concentration measurement 
 
While protein samples were collected from purification or buffer exchange, the 
concentration was increased using Amicon-Ultra centrifugal filters. Firstly, centrifugal 
filter was equilibrated by adding the desired buffer and spinning for 5 min. Protein 
samples were then placed on the center of the filters and spun at 3500 g until the 
appropriate volume was reached. Samples were finally collected by pipetting carefully. 
The concentration of protein samples was determined by measuring the absorbance at 
280nm using a BioSpectrometer (Eppendorf).  
  
7.3.4. Downstream protocols of nucleotide and protein analysis 
 
7.3.4.1. DNA gel electrophoresis 
 
DNA samples include plasmids and PCR products were detected by agarose gel 
electrophoresis. Agarose gels were made by dissolving 1% (w/v) agarose in 1× TAE 
buffer (40mM Tris-acetate, 1mM EDTA, pH8.0) and addition of 1 in 20,000 dilution of 
10mg/ml ethidium bromide solution for visualization of the DNA. 1μl of 6× DNA 
loading dye was mixed with 5 μl DNA sample before loading onto the agarose gel. 
Electrophoresis was performed using horizontal flatbed chambers (BioRad) at a 
constant current of 80 mA. For DNA size estimation, the 1Kb Plus DNA ladder (Figure 





Figure 7.1. Markers used for DNA size estimation (1Kb plus DNA ladder, BioRad) 
 
7.3.4.2. DNA purification 
 
PCR products were purified using a MiniElute PCR purification kit (Qiagen) to remove 
protein contaminants in the sample. In cases where PCR reactions produced multiple 
bands on a gel, the whole PCR reaction mixture was electrophoresed, and the desired 
band was excised for DNA extraction using MiniElute gel extraction kit (Qiagen). In 
both purification and gel extraction, DNA samples were finally eluted with 10 μl sterile 
water. 
 
7.3.4.3. SDS-Page electrophoresis 
 
In this study, protein samples were estimated by sodium dodecyl sulphate 
polyacrylamide gel electrophoresis (SDS-PAGE) using a Novex Mini gel system 
(Invitrogen) using 4% polyacrylamide stacking gel (Appendix 8.3), and 10%, 12% and 
15% polyacrylamide resolving gel (Appendix 8.3). Protein analytes were mixed with 
2× SDS-PAGE loading buffer (Appendix 8.3) and heated at 100°C for 10 min. 
Generally, 5-15 μl samples (with less than approximately 25μg protein) were loaded 




(Dilute from 10× stock, Appendix 8.3), using the constant current setting of 60-80 mA 
until the bromophenol blue dye ran off the gel. The Gel was extracted from the cassette 
then stained with Coomassie Blue (Appendix 8.3) for 30-60 min after being heated in 
microwave for 40 sec. The excess stain was then removed using de-stain solution 
(Appendix 8.3) overnight and the gel was imaged using a Chemidoc-it2 UV 
transilluminator. PageRuler Unstained (Figure 7.2A) and Prestained (Figure 7.2B) 
protein ladder (Thermo Scientific) were used estimate the size of proteins in the sample. 
. 
Figure 7.2. Markers used for protein size estimation: A: Unstained protein ladder (Thermo 
Scientific), B: Prestained protein ladder (Thermo Scientific) 
 
7.3.5. TcTS/Sialidase activity and inhibition assay 
 
The sialidase activity of TcTS and sialidases was determined using 2′-(4-
Methylumbelliferyl)-α-D-N-acetylneuraminic acid (MuNANA) as substrate. 
MuNANA is a non-natural substrate which has been widely used in determination of 
enzymic activity of sialic acid hydrolases or transferases (Potier et al., 1979). When the 
Oxygen-linkage between sialic acid 4-Methylumbellifrerone (4-Mu) is cleaved by 
sialidase or trans-sialidase, the shed 4-Mu can generate a strong fluorescence signal, 
which is significantly higher than the self-fluorescence which is generated by 






Figure 7.3. A: Principle of fluorescence SA enzyme assay using MuNANA (Grienke et al., 
2012) B: Fluorescence generation by different concentrations of MuNANA, compared with 19 
μM 4-Mu sodium salt in enzyme buffer in 100 μl reaction (Marathe, et al. 2013) C: Process of 
fluorescence SA assay. 
 
In this study, we performed SA activity and inhibition assays in Cellstar 96 well solid 
black plates (Greiner). The reaction system, with total volume of 100 μl, was prepared 
by addition of assay buffer (Appendix 8.5), enzyme stock solution and inhibitor (only 













































































temperature for at least 10 min. The stock solution of MuNANA, which has been pre-
incubated at the assay temperature, then was added into the reaction mixture carefully. 
The plate then quickly placed into a FlOUstar Omega multimode microplate reader 
(BMG labtech) and  reading started with the excitation wavelength at 360 nm and 
emission wavelength at 460nm. The assay was normally read for approximately 10min 
and fluorescence signal generated by hydrolyzed 4-Mu was collected and plotted. All 
assays were repeated three times independently. The raw data were analyzed by MARs 
data analysis software (BMG labtech), a linear region of the raw data curves was picked 
and the slope of the curve was calculated using unit RFU/min, which represents the 
activity of the enzyme.  
 
Further analysis of the raw data was performed by GraphPad Prism software.  
 
Km/Vmax/kcat 
To characterize the enzyme, the Km and Vmax are the first parameters to be determined. 
Km/Vmax/kcat assay was run with a constant enzyme concentration and various substrate 
concentrations. The enzyme activity at these different concentrations of substrate was 
recorded and a non-linear fit was performed. The Km and Vax were calculated using 
following equations, in which RFU stands for the fluoresce unit, and [Er] means the 






     =     [  ] 
IC50 
For high throughput screening of the inhibitor candidates and analysis of selectivity of 
inhibitors, half maximal inhibitory concentration (IC50) were tested. The IC50 assay of 
TcTS and sialidases records enzyme activity with a constant concentration of enzyme 
and substrate, and various concentration of inhibitor. Enzyme activity without inhibitor 




of inhibitor can be calculated. IC50 is calculated using the following equation:   
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where min and max are the minimum and maximum limitations of the non-linear curve 
fitting, Hill slope, also known as hill coefficients, is the slope of the non-linear fitting, 
and it can be interpreted to determine the inhibition mechanism and binding 
stoichiometry (Prinz, 2010). The time-dependent inhibition assay also follow the 
procedure but with various pre-incubation times of the enzyme-inhibitor mixture. 
 
Mode of inhibition and Ki 
The assay which detects the mode of inhibition is similar to the Km/Vmax assay, but the 
Km and Vmax are detected in the presence of different concentrations of inhibitor. The 
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Un-competitive inhibition: 
        =     /(1 +  /   ) 





The model fitting results were compared and the one with the least standard error was 
selected as the optimal inhibition model.  
 
7.3.6. Thermodynamic study 
 
The thermodynamic characterization of interactions between TcTS and either inhibitor 
or substrate can be investigated using isothermal titration calorimetry (ITC). Uniquely, 
ITC can detect both binding constants and thermodynamic parameters of the interaction 
between two or more molecules in one experiment without any labelling of the samples.  
 
ITC experiments in this study were performed using a NanoITC instrument (TA 
instrument). Both protein (acceptor) and ligand molecules were dissolved in the same 
buffer by dialysis or another buffer exchange method. Both protein and ligand were pH 
matched and degassed before the experiment. ITC assay was performed by placing the 
protein into the sample cell and the ligand in the syringe. Experimental data was 
analyzed by NanoAnalysis software (TA instrument) and the isothermal parameters ΔH 
and ΔS, and the binding constant Kd were calculated. 
 
The thermodynamic characteristics of the interaction between TcTS and α-
aminophosphonate inhibitor were determined by isothermal titration calorimetry (ITC). 
A purified TcTS sample was dialyzed against the ITC assay buffer (PBS, 50mM NaCl, 
pH 7.5), then concentrated to about 0.11mM. The inhibitor sample was dissolved into 
the same buffer. After degassing, the TcTS and inhibitor samples were loaded into the 
sample cell and syringe of the ITC instrument respectively. The ITC experiment was 
run at 20°C with stirring at 250 rpm. 30 titrations were measured with a gap of 10 mins 
between two titrations. The result was analyzed by NanoAnalysis software 
(manufacturer) and isothermal parameters including ΔH and ΔS and the binding 





7.3.7. Protein crystallography 
 
7.3.7.1.  Crystallization of recombinant TcTS 
 
The crystallisation of TcTS included robot screening (Phoenix nano dispenser, ARI), 
which used sitting drop vapor diffusion; performed in MRC 96-well crystallization 
plate (molecular dimensions, UK) and crystallization screens were sourced from 
Molecular Dimensions, UK. Manual crystallization and co-crystallization trials were 
performed using hanging drop vapor diffusion in 24-well XRL Plates with round 
CrystalClene™ coverslips (Molecular Dimensions, UK). All chemical, without further 
purification, were directly applied for crystallization trials 
 
TcTS has been crystallized, however, due to the complexity and flexibility of the 
protein, it is still not easy to obtain good quality single crystals even from known, 
published, conditions. To ascertain possible new crystallization conditions for TcTS, 
the commercial screens JCSG screen, PEG screen, and PGR screen (Molecular 
Dimensions, UK) were set in 96-well plate using Phoenix crystal robot (ARI 
instrument), 300nl of purified TcTS at 18 mg/ml, was added into each well, with 1:1, 
1:2, 2:1 ratio of protein:mother liquor. Manual screening based on the published 
condition (Condition A: 100mM Tris-HCl, 20% PEG4000, 5% isopropanol, pH 7.5) 
was performed in 24-well plate, with pH range between 7.0 to 8.0, the range of 
PEG4000 percentage between 10% to 30%, and different buffer condition including 
Tris-HCl, HEPES and PBS. The present of salt can help the formation of crystal nuclei, 
therefore a salt screen has also been carried out by adding a wide range of salts based 
on the published crystal condition (NaCl, MgSO4, CuSO4, NiCl2).  
 
Unfortunately, no hit was found in all the commercial screening and salt screening 
experiments. Microcrystals start growing in condition A after two weeks, but fail to 
grow to suitable size for X-ray diffraction after months. A few single crystals were 




obtain larger amount of high quality single crystals, micro and macro seeding has been 
performed in both condition A and condition B. In micro seeding, microcrystals were 
transfer into micro centrifuge tube with 100μl of mother liquor, and broken down by 
vortexing. The seed liquor was diluted by mother liquor in ratios of 1:1, 1:5, 1:10. 1μl 
of diluted seed solution was then mixed with equal volumes of 18mg/ml purified TcTS. 
Unlike micro seeding, macro seeding uses microcrystals directly as seeds, the micro 
crystals were transferred into drops with concentrated protein. Single crystals with 
appropriate size were grown in condition B after few days to weeks.   
 
7.3.7.2. Crystal soaking and co-crystallization 
 
Good inhibitor candidates (48, 51, 53, 54, 59, 61, 62 and 63) from structure-activity 
screening described in Chapter 3 (IC50<0.3mM), known inhibitors DANA and Rhein 
(reported IC50=56μM) (Arioka et al., 2010) were used to attempt crystal soaking with 
TcTS single crystals. For water-soluble compounds, including DANA, lactose, sialic 
acid and α-aminophosphonate compounds, small molecule compounds were prepared 
in final solutions at 5-10mM in crystallization mother liquor. Rhein is only partly 
soluble in aqueous solution, thus, 10% (v/v) of DMSO was added into the 
crystallization liquor and the final concentration of Rhein was 1 μM. For all the ligands, 
1μl of stock solution was added onto a 1μl drop containing a single crystal. The soaked 
crystals were stored in hanging drops at room temperature before being flash-cooled 
using liquid nitrogen.   
 
Co-crystallization was performed with compound 59, purified TcTS (18mg/ml) was 
pre-incubated with 5mM of compound at room temperature for 30mins. Crystallization 
trials using the JCSG, PEG and PGR screens were set up by the crystallography robot 
(Phoenix) at 1:1, 1:2, 2:1 protein: mother-liquor ratio. Hits were observed in condition 
B12 (0.2 M Potassium citrate tribasic monohydrate, 20 % w/v PEG 3350), G8 (0.15 M 
DL-Malic acid, 20 % w/v PEG 3350), G11 (2.0 M Ammonium sulfate, 0.1 M BIS-Tris, 




using 24-well plates. A single crystal was found in condition (0.15 M Potassium citrate 
tribasic monohydrate, 20% w/v PEG 3350).  
 
 
Good inhibitor candidates (IC50 < 0.3 mM) from structure-activity screening described 
in subsequent chapters, the known inhibitors DANA, lactitol and Rhein (Arioka et al., 
2010) were used in crystal soaking trials with TcTS single crystals. Substrate, such as 
SA and lactose, were also applied in soaking experiment in order to interpret the 
mechanisms of inhibitors. For water-soluble compounds, such as DANA, lactose, sialic 
acid and α-aminophosphonate compounds, stock solutions of the small molecule 
compounds were made at 5-10mM in crystallization mother liquor. Rhein is only partly 
soluble in aqueous solution, thus, 10% (v/v) of DMSO was added into the 
crystallization liquor and the final concentration of rhein was 1 μM. For all the ligands, 
1μl of stock solution was added onto 1μl drop containing single crystal. The soaked 
crystals were placed as hanging drops at room temperature before being frozen by liquid 
nitrogen.  
 
Co-crystallization was also performed with compound 59, selected due to having the 
best inhibition effect. Purified TcTS (18mg/ml) was pre-incubated with 5mM of 
compound at room temperature for 30mins. JCSG, PEG, and PGR screenings were 
performed by the crystallography robot (Phoenix) at 1:1, 1:2, and 2:1 protein-mother 
liquor ratio. Hit conditions were optimized by hang-drop, vapor diffusion method in 24 
well plate.    
 
7.3.7.3.  Data collection, processing and refinement 
 
Crystals were cryo-protected with 30% glycerol (w/v) for a few seconds then transfer 
to liquid nitrogen. All data were collected at 100K on the in-house X-ray diffraction 
instrument (Rigaku) or at the synchrotron (beam I03, I04, Diamond light source, 




HKL2000 (Otwinowski et al., 1997), or Xia2 (Winter et al., 2013). The space group of 
most crystals was determined as monoclinic (P1 21 1), but triclinic (P1) and 
orthorhombic (P 21 21 21) were also found in some datasets. The data were scaled using 
SCALA. The Rmerge is calculated by following equation: 
1 1
R ( ) / ( )
N N
merge hkl hkl hkl
hkl j hkl j
I I j I j
 
    
Since the structure of TcTS has been solved, previous published structure 1MS5, 1MR5, 
1S0I (Amaya et al., 2004; Buschiazzo. et al., 2002) were directly used as models for 
molecular replacement using Balbes (Long et al., 2008), CCP4 Phaser (McCoy et al., 
2007) or Phenix Phaser MR (Bunkoczi et al., 2013) using the soaked crystal data. The 
model built by molecular replacement was then refined by Phenix Refine (Afonine et 
al., 2012) or REFMAC5 (Murshudov et al., 2011), the refined model was manually 
fitted and improved using Coot, as well as ligand and solvent building and fitting 
(Emsley and Cowtan, 2004). Coordinate and crystallographic information file (.cif files) 
of inhibitors and other ligands were created by Phenix elbow (Moriarty et al., 2009).The 
Rfactor for refinement is calculate by following equation: 
R ( ) ( ) / ( )factor obs cal obs
hld hld
F hkl F hkl F hkl    
Rfree was calculated as defined by Brunger (1992) for 5% of the total data. The refined 








































8.1. Cloning vectors 
 
Figure 8.1. pTrcHisA vector 




8.2. Recipe of media for bacterial culture  
Table 8.1. Recipe of LB media 
Component g/L 
Trypton 10 
Yeast extract 5 
NaCl 10 
 
   Table 8.2. Recipe of TB media 
Component g/L 
Trypton 12 








   Table 8.3. Recipe of SOC media 
Fomular g/L 
Trypton 20 


















8.3.  Recipe of SDS-PAGE Gels and buffers 
Table 8.4. Recipe of SDS-PAGE gels 
Component 
10% running gel 12% running gel 4% Stacking gel 
Volume  
40% Acrylamide 2.0 ml 2.4 ml 0.5 ml 
ddH2O 3.8 ml 3.4 ml 3.1 ml 
1.5M Tris, pH 8.8 2.0 ml 2.0 ml - 
0.5M Tris, pH 6.8 - - 1.25 ml 
TEMED 8 μl 8 μl 5 μl 
10% Aps 80 μl 80 μl 50 μl 
 
 
Table 8.5. Recipe of 2× SDS-PAGE sample buffer 
Component Volumn (ml) 
1M Tris, pH 6.8 2 
50% glycerol 4.6 
10% SDS 1.6 
0.5% bromophenol blue 0.4 
 β-mercaptoethanol 0.4 
 
Table 8.6. Recipe of 10×Tris-Glycine running buffer  
Component weight (g) 
Tris base 30 
glycine 144 
SDS 10 
Dissolve the components above in 1000ml of ddH2O, 
 no pH adjustment is required 
 
Table 8.7. Recipe of coomassie solution for SDS-PAGE staining 
Component weight/volume 
Coomassie blue R-250 0.25 g 
EtOH 100 ml 
ddH2O 100 ml 
 
Table 8.8. Recipe of destain solution for SDS-PAGE  










8.4. Recipes of TcTS/sialidase activity buffer 
 
TcTS kinetic assay buffer: 20mM Tris, 50mM NaCl, 0.01% Triton X100, pH7.5 
 
CpNA/SpNA kinetic assay buffer: 100mM NaOAc, 2mM CaCl2, 0.01% Triton X100, 
pH5.0. 
 
8.5. DNA sequences 
 























































































































































































































8.6. Interaction details of TcTS and inhibitors 
 













Mode of Interaction 
Crystal 1, compound 51, P1 21 1 
540 Glu Naphthalene No LT* 3.6 
Hydrophobic 
interaction 










Yes CA 3.33 Hydrogen bond 
Crystal 2, compound 54, P1 21 1 
540 Glu Naphthalene No LT 3.79 
Hydrophobic 
interaction 










Yes CA* 3.3 Hydrogen bond 
Crystal 3, compound 54, P 21  21  21 
522 His Naphthalene No LT 3.77 
Hydrophobic 
interaction 










Yes LT 2.32 Hydrogen bond 
579 Pro Nitro oxygen Yes LT 3.5 Salt bridge 










Domain Distance (Å) Mode of Interaction 
Crystal 4, compound 48, P 21  21  21,  Hilex binding site 




CA 3.8 Hydrogen bond 
376 Arg Anthracene CA 3.5 π-Cation interaction 








CA 3 Salt bridge 
Crystal 4, compound 48, P 21  21  21,  Inter-domains binding site 
225 Ala Anthracene CA 3.71 Hydrophobic interaction 
246 Val Anthracene CA 3.8 Hydrophobic interaction 
249 Arg Anthracene CA 3.9 Hydrophobic interaction 
249* Arg Anthracene CA 3.7 π-Cation interaction 
249 Arg Anthracene CA 3.8 π-Cation interaction 
250 Arg Anthracene CA 4 Hydrophobic interaction 
252 Leu Anthracene CA 3.5 Hydrophobic interaction 








LT 3.1 Salt bridge 




LT 3.4 Hydrogen bond 










Figure 8.8.1. Full multiple sequence alignment result of TcTS sequences of CL banner strains 




allosteric binding site residues are highlighted by green box under the alignment results. The 
conversation of these residues within TcTS isoform has been further highlighted in yellow 
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